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Cancer — a short introduction
Cancer is the name of a group of diseases characterized by uncontrolled growth and
spread into surrounding tissue. The first description of cancer dates back to an ancient
Egyptian surgery textbook from about 1700 BC, which was probably a copy of a much
older papyrus from 3000 to 2500 BC [1]. Although the Egyptians did not use the word
cancer, the textbook described several cases of breast tumours that were removed with
a “fire drill” [2, 3]. The Greek physician Hippocrates (460–370 BC) was the first one to
refer to the disease as carcinos and carcinoma, which was later translated into cancer.
Carcinos is the Greek word for crab, probably chosen due to the resemblance of the
spreading of tumours to the legs and claws of a crab [3].
Nowadays, cancer is recognized as a worldwide health problem with over
14 million new cases in 2012. The number of new cancer cases is expected to increase
and is estimated to reach almost 24 million by 2035 [4]. Even though the different
treatment options have substantially improved over the past decades, survival for
many cancer types remains poor, making cancer one of the leading causes of mortality
and morbidity [4].
Cancer cells are mutated versions of our own cells. The mutations corrupt
the regulatory systems in the cell and disturb processes such as development, cell
growth and proliferation [5]. Despite the mutations, cancer cells are very similar
to healthy cells and therefore a difficult target for anticancer therapies. Further
complicating treatment is the fact that cancer is not one disease, but a collection of
over 200 distinct cancer types [6]. Even for one type of cancer, genetic differences
are found between patients (interpatient heterogeneity), within the primary tumour
(intratumour heterogeneity), between metastases (intermetastatic heterogeneity), and
within metastatic lesions (intrametastatic heterogeneity) [7].
Cancer characteristics
The diversity and complexity of cancer is believed to be a result of a number of
underlying processes, referred to as “hallmarks of cancer”. These hallmarks distinguish
healthy cells from cancerous cells. The hallmarks are: (I) self-sufficiency in growth
signals, (II) insensitivity to anti-growth signals, (III) tissue invasion and metastasis,
(IV) limitless replicative potential, (V) sustained angiogenesis, (VI) evading apoptosis,
(VII) avoiding immune destruction, (VIII) tumour-promoting inflammation, (IX)
genome instability and mutation, and (X) reprogramming energy metabolism [8, 9].
Understanding the hallmarks of cancer can help improve the early detection of cancer,
better develop targeted strategies, tailor treatments, and improve follow-up. Three
hallmarks, crucial in the work presented in this thesis, will be discussed in more detail.
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The first hallmark, self-sufficiency in growth signals, is one of the most
fundamental cancer characteristics. Normal cells require external signals to grow and
divide. Cancers, however, can deregulate these signals and control their own growth.
They can stimulate proliferation by producing growth factors, by activating normal
cells to produce growth factors for them, by increasing the number of growth factor
receptors, or by altering components downstream of the growth factor receptors [9].
An example of a growth factor receptor often overexpressed or mutated in human
tumours is the epidermal growth factor receptor (EGFR) [10, 11]. Elevated levels of
EGFR have been correlated to a poor outcome in patients [12].
Sustained angiogenesis, another cancer hallmark, means that tumours can activate
the formation of new blood vessels from pre-existing vessels. Tumours, like normal
organs, require access to nutrients and oxygen, and need to be able to dispose of waste
[13]. A developing tumour will first rely on diffusion for its nutrient supply, however,
as soon as the tumour starts to grow beyond a size of 1–2 mm, this will no longer be
sufficient and blood vessels become essential for further growth [14]. Tumours activate
angiogenesis to produce these new blood vessels. Angiogenesis is tightly regulated in
adults and normally only temporarily enabled in processes such as wound healing. In
contrast, almost all tumours activate angiogenesis and sustain its activation [9]. The
imbalance in tumours between pro- and anti-angiogenic signalling creates a highly
irregular and abnormal vasculature, with a heterogeneous blood flow. The vessels are
dilated, leaky, tortuous and interconnected, and often fail to supply enough oxygen
throughout the tumour [14, 15]. Regions that are deprived of oxygen as a consequence,
also referred to as tumour hypoxia, are more treatment resistant, and stimulate a more
aggressive and invasive tumour type [16, 17].
Finally, tumours have the ability to reprogram their energy metabolism. In order
to support the uncontrolled proliferation of tumour cells, adjustments of the energy
metabolism are required [9]. In normal cells, energy is obtained by first processing
glucose via an oxygen independent process, called glycolysis, followed by an oxygen
dependent pathway, called oxidative phosphorylation. In hypoxic regions, tumours
depend on the less energy efficient glycolysis for their energy supply. Even in
the presence of oxygen, tumours cells will often resort to this oxygen independent
pathway, referred to as the Warburg effect [18]. To compensate for the less energy
efficient metabolism, tumours will upregulate glucose transporters to increase the
import of glucose into the cytoplasm [9].
Lung cancer and head and neck cancer
The two types of cancer studied in this thesis are lung cancer, and head and neck
cancer. Lung cancer is the most common cause of cancer related deaths worldwide [4].
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The patient prognosis is highly depending on how advanced the disease is. Patients
with locally advanced lung cancer have a five-year survival rate of only 15 to 20 %
[19]. Lung cancers can be subdivided in non-small cell lung cancer (around 85 %
of all lung tumours), and small cell lung cancer (around 15 %). Non-small cell
lung cancers (NSCLC) are further divided in three major subtypes: squamous-cell
carcinoma, adenocarcinoma, and large-cell lung cancer [20]. The vast majority of lung
cancer cases are linked to tobacco smoking [21].
Head and neck cancers (HNC) are cancers that arise from the mouth, nose, throat,
larynx or salivary glands. The majority of the cancers, about 95 %, begins in the
squamous cells that line mucosal surfaces, the so-called head and neck squamous
cell carcinoma (HNSCC) [22]. Treatment is often complex due to the proximity of the
tumour to vital organs that provide breathing, swallowing, and speech. Tobacco and
alcohol use are the most important risk factors for HNC [23].
Treatment of cancer
Cancer treatment options highly depend on the type of cancer, the advancement of
the disease, and patient related factors. The most common treatments are surgery,
chemotherapy, and radiotherapy. Surgery aims to physically remove the tumour;
chemotherapy targets rapidly dividing cells with systemic drugs; radiotherapy uses
ionizing radiation to kill cancer cells. Other treatment options include targeted
therapy, immunotherapy and hormone therapy. Often a combination of these
therapies is used to optimize treatment outcomes.
It is estimated that roughly 75 % of all lung cancers and head and neck squamous-
cell carcinomas will benefit from radiotherapy as part of their treatment [24]. In
patients with early stage NSCLC, surgery is the first treatment of choice [25]. However,
if patients have contraindications to surgical resection, high dose radiotherapy is
prescribed [19]. Most of the NSCLC patients will not have an early stage cancer, but
will present with advanced disease at the time of diagnosis [20]. These patients, if not
suitable for surgery, normally receive radiotherapy combined with chemotherapy, or
only chemotherapy if the disease is metastasized.
Treatment approaches in head and neck vary depending on the tumour site. For
early disease (about one third of the patients) both surgery and radiotherapy are viable
options. In locally advanced HNSCC, radiotherapy is combined with chemotherapy,
with or without surgery [23, 26]. In HNC targeted therapies are also being investigated,
focussing mostly on specific targeting of EGFR. The monoclonal antibody cetuximab
is an example of such a targeted therapy approved for treatment in HNC. Monoclonal
antibodies (mAb), i.e. antibodies that originate from one unique parent cell and are
identical, specifically bind to antigens on the tumour surface, for example EGFR [27].
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Medical imaging in oncology
Medical imaging has a vital role in the modern management of cancer. Medical
imaging encompasses a wide range of non-invasive or minimally invasive modalities
that provide a visual representation of the human body. Imaging is fundamental
for cancer screening, diagnosis, staging, treatment, and response monitoring [28].
Radiotherapy heavily relies on medical imaging for treatment planning, patient
positioning, and treatment verification [29]. After therapy, follow-up scans are
performed routinely with different imaging techniques.
Medical imaging modalities can be roughly divided in two categories: techniques
that visualize anatomy and techniques that assess functional or biological properties
[30]. Magnetic resonance imaging (MRI) and computed tomography (CT) both
provide anatomical information. CT is based on X-rays, while MRI makes use of the
behaviour of nuclei in a magnetic field. Both techniques are commonly used to study
the tumour size and morphology, and the location of the tumour relative to other
organs. By adding contrast media or by adapting scanning protocols, both modalities
can also provide functional information. Other modalities that provide functional
information are positron emission tomography (PET) and single-photon emission
computed tomography (SPECT) techniques. PET and dynamic contrast-enhanced CT
imaging will be described in more detail in the next paragraphs.
Positron emission tomography
Positron emission tomography is a nuclear imaging modality based on positron
emitting radionuclides [31]. The radionuclides are linked to biologically active
molecules or drugs that act as carriers. These radionuclide labelled compounds,
i.e. PET tracers, are injected in the body, accumulate in specific regions over time
depending on the tracer, all the while releasing positrons. The positrons react in the
body with nearby free electrons and in this annihilation reaction, a pair of gamma
photons are released, travelling in opposite directions. The gamma photons are
measured with a ring of detectors around the patient. The line in which the photons
travel can be used to reconstruct the origin of the signal, to determine the location
of the accumulated PET tracer (e.g. inside the tumour). A schematic drawing of PET
imaging is shown in Figure 1.1. PET is commonly combined with CT, or more recently
with MRI, to provide both functional and anatomical information in 3D in one imaging
session.
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Figure 1.1. Schematic drawing of a patient in a PET scanner. The positron-emitting radionuclide
has accumulated in various body tissues after some time. The higher concentration leads to
more gamma photons being emitted from those regions and so the map of activity can be
reconstructed.
Selecting PET tracers to visualize different biological processes
Depending on the PET tracers used, different biological processes can be visualized.
By far the most widely used PET tracer, and the one most frequently used in the
clinical workflow, is fluorodeoxyglucose (18F-FDG), a glucose analog labelled with the
radionuclide Fluorine-18. Just like glucose, FDG will be actively transported to cells
with a high glucose demand. However, unlike glucose, FDG cannot undergo glycolysis
and will get trapped in the cell after phosphorylation [32]. Generally, tumours have
an upregulated glucose metabolism, as discussed previously as one of the hallmarks
of cancer. As a consequence of this high glucose metabolism, a high accumulation of
FDG is found in tumours. A disadvantage of FDG PET is that it is not tumour specific;
also normal tissues with a high glucose metabolism or inflamed tissue will show up on
an FDG PET scan.
Another tumour characteristic that can be visualized using PET is tumour hypoxia.
Hypoxia, as described before, caused by the rapid tumour growth in combination with
an underdeveloped vasculature, has been related to a more aggressive and treatment
resistant tumour phenotype. The majority of hypoxia PET tracers are based on
nitroimidazoles. Nitroimidazoles passively diffuse through a cell membrane where
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they are reduced into reactive radicals. This process is reversible in the presence
of oxygen; the tracer is immediately reoxidized and can freely flow out of the cell
again. In the absence of oxygen however, the radicals are further reduced, react with
macromolecules in the cell, and get trapped [33]. 18F-MISO, 18F-FAZA and 18F-HX4 are
some examples of nitroimidazole-based PET tracers [34].
A third promising group of PET tracers is based on monoclonal antibodies
(mAb). Monoclonal antibodies, e.g. cetuximab (introduced above), can specifically
bind to antigens on the tumour surface. This enhances the immune system to
attack the tumour cells, or targets tumour growth factor receptors, to restrict tumour
proliferation. By labelling the mAb with positron-emitting radionuclides, a technique
called immuno-PET [35], the expression of the antigens can be quantified and the
efficiency of the mAb treatment can be assessed. The binding process of the mAb to
the antigens is relatively slow, hence a long lasting positron emitting radionuclide is
needed with a long half-life, for example Zirconium-89 (89Zr) or Iodine-124 (124I) [36].
Dynamic contrast-enhanced CT
Dynamic contrast-enhanced CT (DCE-CT) is a technique that dynamically images the
flow of contrast material in a tumour to gain insight into the tumour vasculature [37].
First, a baseline CT image is acquired without any contrast material. Next, a bolus of
iodinated contrast agent is injected intravenously and a series of CT images is acquired
of the tumour region. The changes in enhancement on the CT are directly proportional
to the concentration of contrast material [37]. This enhancement over time is used to
construct time-attenuation curves, as shown in the box in Figure 1.2.
DCE-CT is used to extract several physiological parameters related to the tumour
vasculature. In the first 45–60 seconds after injection of the contrast agent, i.e. first
pass, the majority of the contrast agent is intravascular [38]. This phase can be used
to assess the perfusion of the tumour, i.e. blood flow, and the blood volume. After
the first phase, the contrast agent starts passing into the extravascular space. The
amount of contrast agent in the extravascular space will increase over time until a
balance is reached between the contrast material passing from the intravascular space
to the extravascular space and from the extravascular space back into the vasculature.
To acquire knowledge about vascular permeability, the DCE-CT scans should include
images acquired around two to ten minutes after injection that will show this transition
from the vascular to the extravascular space and back [38, 39].
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Figure 1.2. Dynamic-contrast enhanced CT image acquisition. A bolus of contrast material is
injected in the patient. The distribution of this contrast is followed by acquiring a series of CT
scans, centred around the tumour. The resulting time-attenuation curve (displayed in the top
right box) can be used to model tumour vasculature.
Functional imaging for personalized radiotherapy
The main goal of personalized therapy is to tailor treatment to improve patient
outcome and/or reduce treatment related toxicities [40]. Functional imaging in
radiotherapy has the potential to significantly improve staging of cancer, targeting of
radiotherapy, stratification of patients, and prediction and monitoring of therapeutic
efficacy and toxicity [41]. Tumour stage and functional imaging characteristics can
help selecting the most beneficial treatment for a certain patient. For example,
functional imaging might predict if there is benefit of adding targeted therapies to
radiotherapy. In patients where no benefit is expected, the targeted therapy will not be
prescribed and the patients are not exposed to any unnecessary additional treatment
induced toxicities.
One major challenge in radiotherapy is the definition of the target volume. Modern
irradiation techniques allow very precise and conformal deposition of radiation dose
in a target. The more precise this delivery is, the more important it becomes that
all tumour lesions are correctly identified. FDG PET imaging is widely used to aid
target delineation. Adding this functional imaging modality has shown to improve
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target definition, over anatomical imaging alone, in several tumour types [42, 43].
Functional imaging also allows integrating intratumour heterogeneities into treatment
planning. Traditionally, radiotherapy doses are delivered uniformly throughout the
whole tumour. However, since tumour are radiobiologically heterogeneous, not all
tumour regions will achieve the same cell damage with the same radiation dose.
Hence, if the spatial radioresistance information is known, the radiation dose can be
redistributed inside the tumour based on this information acquired from functional
imaging. This spatial redistribution of the radiation dose is a technique also referred
to as dose painting [44].
Objective and outline of the thesis
The aim of this thesis is to explore the use of functional imaging to characterize the
tumour and tumour subvolumes, and subsequently to use these functional imaging
characteristics for the prediction of patient prognosis, for patient stratification, and
for treatment adaptation in non-small cell lung cancer and head and neck cancer. We
hypothesize that functional imaging could substantially contribute to the optimization
and personalization of radiotherapy.
Following the introduction, the thesis is divided in four parts. In Part 1, non-
invasive imaging of drug uptake is described. The drug assessed in this part is the
EGFR targeting monoclonal antibody cetuximab. The benefit of addition of cetuximab
to radiotherapy widely varies between patients. Most likely, cetuximab treatment is
beneficial in some, but not all, patients. Cetuximab requires adequate expression of
EGFR in the tumour and cetuximab has to be able to reach the tumour. We hypothesize
that the accessibility of the tumour to cetuximab might be a factor in treatment success
and therefore an important predictive biomarker. To be able to visualize cetuximab
uptake in the tumour, cetuximab is labelled with the PET tracer Zirconium-89. In
Chapter 2, first the safety of 89Zr-cetuximab is evaluated in a clinical phase I trial.
Next, the uptake of the labelled drug is quantified in a larger head and neck cohort,
as described in Chapter 3.
Part 2 describes the use of the functional imaging techniques for visualizing
hypoxia (HX4 PET) and vasculature using DCE-CT, for outcome prediction and
treatment adaptation. In Chapter 4, the results of a clinical trial on nitroglycerin
in NSCLC are reported. Nitroglycerin is a vasodilating drug, commonly used in the
treatment of cardiac diseases, repurposed to reduce hypoxia levels in cancer. In a
window-of-opportunity trial, hypoxia and tumour vasculature are assessed at baseline
and after applying a nitroglycerin patch. The chapter reports the prognostic value
of hypoxia PET and DCE-CT imaging at baseline. Changes between the baseline
scans and scans with nitroglycerin patch are used to study the effect of nitroglycerin
20 Chapter 1
on tumour hypoxia and vasculature to predict the potential benefit of the addition
of nitroglycerin to radiotherapy treatment. Chapter 5 explores hypoxia imaging for
treatment adaptation. In this chapter, a planning study is presented assessing the
feasibility of radiotherapy dose painting based on hypoxia HX4 PET imaging in NSCLC.
In Part 3, advanced image analysis techniques are used to combine multiple
functional imaging parameters, i.e. multiparametric imaging, to assess multiple
tumour characteristics simultaneously. In these two chapters, a data set of NSCLC
patients containing anatomical CT, FDG PET, HX4 PET, and DCE-CT imaging is used.
In Chapter 6, virtual hypoxia PET images are generated from FDG PET/CT and DCE-
CT. Hypoxia imaging provides valuable information about treatment resistance and
can be utilized for treatment adaptation (shown in Chapter 5). Hypoxia PET is
unfortunately not widely available. We proposed a technique to extract information
on hypoxia based on widely available imaging techniques (FDG PET/CT end DCE-
CT). Chapter 7 introduces a methodology to combine hypoxia PET/CT, FDG PET/CT
and DCE-CT on a subvolume level. The multiparametric characteristics of all patients
are combined to identify high-risk subvolumes in NSCLC related to a worse patient
prognosis.
To conclude, Chapter 8 contemplates the future steps to be taken in multipara-
metric imaging in oncology. Chapter 9 provides a general discussion and thoughts on
future perspectives on functional imaging for personalized radiotherapy.
The outline of the thesis is schematically illustrated in Figure 1.3.
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Figure 1.3. Schematic outline of the thesis. The main functional imaging modalities used are
89Zr-cetuximab PET/CT, FDG PET/CT, hypoxia HX4 PET/CT, and dynamic contrast-enhanced
CT (DCE-CT). Patients with non-small cell lung cancer (NSCLC) and head and neck cancer
(HNC) are examined.
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Abstract
Background and purpose PET imaging of cetuximab uptake may
help select cancer patients with the highest chance of benefiting from
cetuximab treatment. The aim of this phase I trial was to determine the
safety of the PET tracer 89Zr-cetuximab and to assess the PET uptake in
the tumour.
Methods Two dose schedules were used; two consecutive doses of
60 MBq 89Zr-cetuximab or a single dose of 120 MBq, both preceded by
400 mg/m2 of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored
twice weekly. PET/CT scans were acquired on day 4, 5, and 6 (step 1)
or 5, 6, and 7 (step 2). Because tumour uptake could not be assessed
satisfactorily, a third step was added including EGFR overexpressing
tumours.
Results Nine patients were included (six NSCLC; three HNC). No
additional toxicity was associated with administration of 89Zr-cetuximab
compared to standard cetuximab. A tumour-to-background ratio (TBR)
larger than 1 was observed in all but one patient, with a maximum of
4.6. TBR was not different between dose schedules. There was a trend
for higher TBRs at intervals larger than five days after injection of 89Zr-
cetuximab.
Conclusions Both presented 89Zr-cetuximab administration schedules
are safe. The recommended dose for future trials is 60 MBq, with a
minimum time interval for scanning of six days.
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Introduction
Monoclonal antibodies are increasingly used in anticancer treatment to specifically
target receptors at the surface of tumour cells, either as a monotherapy or in
combination with radiotherapy or chemotherapy. Cetuximab is such a monoclonal
antibody that specifically blocks the epidermal growth factor receptor (EGFR)
which is overexpressed in many human malignancies [1, 2]. EGFR activation and
overexpression appear to be important tumour cell mechanisms in the development of
resistance to radiation and chemotherapy, resulting in decreased rates of local tumour
control and survival [3].
A randomized phase III trial in head and neck cancer showed improved survival
by adding cetuximab to radiotherapy [4]. However, cetuximab combined with
radiotherapy failed to show any benefit over chemoradiotherapy [5]. The addition of
cetuximab to chemoradiotherapy did also not show benefit in head and neck cancer
[6] or non-small cell lung cancer [7, 8]. Selection of patients with the highest chance
of benefit from cetuximab treatment is of obvious relevance, also in view of its high
costs. The mechanisms underlying clinical response or resistance to EGFR targeting
cetuximab treatment combined with radiotherapy are, however, largely unknown
[9, 10].
Non-invasive visualization and quantification of tumour uptake of cetuximab may
contribute significantly to the selection of patients and determination of the needed
dosage [11]. Several methods using nuclear imaging have been proposed [12, 13].
As the biologic half-life of cetuximab in blood is 65–95 hours [14], a radioactive
tracer with a long half-life is needed to visualize its uptake. Zirconium-89 (89Zr),
with a half-life of approximately 78 hours, is an example of such a positron emission
tomography (PET) tracer that can successfully be labelled to cetuximab and has shown
promising results in animal models [15–17]. In a preclinical study, uptake of 89Zr-
cetuximab was demonstrated only in EGFR positive tumours. However, it was shown
that 89Zr-cetuximab uptake did not correlate with EGFR expression levels, implying
that pharmacokinetic and -dynamic factors influence the cetuximab accumulation in
tumours [16].
Here, we report the results of a phase I study with as primary aim determining the
safety of Zirconium-89 labelled cetuximab. Quantification of 89Zr-cetuximab uptake
in the tumour is a secondary end point. In addition, we aimed to get an indication of
the optimal radioactivity dose and imaging time point to direct future phase II studies.
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Methods
Patient selection
Patients with a histologically confirmed solid cancer without curative treatment
options were eligible. Inclusion criteria were: WHO performance status zero to
two; adequate bone marrow, adequate hepatic and renal function; life expectancy
of more than three months and written informed consent. Patients with a recent
(< three months) myocardial infarction, uncontrolled infectious disease, pregnancy,
previous administration of cetuximab or concurrent treatment with anticancer agents
or radiotherapy were excluded.
Study design
A study design with two different dose schedules was used (Figure 2.1). In both
steps, 89Zr-cetuximab was administered within one hour after administration of the
loading dose of unlabelled cetuximab. Six patients were included, three in each dose
schedule. If in any patient grade two or higher toxicity was observed related to 89Zr-
cetuximab administration, thee extra patients would be included in this dose step.
When at maximum one out of six patients experienced grade two toxicity, the step was
considered safe.
The study design anticipated the future aim, which is to determine the tumour
uptake of 89Zr-cetuximab before and during therapy. Therefore, in the first dose
schedule (step 1), toxicity of two consecutive low doses of 89Zr-cetuximab was
investigated. A standard loading dose of 400 mg/m2 cetuximab, followed by 10 mg
of 89Zr-cetuximab (60 MBq) was administered on day 0. A second injection with a
maintenance dose of 250 mg/m2 of cetuximab, followed by 10 mg of 89Zr-cetuximab
(60 MBq) was administered on day 14.
As a larger radioactivity dose of 89Zr-cetuximab is possibly needed to obtain the
best image quality, toxicity of a single larger dose was investigated in a second dose
schedule (step 2). A loading dose of 400 mg/m2 of cetuximab was administered
followed by injection of 10 mg of cetuximab labelled with 120 MBq 89Zr.
During inclusion in step 2, a study amendment was written based on the first
results of the image analysis. It was decided that if the secondary endpoint (assessment
of tumour 89Zr-cetuximab uptake) could not be satisfactorily assessed based on the
first six patients, a third step would be added in which three patients were included
with an EGFR overexpressing tumour based on recent immunohistochemistry. For
these patients, the administration schedule was the same as in step 2. The study
protocol was approved by the Medical Ethics Review Committee and the radiation
safety committee. The study is listed in ClinicalTrials.gov number NCT00691548.
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Figure 2.1. Timeline of the study: 89Zr-cetuximab injection (grey arrows) and the acquiring
of 89Zr-cetuximab PET/CT scans (black arrows). In step 2, PET/CT scans on day 3 and 7 after
injection were optional and depended on the imaging results in step 1. If in step 1, two or more
patients had a higher tumour-to-background ratio (TBR) on day 4 than on day 5, an additional
scan on day 3 would be performed. If in step 1, two or more patients had a higher TBR on day 6
than on day 5, an additional scan on day 7 would be performed. Patients included in step 3 were
scanned at one time point only, based on the imaging results of step 1 and 2.
EGFR expression and mutation status
In all patients, biopsies of the primary tumour were taken before the start of treatment.
For patients included in step 3, a recent biopsy of the primary tumour or from a
metastatic lesion had to be available, without any antitumour treatment between
the biopsy and inclusion. After inclusion, EGFR expression and mutation status
(exons 18–21) as well as KRAS mutation (codons 12 and 13) were assessed on these
biopsies [18]. EGFR expression was analysed with the EGFR pharmDx qualitative
immunohistochemical kit system (Novocastra and Dako, Denmark). To quantify
EGFR expression, both EGFR membrane staining intensity and the percentage of
EGFR expressing cells were taken into account. EGFR membrane staining intensity
was expressed as a score between 0 (none) and 3+ (strong). The percentage of
cells staining at different intensities was assessed visually. Subsequently, EGFR
immunohistochemistry (IHC) scores were defined on a scale of 0–300 using a formula
combining percentage of staining cells and staining intensity [19]. Tumours were
divided in showing low (< 200) and high (≥ 200) EGFR expression. This threshold was
based on the results of the FLEX study [20, 21].
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Toxicity scoring
Toxicity was assessed during treatment, and twice weekly after treatment until 14 days
after the last injection, according to the CTCAE 3.0 scoring system. At baseline, and on
day 7 and day 14 after injection, blood testing was performed for haematology, kidney
and liver function.
The most common side effect of cetuximab administration that was anticipated
for was skin toxicity (acneform rash) [22]. As skin toxicity is a known side effect of
unlabelled cetuximab administration and this trial aimed to investigate the safety of
labelled cetuximab, skin toxicity was not regarded as a dose limiting side effect.
Synthesis of 89Zr-cetuximab
89Zr was produced by a (p,n) reaction on natural 89Y as described by Verel et al. [23].
Subsequently, labelling of 89Zr to the mAb cetuximab was performed as previously
reported [24].
PET/CT imaging
PET/CT imaging was performed at day 4, 5, and 6 after injection in dose step 1.
Imaging intervals in step 2 were adapted based on the TBRs at subsequent days
in step 1. Patients included in step 3 were scanned at one time point only,
based on the imaging results of step 1 and 2. Furthermore, an optional 18F-
fluorodeoxyglucose (FDG) PET scan was performed within the study period, at
least 24 hours before or 12 days after 89Zr-cetuximab administration (≥ four times
the half-life of cetuximab). In the first patient that underwent an FDG PET scan
after the 89Zr-cetuximab administration, an extra PET/CT scan was performed at
day 12, preceding FDG injection, to assess remaining activity associated with the 89Zr-
cetuximab administration.
Image analysis
Tumour sites and normal tissues were manually delineated on one of the 89Zr-
cetuximab PET/CT scans (day 6 or 7) by the same observer (JvL). For one patient,
delineations were performed on the FDG PET/CT scan. Tumour sites were delineated
based on the CT using FDG PET information when available. To quantify uptake in
muscle and liver, a transversal CT slice of the subscapular muscle and the liver was
delineated. The resulting regions of interest were subsequently projected onto the
other 89Zr-cetuximab PET/CT scans and FDG PET scan through coregistration of the
corresponding CT images using rigid registration.
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The mean, maximum and peak standardized uptake value (SUVmean, SUVmax and
SUVpeak, respectively) were determined using in-house developed dedicated software.
The tumour SUVpeak was defined by calculating the mean SUV in a sphere with a
diameter of 1.2 cm within the tumour region with the highest activity. Tumour-to-
background ratio (TBR) was calculated by dividing tumour SUVpeak by SUVmean in the
aortic arch.
For patients in whom an additional 18F-FDG PET scan was performed, the FDG
PET and 89Zr-cetuximab PET uptake were visually compared.
Results
Patient characteristics are shown in Supplementary Table S2.1, tumour characteristics
in Table 2.1. Nine patients, with a median age of 62 years (range: 53–75), were
included. The third patient was excluded from the study before injection of 89Zr-
labelled cetuximab, because of malignant hypertension during administration of the
unlabelled cetuximab. The blood pressure normalized within two hours of observation
without further consequences. Therefore an extra patient (patient 4) was included in
dose step 1. Only two patients were included in step 3 of the study. Given the slow
accrual, and since this step was not necessary to reach the primary endpoint, it was
decided to close this step prematurely.
From the nine patients included, six had non-small cell lung cancer (NSCLC)
and three had head and neck cancer (HNC). All patients had previously undergone
anticancer therapy. In one patient, EGFR expression and mutation, and KRAS
mutation status of the primary tumour could not be assessed due to insufficient
quantity of histological material. In the other patients, six of the seven primary
tumours showed high EGFR expression, while none showed a mutation of the EGFR
gene. An example of IHC staining in a biopsy with high EGFR expression is shown in
Supplementary Figure 2.2 (patient 6). In the only patient with low EGFR expression,
the primary tumour showed a mutation in the KRAS gene. One of the two patients
included in step 3 showed high EGFR expression on a recent tumour biopsy. The recent
specimen of the second patient contained insufficient material to allow a reliable EGFR
analysis.
Each patient received 89Zr-cetuximab administration as planned. Patients
included in step 1 and 2 underwent the 89Zr PET/CT scans at three consecutive days,
except for patient 6 who could not undergo the first scan due to pain. Patient 4,
included in step 1, was scanned at day 5–7 instead of day 4–6 because of logistical
reasons. In two patients (patient 2 and 4) enrolled in the first dose step, the series
of PET/CT scans after the second injection could not be performed due to pain and
dyspnoea. Patients included in step 3 were scanned at day 6 after injection. Four
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Table 2.1. Tumour characteristics, and FDG PET and 89Zr-cetuximab PET uptake in the tumour and normal tissues.
Primary tumour Schedule FDG PET 89Zr-cetuximab PET
Mutation** Tumour Liver Muscle
Patient Site Histology KRAS EGFR EGFR IHC score SUVmax TBRpeak SUVpeak SUVmax SUVmean SUVmax SUVmean SUVmax SUVmean
1 Lung SCC NA NA NA step 1 11.3 2.8 4.7 7.1 1.8 NA NA 3.4 0.6
2 Lung LCC + - 80 step 1 NA 3.1 4.3 7.8 2.1 NA NA 2.6 0.6
3* Lung LCC NA NA NA step 1 NA NA NA NA NA NA NA NA NA
4 Lung AC - - 280 step 1 NA 4.6 3.8 7.6 1.3 8.1 5.5 1.4 0.4
5 Lung SCC - - 240 step 2 10.2 1.0 1.2 1.6 0.8 7.8 5.7 1.0 0.2
6 Lung AC - - 290 step 2 7.6 1.7 3.6 6.6 1.9 9.9 9.2 1.3 0.3
7 Oropharynx SCC - - 300 step 2 11.3 3.2 3.0 4.3 2.0 7.0 5.3 1.6 0.3
8 Oropharynx MC - - 270 step 3 NA 1.4 4.4 6.2 3.2 7.1 6.8 1.8 0.8
9 Oropharynx SCC - - 290 step 3 NA 1.5 4.8 6.9 3.0 18.4 12.5 1.2 0.4
*Excluded patient.
**KRAS: codons 12 and 13; EGFR: exons 18–21.
Abbreviations: SCC = squamous cell carcinoma; LCC = large cell carcinoma; AC = adenocarcinoma; MC = muco-epidermoid carcinoma; NA = not assessable.
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patients underwent an FDG PET scan within the study period, at an interval of 12 or
13 days after the injection of 89Zr-cetuximab.
An overview of the toxicity per patient is presented in Supplementary Table 2.2. No
toxicity other than skin rash was observed in any of the patients. Of the eight patients
that received the full cetuximab administration, three patients experienced grade one
toxicity, and four experienced grade two acne form rash. No changes were observed
for haematological, kidney and liver function compared to baseline.
89Zr-cetuximab PET images of all patients are shown in Figure 2.2 (coronal) and
Figure 2.3 (transversal). Tumour and normal tissue uptake values of 89Zr-cetuximab
are shown in Table 2.1. All but one patient had a peak TBR larger than 1 at any of
the imaging time points. For each patient, the 89Zr-cetuximab image with the highest
TBR was selected for further analyses. For patients in dose step 1, only the scans after
the first 89Zr-cetuximab injection were analysed, since for two of the three patients
PET/CT scans could not be acquired in the second week. The average peak TBR
was 2.4 (range: 1.0–4.6). The average tumour SUVmax and SUVmean were 6.0 (range:
1.6–7.8) and 2.0 (range: 0.8–3.2), respectively. The average SUVmax and SUVmean for
the liver were 9.7 (range: 7.0–18.4) and 7.5 (range: 5.3–12.5). For muscle, the average
SUVmax and SUVmean were 1.8 (range: 1.0–3.4) and 0.4 (range: 0.2–0.8). Both SUVmax
and SUVmean of the tumour were significantly higher than the muscle SUVmax and
SUVmean.
The FDG PET and 89Zr-cetuximab scans of the four patients with an FDG
PET/CT scan are shown in Figure 2.4. Visual comparison showed a remarkable
mismatch between FDG PET and 89Zr-cetuximab PET uptake in one patient (patient
1, Figure 2.4). No direct relationship was observed between the EGFR IHC score and
TBR.
For the patients in dose step 1, the average peak TBR at day 4, 5, and 6 after the
first injection was 1.3 (range: 1.2–1.4), 2.1 (range: 1.7–2.7) and 3.1 (range: 1.7–4.6),
respectively (Figure 2.5). As the highest TBR was found at day 6 after injection, imaging
in dose step 2 was performed at day 5, 6, and 7. For patients in dose step 2, the average
peak TBR at day 5, 6, and 7 after injection was 1.7 (range: 0.9–2.4), 1.6 (range: 1.0–2.7)
and 2.0 (range: 0.9–3.2) (Figure 2.5). The peak TBR of patients included in step 3 was
1.4 and 1.5 (day 6). At the regular imaging time points, the highest peak TBR was seen
in patient 4 (4.6), at day 6 after injection. In patient 1, an extra PET/CT scan was
performed at day 12 after injection. The TBR at this time point was higher than the
maximum TBR for this patient at the regular imaging time points (2.8 at day 12 versus
1.7 at day 6).
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step 1 - 6 days p.i. - 60 MBq step 1 - 6 days p.i. - 60 MBq step 2 - 6 days p.i. - 120 MBq
step 3 - 6 days p.i. - 120 MBqstep 3 - 6 days p.i. - 120 MBqstep 2 - 7 days p.i. - 120 MBqstep 2 - 7 days p.i. - 120 MBq
Figure 2.2. 89Zr-cetuximab PET maximum intensity projections of all patients. The GTV of
the primary tumour is overlaid in blue. The notes underneath the images indicate in which
dose step the patients were included, how many days postinjection the displayed images were
acquired and the dose of 89Zr-cetuximab (2 × 60 MBq or 1 × 120 MBq) administered. The scans
with the highest TBR in the primary tumour were selected. For dose step 1, the images after the
first injection were analysed.
Discussion
The current phase I trial is the first study in HNC and NSCLC evaluating the safety of
89Zr-cetuximab. It is a first step towards a new patient selection method for cetuximab
treatment or the addition of cetuximab to radiotherapy. 89Zr-cetuximab has until now
only been evaluated in human patients with colorectal cancer [25]. In this study, no
additional toxicity was associated with 89Zr-cetuximab administration. Acne form
eruption ≤ grade two was observed in 88 % of patients, a rate comparable to that
found with therapeutic administration of cetuximab [4, 22, 26]. One patient developed
malignant hypertension during the administration of unlabelled cetuximab. Although
rare, this side effect has been described previously [27].
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Figure 2.3. 89Zr-cetuximab PET/CT images at tumour level showing uptake in SUV. The primary
tumour is delineated in blue. The scans with the highest TBR in the primary tumour were
selected.
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89Zr-cetuximab FDG
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Figure 2.4. Correlation between 89Zr-cetuximab PET and FDG PET uptake for the four patients
receiving both scans. PET uptake is shown in SUV. The primary tumour is delineated in blue.
The 89Zr-cetuximab scans with the highest TBR in the primary tumour were selected.
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Figure 2.5. 89Zr-cetuximab tumour-to-background ratios at different time points after injection
of the tracer. The patients displayed with a black line were included in dose step 1; the patients
with a grey line in dose step 2; the patients with a single black marker in dose step 3.
Tumour uptake of 89Zr-cetuximab
It should be emphasized that no definitive conclusions can be drawn given the small
amount of patients as well as the heterogeneity in tumour type and previous treatment.
All but one patient that completed the study showed a peak TBR larger than 1. Visually,
however, the 89Zr-cetuximab images showed a rather patchy distribution, without
evident specific uptake of 89Zr-cetuximab within the tumour. Visually comparing the
89Zr-cetuximab images of NSCLC and HNC patients showed more discernible tumour
uptake be present in at least one of the HNC patients (patient 8, Figure 2.3).
No direct relationship was observed between EGFR IHC score and TBR, similar
to the findings in our preclinical study [16]. There are several considerations that
argue a direct relationship between EGFR expression assessed in biopsy specimens
and response to cetuximab treatment. Firstly, as expression of EGFR can be induced
by radiation and chemotherapy, it is possible that an initially EGFR negative tumour
may become positive early during therapy, thereby still benefiting from cetuximab
treatment [28, 29]. Secondly, EGFR expressing tumours will not respond to cetuximab
when cetuximab does not reach therapeutic concentrations in the tumour because of
e.g. interstitial pressure and vascular perfusion changes [30].
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Recommended 89Zr-cetuximab dose and time interval for scanning
A large divergence was observed in the time curves of the TBR. Hence, no optimal
imaging time point can be derived from these data. However, we advise a time delay
of at least six days after injection, as five of the six patients that were scanned at
day 5 and 6 showed a higher TBR at day 6. This is in line with a study in colorectal
cancer that also found 6 days postinjection to be the optimal imaging time point
[25]. In the only patient that was scanned after a substantially longer time interval
(12 days after administration), the highest TBR was found at this time point. This
late rise in TBR suggests that a later imaging time point might result in more optimal
tumour visualization. Due to decay, however, accurate quantification at such long time
intervals may be biased by increased noise levels.
Although no definitive conclusions can be drawn regarding the dosage of labelled
cetuximab in view of the different tumour characteristics in the two dose schedules,
the current results do not indicate that a higher dose would result in more optimal
TBRs. Therefore, taking into account the ALARA (as low as reasonably achievable)
principle, a dose of 60 MBq of 89Zr-cetuximab is recommended for future study.
Recommendations for further study
There are some other factors of which the influence on tumour visualization should
be assessed in future studies. First, the loading dose administered in this study
(400 mg/m2), which is the standard therapeutic regimen, might be suboptimal to
enable adequate tumour visualization. A loading dose of cetuximab is required as
cetuximab first binds irreversibly to EGFR expressing liver cells. Therefore tumour
cells are only targeted after the liver has been saturated. This rationale is supported by
animal studies. In addition, the positive correlation between skin toxicity and response
to cetuximab implies that skin saturation only occurs after the liver has been saturated
[31, 32]. The liver SUVmax and SUVmean in the current trial were rather high, implying
that EGF receptors in the liver were still not saturated by the loading dose.
Based on the promising clinical results of adding cetuximab to radiotherapy in
HNC [4], and the imaging data from the current study suggesting specific 89Zr-
cetuximab PET uptake in at least one of the HNC patients, a clinical trial was started
(ARTFORCE head and neck trial, ClinicalTrials.gov: NCT01504815 [33]). Unfortunately,
due to slow accrual, complexity of 89Zr-cetuximab imaging for both patients and
radiotherapy departments, and discontinuation of the funding of cetuximab, the
study was amended and 89Zr-cetuximab imaging, and cetuximab treatment were
discontinued.
In conclusion, the administration of 89Zr-cetuximab to image in vivo cetuximab
uptake is safe and not associated with any additional toxicity compared to unlabelled
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cetuximab. The recommended time interval between cetuximab administration and
imaging is at least six days. The recommended 89Zr-cetuximab dose is 60 MBq. Further
research is needed to explore the optimal loading dose of non-labelled cetuximab and
the relationship between 89Zr-cetuximab and EGFR expression.
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Supplementary data
Table S2.1. Patient characteristics.
Patient Age (years) Sex Length (m) Weight (kg) WHO PS Prior therapy
1 72 Male 1.85 75 0 CTx
2 61 Male 1.76 82 1 CTx, RT
3* 55 Female 1.56 61 0 CTx
4 75 Male 1.79 74 2 CTx
5 53 Male 1.80 91 1 CTx
6 63 Male 1.78 86 0 CTx
7 63 Male 1.86 95 1 RT, CTx
8 59 Female 1.67 60 1 S, CTx
9 62 Male 1.71 60 1 CTx, RT
*Excluded patient.
Abbreviations: WHO PS = World Health Organisation performance status; CTx =
chemotherapy; RT = radiotherapy; S = surgery.
Figure S2.1. EGFR immunostaining.
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Table 2.2. Toxicity scoring.
Patient Injected activity (MBq) Vital signs** Toxicity scoring** Medication**
Haematology Liver function Renal function Skin Symptoms
1 2 × 60 0 0 0 0 2 0 1***
2 2 × 60 0 0 0 0 1 0 0
3* none NA NA NA NA NA NA NA
4 2 × 60 0 0 0 0 0 0 0
5 120 0 0 0 0 2 0 1***
6 120 0 0 0 0 2 0 1***
7 120 0 0 0 0 1 0 0
8 120 0 0 0 0 2 0 0
9 120 0 0 0 0 1 0 1***
Toxicity was scored before study entry (baseline) and at day 7 and day 14 after cetuximab administration.
NA = not assessed because of premature exclusion from the study.
*Excluded patient.
**Every change in vital signs or medication compared to the baseline values was scored, with “0” indicating no change.
***Doxycycline 100 mg, Hydroxyzine 25 mg, Metronidazolcream 10 mg/g.
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Abstract
Introduction Biomarkers predicting treatment response to the mono-
clonal antibody cetuximab in locally advanced head and neck squamous
cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumour ac-
cessibility is an important factor in treatment success of the EGFR target-
ing drug. We quantified uptake of cetuximab labelled with Zirconium-89
(89Zr) using PET/CT imaging.
Material and Methods Seventeen patients with stage III–IV LAHNSCC
received a loading dose unlabelled cetuximab, followed by 10 mg
54.5 MBq ± 9.6 MBq 89Zr-cetuximab. PET/CT images were acquired at
either 3 and 6, or 4 and 7 days postinjection. 89Zr-cetuximab uptake
was quantified using standardized uptake value (SUV) and tumour-to-
background ratio (TBR), and correlated to EGFR immunohistochemistry.
TBR was compared between scan days to determine optimal timing.
Results Uptake of 89Zr-cetuximab varied between patients (day 6–7:
SUVpeak range 2.5–6.2). The TBR increased significantly (49 % ± 28 %,
p< 0.01) between the first (1.1± 0.3) and second scan (1.7± 0.6). Between
groups with a low and high EGFR expression a significant difference
in SUVmean (2.1 versus 3.0) and SUVpeak (3.2 versus 4.7) was found,
however, not in TBR. Data is available at www.cancerdata.org (DOI:
10.17195/candat.2016.11.1).
Conclusion In conclusion, 89Zr-cetuximab PET imaging shows a large
interpatient variety in LAHNSCC and provides additional information over
FDG PET and EGFR expression. Validation of the predictive value is
recommended with scans acquired at 6 or 7 days postinjection.
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Introduction
Locally-advanced head and neck squamous cell carcinomas (LAHNSCC) are challeng-
ing to treat. The majority of patients presents with locally advanced cancers at the time
of diagnosis [1]. Although advances in surgery, radiotherapy and systemic therapy have
improved survival over the last decade, the prognosis remains poor [2]. Patients with
advanced locoregional disease require multimodality treatment [3]. For (function-
ally) irresectable tumours, radiotherapy is combined with concurrent cisplatin [4, 5],
or with the targeted drug cetuximab [6]. Cetuximab is a human-mouse chimeric mon-
oclonal antibody targeting the epidermal growth factor receptor (EGFR). This receptor
activates several pathways that are involved in cell proliferation and survival. The EGF
receptor is overexpressed in most LAHNSCC and is related to radio- and chemotherapy
resistance [7, 8]. Cetuximab binds to the extracellular domain of EGFR, blocks ligand
binding and, as a result, prevents receptor activation [9–12].
Radiotherapy combined with either cisplatin or cetuximab have both shown
improved treatment results over radiotherapy alone [6, 13]. However, addition of
cetuximab to chemoradiotherapy, or substituting radiotherapy combined cisplatin
by cetuximab did not show any additional benefit [14–16]. Most likely not all
patients will benefit equally from the same treatment, for example due to intertumour
heterogeneity or patient related factors, making patient tailored treatment essential.
Several measures were proposed for predicting cetuximab treatment efficacy,
including drug-induced skin rash, EGFR protein expression and EGFR gene mutations
[17, 18]. So far, the predictive value of these markers has been inconclusive. We
hypothesize that the accessibility of the cetuximab into the tumour is an important
predictive marker in the treatment efficacy [19]. In tumours lacking EGFR expression,
response to the targeted drug is unexpected regardless of accessibility, while in
tumours with an EGFR overexpression, the accessibility of the tumour is expected to
be a determining factor in drug uptake. Imaging with radioactive labelled cetuximab
could be used to non-invasively quantify the uptake of cetuximab. Ultimately, drug
uptake imaging could be applied in the clinic for pretreatment patient selection (e.g. in
combination with decision support systems [20, 21]), and treatment evaluation during
therapy.
Since antibodies such as cetuximab have a long half-life in the blood pool
(69–95 hours) radioactive labelling with the long-lived positron emitter Zirconium-89
(89Zr) was chosen (half-life of 78 hours) [22, 23]. Aerts et al. [19] proved in an animal
study that in vivo imaging of 89Zr-cetuximab is feasible and also showed a disparity
between 89Zr-cetuximab uptake and EGFR expression of the tumour cells. Moreover,
it was shown in a phase I first in human study that 89Zr-cetuximab can be safely
administered to patients [24].
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The main aims of this study were to quantify the uptake of 89Zr-cetuximab in
the tumour and involved lymph nodes in patients with LAHNSCC, and to determine
optimal timing of imaging after 89Zr-cetuximab administration. The secondary aim
was to correlate 89Zr-cetuximab uptake with EGFR expression, and metabolic activity
as determined by 18F-fluorodeoxyglucose (FDG) PET/CT scan.
Materials and methods
Patient selection and treatment protocol
Patients with previously untreated, histologically proven stage III–IV, T3–T4 squamous
cell carcinoma of the oropharynx, oral cavity or hypopharynx, were included in the
multicentre clinical ARTFORCE trial (ClinicalTrials.gov: NCT01504815). The trial was
approved by the appropriate Medical Ethics Review Committee. After giving written
informed consent, patients underwent a double randomization: 1. standard radiation
dose of 70 Gy, or dose redistribution to the primary tumour to a maximum of 84 Gy on
the FDG-avid area and a dose gradient from 70 to 64 Gy in the remainder of the primary
tumour; 2. cisplatin or cetuximab concurrently with radiotherapy. The study protocol
is described in detail by Heukelom et al. [25]. For all treatment arms, pretreatment
imaging consisted of one FDG PET/CT scan and two 89Zr-cetuximab PET/CT scans.
The 89Zr-cetuximab PET/CT scans were solely used for research purposes and did not
influence any clinical decisions.
18F-FDG PET/CT image acquisition
Pretreatment FDG PET/CT scans were acquired at least one day before 89Zr-cetuximab
administration using the standard clinical protocol following EANM guidelines [26].
All patients were scanned in treatment position: on a flat table top and immobilized
using a personalized radiotherapy mask with neck rest and with their arms by their
sides.
89Zr-cetuximab PET/CT image acquisition and analysis
Labelling of cetuximab with Zirconium-89 was performed as described by Verel
et al. [27]. Data on the quality of the labelling process can be found in the
Supplementary data. Patients first received an intravenous loading dose of unlabelled
cetuximab of 400 mg/m2, directly followed by 10 mg 89Zirconium labelled cetuximab
of 55 MBq (range: 29–62 MBq). 89Zr-cetuximab PET/CT images were acquired at 4
and 7 days postinjection (p.i.), corresponding to day -3 and day 1 of radiotherapy.
Alternatively, patients could be scanned on day 3 and 6 p.i. for logistic reasons. If
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89Zr-cetuximab PET/CT imaging and the first radiotherapy fraction were scheduled
on the same day, the PET scan was always acquired before radiotherapy. Patients
were scanned in radiotherapy treatment position wearing a personalized radiotherapy
mask on either a Philips Gemini TF 16 PET/CT scanner (Philips Healthcare, Best,
the Netherlands) or Siemens Biograph TruePoint scanner (Siemens Medical Solutions,
Erlangen, Germany). Scans were acquired with a minimum time per bed position of 3
minutes. The Philips PET images were reconstructed using an ordered-subsets time
of flight reconstruction technique (BLOB-OS-TF), with 3 iterations and 33 subsets.
The Siemens images were reconstructed with a point spread function algorithm (PSF),
with either 4 iterations and 14 subsets or 3 iterations and 21 subsets. One scan
was reconstructed using the 2D OSEM algorithm with 4 iterations and 8 subsets.
All scans were corrected for attenuation, scatter, and 89Zr decay. Images acquired
with the Philips Gemini PET/CT system were additionally smoothed with a Gaussian
filter (full width at half maximum of 7 mm) to match the noise levels of the different
scanners, as described by Makris et al. [28]. The PET/CT images are publicly available
at www.cancerdata.org [29].
Tumour delineation
Gross tumour volumes of the primary tumour (GTVprim) and involved lymph nodes
(GTVln) were delineated by an experienced radiation oncologist during the clinical
radiation treatment planning process and subsequently propagated to the different
scans for further analysis. The delineations were performed either on a dedicated
planning CT scan, or on the pretreatment FDG PET/CT scan. In case a dedicated
planning CT was acquired, the CT scan was first rigidly registered to the CT scan of
the FDG PET/CT scan after which the contours were propagated to the FDG PET/CT
scan. Thereafter, the CT images of the FDG PET/CT scan were rigidly registered to
the CT images of the 89Zr-cetuximab PET/CT scans. The tumour delineations were
copied onto the 89Zr-cetuximab scan. All registrations and propagated delineations
were visually checked and no registration difficulties were observed. The aortic arch
was contoured for assessment of unspecific background uptake of the tracer.
Quantification of PET tracer uptake
PET/CT images were analysed using in-house developed Matlab-based software
(The MathWorks Inc., Natick, MA). For the FDG PET/CT scan and 89Zr-cetuximab
PET/CT scans, tracer uptake was quantified using standardized uptake values (SUV)
normalized to body weight. The mean uptake (SUVmean), maximum uptake (SUVmax),
and peak uptake (SUVpeak) were assessed inside the delineated tumour sites. SUVpeak
is defined as the mean SUV in a 3D sphere with a diameter of 1.2 cm centred at the
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tumour location with the highest activity. For the primary tumour, the GTV was used
as region of interest. For the smaller lymph nodes, the clinical target volume (CTVln)
was used as region of interest, which consisted of an isotropic 5 mm extension of
the GTVln. SUVmax and SUVpeak were calculated for the lymph nodes. The average
uptake in the aortic arch was calculated and the tumour-to-background ratio (TBR), as
defined as the SUVpeak in the tumour divided by SUVmean of the aorta, was determined.
To determine the optimal 89Zr-cetuximab scan time point, we compared the contrast
between the tumour and background activity for the first and second scan, and
selected the time point with the highest 89Zr-cetuximab TBR.
The stability of the 89Zr-cetuximab uptake patterns were compared between the
two scans. The second scan was registered to the first scan using a rigid registration
and the GTV contours of the primary tumours were copied from the planning CT to the
first 89Zr-cetuximab scan. All registrations were visually checked and no registration
problems were observed. A voxel-based correlation between the SUV values of the two
scans was calculated.
Finally, 89Zr-cetuximab images were compared to FDG PET/CT images. The peak
89Zr-cetuximab uptake and peak FDG uptake for the primary tumour were compared.
In addition, the location of the high uptake regions on the 89Zr-cetuximab and FDG
PET/CT scans were compared. For both the first and second 89Zr-cetuximab scan,
high uptake regions were defined as the volume with a TBR above 1.2 or 1.4. Two
cutoff values were used because it is still not well defined which cutoff value best
quantifies significant 89Zr-cetuximab uptake. For the FDG PET/CT scans voxels with
a SUV above 50 % of the SUVmax were defined as high uptake region. The overlap
between the different volumes was assessed using a DICE similarity score, defined as
twice the intersecting volume divided by the sum of both volumes.
EGFR expression
For all patients a pretreatment biopsy of the primary tumour was taken, as part of
the regular diagnostic examination. Part of the tumour sample was archived in a
paraffin block and later used for EGFR expression analysis. The archived samples
were obtained from the Maastricht Pathology Tissue Collection (MPTC) and NKI-
AVL Core Facility Molecular Pathology & Biobanking (CFMPB). Collection, storage
and use of tissue and patient data were performed in agreement with the “Code for
Proper Secondary Use of Human Tissue in the Netherlands”. The EGFR expression
assessment was performed with an EGFR pharmDx qualitative immunohistochemical
kit, consisting of two antibodies (Novocastra and Dako, Denmark). All samples were
analysed on the same day in the same lab. EGFR staining intensity was analysed
using a light microscope. The percentages of cells with weak, moderate and strong
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membranous EGFR staining were scored. An EGFR immunohistochemistry (IHC)
score, between 0–300, was calculated according to the formula: EGFR IHC score = 1 ×
% cells weak staining + 2 ×% cells moderate staining + 3 ×% cells strong staining [30].
Tumours with an IHC score < 200 were classified as low EGFR expression; tumours
with an IHC score ≥ 200 as high EGFR expression. This division was based on results
of the FLEX study [31]. The EGFR expression was correlated to the 89Zr-cetuximab
imaging parameters. The EGFR low and EGFR high expression group were compared.
Statistics
To evaluate the optimal time point for 89Zr-cetuximab imaging, the TBR of the primary
tumour on the first and second scan were compared using a paired student t-test. The
Pearson correlation coefficient was used to calculate the correlation between the 89Zr-
cetuximab TBR in the primary tumour and lymph nodes, to determine the spatial
stability between the two 89Zr-cetuximab scans, and to determine the correlation
between 89Zr-cetuximab and FDG peak uptake in the primary tumour. A Mann-
Whitney U exact test was used to assess the 89Zr-cetuximab parameters between the
EGFR high and low uptake groups. Results are presented as mean ± one standard
deviation and p-values < 0.05 were considered statistically significant.
Results
The first 17 patients (12 males, 5 females; age range: 45–68 years) enrolled in
the ARTFORCE study received 89Zr-cetuximab imaging and were analysed. After
a minimum follow-up of two years, three patients presented with a locoregional
recurrence and three patients developed metastases. (Supplementary Table S3.1).
Average primary tumour volume was 41.7 cm3 ± 24.7 cm3. Sixteen of the seventeen
patients had regional lymph nodes metastases. Fifteen patients had 89Zr-cetuximab
scans at two time points available for analysis. For two patients only the scan at the
second time point could be used. One of those patients refused a scan and for the
other patient a scan was excluded from analysis because the aortic arch was not in the
field of view. Those two patients were excluded for the optimal timing and temporal
stability analysis; the data was used for the other analyses. All patients underwent
pretreatment FDG PET/CT scan. The patient and tumour characteristics are listed in
Table 3.1.
Quantitative PET analysis showed a large interpatient variety of tracer uptake. For
the first scan the SUVpeak ranged from 2.5–6.2 between patients, SUVmax from 2.8–7.9,
SUVmean from 1.8–4.0 and TBR from 0.7–2.1. For the second scan the SUVpeak ranged
from 2.5–6.2, SUVmax from 2.9–7.7, SUVmean from 1.6–3.9 and, TBR from 1.0–2.6.
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Table 3.1. Patient characteristics.
Tumour stage
Patient Age Sex tumour site
Primary
T N M staging
TNM group
volume (cm3)
Primary tumour
(p16)
HPV status
score
EGFR IHC
1 61 M Oropharynx T3 N1 M0 III 20 + 270
2 65 M Oral cavity T4 N1 M0 IV 54 NA 210
3 55 M Oropharynx T4 N2b M0 IV 53 - 184
4 56 F Oropharynx T3 N2b M0 IV 11 + 207
5 66 F Oropharynx T4b N2b M0 III 30 - 245
6 45 M Oral cavity T4a N2c M0 II 98 NA 210
7 62 M Oropharynx T3 N3 M0 IV 44 + 80
8 57 M Oropharynx T3 N0 M0 III 20 - 235
9 68 M Hypopharynx T4 N2b M0 IV 41 NA 1
10 63 M Oropharynx T4 N2c M0 IV 42 + 10
11 64 M Oral cavity T4 N2b M0 IV 78 NA 70
12 60 F Oral cavity T4 N1 M0 IV 21 NA 212
13 50 M Oral cavity T4 N2b M0 IV 76 NA 200
14 55 F Oropharynx T4 N1 M0 IV 51 + 180
15 68 F Oropharynx T3 N2c M0 IV 30 + 225
16 55 M Oropharynx T3 N2b M0 IV 10 - 5
17 67 M Hypopharynx T3 N2c M0 IV 29 NA 285
Abbreviations: M = male, F = female, NA = not assessed. HPV status was assessed with p16 immunohistochemistry.
Table 3.2. 89Zr-cetuximab uptake on scan 1 and 2, the difference of scan 2 compared to scan 1,
and FDG PET uptake.
scan 1
89Zr-cetuximab
scan 2
89Zr-cetuximab
89Zr-cetuximab (%)
Difference
FDG
Primary tumour SUVpeak 4.1±1.2 4.0±1.2 −1.3±9.4 14.3±6.9
SUVmax 5.0±1.8 4.9±1.6 1.5±12.1 17.6±7.8
SUVmean 2.6±0.7 2.6±0.7 −0.6±11.9 6.4±2.8
TBR 1.2±0.4 1.7±0.6 49.1±28.1
Lymph nodes SUVpeak 3.4±1.0 3.4±1.2 −7.6±12.9 8.3±5.2
SUVmax 4.1±1.2 4.1±1.6 −3.5±12.7 10.9±5.6
TBR 0.9±0.2 1.4±0.5 43.3±35.0
Aortic Arch SUVmean 3.6±0.9 2.5±0.9 −31.7±13.4
Average SUVpeak, SUVmax, SUVmean, and TBR values for the primary tumour and the
lymph nodes, for the first and second 89Zr-cetuximab PET/CT scan are shown in Table
3.2. The imaging features for the individual patients are shown in Supplementary
Table S3.1 for the primary tumour, and in Supplementary Table S3.2 for the lymph
nodes. The 89Zr-cetuximab TBR in the primary tumour was for all patients higher
on the second scan compared to the first scan. The TBR increased on average with
49 % ± 28 % (p < 0.01), indicating an improved imaging quantification profile at the
later time points. The two 89Zr-cetuximab scans of an example patient are shown in
Figure 3.1. In Figure 3.2 the TBR is plotted as function of the number of days after
89Zr-cetuximab administration for the individual patients.
In patients with a high 89Zr-cetuximab uptake in the primary tumour, in general
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Figure 3.1. PET maximum intensity projections (MIP) (top row) and fused PET/CT images
showing PET uptake in SUV (bottom row) of the two 89Zr-cetuximab scans and the FDG PET/CT
(patient 6). The GTV for the primary tumour is depicted in blue; the CTV for the lymph nodes in
cyan. Only the largest lymph node is displayed in the MIP.
also an elevated maximum uptake in the lymph nodes was observed, as shown in
Supplementary Figure S3.1. For the second scan a strong, significant correlation was
found between the TBR in the lymph nodes and primary tumour (r = 0.76, p < 0.01).
The voxel-based comparison between the two 89Zr-cetuximab uptake patterns,
showed correlation coefficients ranging from 0.18–0.86, see Supplementary Table S3.1.
The patients with a low 89Zr-cetuximab uptake (TBR< 1.2) had correlation coefficients
of 0.18, 0.20 and 0.66. Excluding these patients with low uptake levels, resulted for the
remaining 13 patients in an average spatial correlation of 0.68 ± 0.11 between the two
scans.
In Figure 3.1 (C and F) FDG PET/CT scan is displayed. No correlation was found
between the FDG SUVpeak and
89Zr-cetuximab SUVpeak in the primary tumour, for the
first (r = 0.11, p = 0.69) or second 89Zr-cetuximab PET/CT scan (r = 0.46, p = 0.07).
Comparison of the high spatial uptake regions showed only minor overlap between
high 89Zr-cetuximab uptake regions (TBR > 1.2 or 1.4) and high FDG uptake regions
(> 50 % of SUVmax). The volumes of the high uptake regions and DICE scores are shown
in Table 3.3.
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Figure 3.2. The tumour-to-background ratio (TBR) of 89Zr-cetuximab in the primary tumour
(left), and the maximum TBR in the lymph nodes (right) plotted as a function of the number of
days between 89Zr-cetuximab administration and PET/CT imaging. The bars depict the mean
uptake for the individual scan points. Each patient is depicted with a different colour. Two
patients (white marks) were only scanned on one day.
Table 3.3. Volumes of high uptake regions of 89Zr-cetuximab and FDG PET. Overlap comparison
between high 89Zr-cetuximab and high FDG PET uptake regions using the DICE similarity
coefficient.
89Zr-cetuximab scan 1 89Zr-cetuximab scan 2
TBR > 1.2
89Zr-cetux
TBR > 1.4
89Zr-cetux
SUVmax
FDG > 50%
TBR > 1.2
89Zr-cetux
TBR > 1.4
89Zr-cetux
SUVmax
FDG > 50%
Volume (cm3) 20.7 ± 6.4 7.2 ± 6.6 28.4 ± 11.4 21.7 ± 4.7 6.6 ± 4.3 28.3 ± 11.5
DICE 0.4 ± 0.2 0.2 ± 0.2 0.4 ± 0.1 0.2 ± 0.1
The EGFR IHC scores showed seven tumours (41 %) with a low EGFR expression,
IHC < 200, (IHC: 76 ± 79) and ten tumours (59 %) with a high expression, IHC ≥ 200,
(IHC: 230 ± 29). Based on the second 89Zr-cetuximab PET/CT scan, the SUVmean was
2.1 ± 0.5 and 3.0 ± 0.6 for the low and high EGFR expressing group respectively. The
SUVpeak was 3.2 ± 0.6 and 4.7 ± 1.1 respectively, the TBRmean 1.0 ± 0.3 and 1.2 ± 0.3,
and the TBRpeak 1.6 ± 0.6 and 1.8 ± 0.5, where TBRmean and TBRpeak are the SUVmean
and SUVpeak divided by the background uptake. The SUVmean (p < 0.01) and SUVpeak
(p < 0.01) were significantly different between the low and high EGFR expression
groups, however for the TBRmean (p = 0.315) and TBRpeak (p = 0.417) no statistical
significance was observed. In the group with a low EGFR expression, three out of seven
(42 %) patients had a high 89Zr-cetuximab TBR (TBRpeak > 1.4); in the group with high
EGFR expression seven out of ten (70 %) patients had high uptake (TBRpeak > 1.4). In
Figure 3.3 the PET parameters as a function of EGFR IHC scores are shown.
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Figure 3.3. Correlation between the EGFR immunohistochemistry (IHC) score and the 89Zr-
cetuximab peak and mean TBR, and peak and mean SUV in the primary tumour. The PET
parameters are calculated for the second 89Zr-cetuximab scan (6 or 7 days postinjection). An
EGFR IHC score ≥ 200 (dashed line) is classified as high EGFR expression, an IHC score < 200 as
low EGFR expression.
Discussion
This study analysed 89Zr-cetuximab PET/CT imaging at two time points before
radiotherapy treatment, to determine the optimal timing of 89Zr-cetuximab imaging,
the spatial stability of the 89Zr-cetuximab uptake patterns, and the uptake in the
primary tumour compared to the lymph nodes to allow future use in treatment
selection. Furthermore, 89Zr-cetuximab uptake was compared with EGFR expression
and metabolic activity as determined by FDG PET/CT.
The later 89Zr-cetuximab imaging time points were associated with increased
tumour-to-background ratios in all patients, therefore, imaging at 6 or 7 days
postinjection is recommended for future studies. This is in agreement with the results
in advanced colorectal cancer [32], where also 6 days postinjection was described as
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optimal imaging time point. The imaging time point did not influence the average
peak or maximum uptake; the improvement in TBR between the time points is due
to a decrease in background activity, see Supplementary Table S3.3. The voxel-based
comparison between the two 89Zr-cetuximab scans showed that there is a correlation
for patients with sufficient uptake of the tracer. The correlation is moderate however,
indicating that there is a minor change in spatial uptake patterns over time.
As anticipated, a large variation in 89Zr-cetuximab uptake was found between
patients. The TBR on the second scan ranged from the background level (TBR
around 1.0) to a TBR of 2.6 times the background level. This interpatient variety
could possibly be exploited and used to select tumours that can be targeted by
the monoclonal antibody to ultimately predict treatment outcome. However, more
research is required to determine which of the calculated measures (SUVmean, SUVpeak,
SUVmax, TBR) best reflects the accessibility of the drug to the tumour. To be able to
use 89Zr-cetuximab PET/CT imaging for patient selection, the antibody uptake should
be related to treatment outcome and an appropriate measure for differentiating the
responders and non-responders should be determined. The studied group of patients
was unfortunately too small and the received treatments too heterogeneous to link
treatment outcome to 89Zr-cetuximab uptake. A sample of more than 17 patients is
needed to define such a measure.
The exploratory analysis comparing high uptake regions on the 89Zr-cetuximab
PET/CT images with the high uptake regions on FDG images revealed only minor
overlap (DICE < 0.6 for TBR > 1.2). A correlation between the two tracers
could be hypothesized given that EGFR influences proliferation and thereby glucose
metabolism. However, many factors other than EGFR expression contribute to a
difference in metabolism. Studies linking proliferation to FDG uptake have shown
conflicting results [33, 34].
A significant difference in 89Zr-cetuximab SUV was found between the groups with
a high and a low EGFR expression. The tumours with a high expression had on average
a higher 89Zr-cetuximab SUVmean and SUVpeak. However, when we compared the TBR
between the two groups, no significant difference was observed. In tumours lacking
EGFR expression, response to the targeted drug was unexpected, while in tumours
with an EGFR overexpression, the accessibility of the tumour was hypothesized to be
a determining factor in drug uptake. As expected, in the tumours with high EGFR
expression a mix of low and high 89Zr-cetuximab uptake was observed. Remarkably,
high 89Zr-cetuximab PET uptake was also observed in the low EGFR expression
group. The patient with the lowest EGFR IHC score had the overall highest 89Zr-
cetuximab TBR. A limitation of this kind of analysis and a possible explanation
for this remarkable result is the fact that EGFR expression was only determined for
one sample which might not represent the whole tumour [35]. In contrast to a
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single biopsy, 89Zr-cetuximab imaging can give a 3D uptake pattern of the entire
tumour. Another limitation of a single biopsy is the questionable reproducibility of
EGFR staining. Interobserver variability, differences in tissue fixation techniques, and
increased storage time of the samples could negatively influence reproducibility. For
example, Chung et al. [36] found that cetuximab shows activity in tumours that do not
express EGFR and concluded that EGFR determined by immunohistochemistry might
not reflect the tumour biology.
A high correlation was observed between the 89Zr-cetuximab uptake in the primary
tumour and the lymph nodes. This might indicate that uptake of the drug is
mainly determined by intrinsic characteristics of the tumour cells. Interestingly, the
Bonner trial [6] showed in an exploratory subgroup analysis an increased benefit for
addition of cetuximab to radiotherapy over radiotherapy alone for patients with nodal
involvement, while there was no benefit for patients without nodal involvement. Our
data shows that a patient with uptake of cetuximab in the primary tumour will most
likely also have cetuximab accumulating in the lymph nodes.
A limitation of this study is the use of different PET scan settings, e.g. voxel
size, slice thickness, scan time, and various PET reconstructions algorithms. This
complicates quantitative analysis and comparison between patients. After inclusion
of the first patients in this study, Makris et al. [28] published work highlighting the
importance of harmonization of scan protocols. These suggested scan protocols were
adopted. Thereafter, their recommendations regarding image analysis were followed
to improve the conformity between scans. For example, scans acquired on a Philips
scanner were additionally smoothed and SUVpeak was used as measure of tracer
uptake since this parameter is less susceptible to noise.
Other factors that could have influenced the imaging results are the cold loading
dose and the extra margin for the lymph nodes. A loading dose was used to prevent all
labelled antibody going to the liver. As a proof of principle, it was shown before that
without a loading dose less than 10 % of the injected 89Zr-cetuximab dose was available
in the blood, while after a loading dose of 500 mg/m2 80 % of the injected tracer
was detected in the blood and available for tumour targeting [32]. For this study the
recommended therapeutic dose of cetuximab (400 mg/m2) was used as a loading dose
to best represent the clinical situation and to visualize how much cetuximab would
reach the tumour during treatment. For the lymph nodes, we decided to use the CTV
as region of interest. This additional margin, that was added to compensate for small
registration uncertainties, would influence the SUVmean of the region. Therefore, only
the SUVmax and SUVpeak were calculated for the lymph nodes. Smaller lymph nodes
might suffer from underestimation of the uptake due to partial volume effects.
The ARTFORCE trial was designed to select the most effective treatment, cisplatin
or cetuximab, for individual patients. The original design consisted of four treatment
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arms (two with cisplatin and two with cetuximab). All treatment arms were preceded
by an 89Zr-cetuximab pretreatment imaging step which was solely used for research
purposes. The use of a long-lived positron emitter complicated procedures for the
radiotherapy departments, patients were confronted with an extra radiation burden
(0.61 mSv/MBq [37]) and additional guidelines had to be followed by the patient during
two weeks after injection to limit radiation exposure to others. The resulting slow
accrual in combination with discontinuation of the funding of cetuximab resulted
in an amendment of the trial excluding 89Zr-cetuximab PET/CT imaging and the
cetuximab treatment arms. The imaging results of all patients undergoing the 89Zr-
cetuximab PET/CT imaging were presented in this study.
In conclusion, the PET tracer 89Zr-cetuximab showed a large variation in 89Zr-
cetuximab tumour-to-background ratio between patients. This interpatient variety
could possibly be exploited and used to select tumours that can be targeted by
the monoclonal antibody to ultimately predict treatment outcome. 89Zr-cetuximab
imaging provides additional information about the accessibility of the drug into the
tumour which is not provided by FDG PET or EGFR expression. Validation of the
predictive value is recommended with scans acquired 6 to 7 days postinjection to
obtain high tumour-to-background uptake levels. For future studies a trial design
should be chosen that incentivizes patients to participate, e.g. by linking research and
therapeutic consequences.
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Supplementary data
Labelling of 89Zr-cetuximab
89Zr-cetuximab is produced in compliance with the current Good Manufacturing
Practice at the VU University Medical Center. The radiochemical purity was measured
by TLC and SEC-HPLC and was 98.4 % ± 0.4 % and 98.5 % ± 1.4 %, relatively. The
mean immunoreactive fraction was 96.6 % ± 2.3 %. The filter integrity was on average
3.7 bar ± 0.5 bar. The edotoxin content was for each batch smaller than 0.3 EU/ml.
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Figure S3.1. Correlation between the 89Zr-cetuximab tumour-to-background ratio in the
primary tumour and the maximum TBR of the involved lymph nodes for scan 1 (r = 0.446,
p = 0.095) and scan 2 (r = 0.764, p < 0.01).
Table S3.1. Imaging characteristics for the 89Zr-cetuximab scans and FDG PET/CT scan for the primary tumour. Treatment characteristics and treatment outcome are
also presented.
FDG PET/CT 89Zr-cetuximab PET/CT scan 1 89Zr-cetuximab PET/CT scan 2 scans
89Zr-cetuximab
Correlation
Treatment # arm recurrence
Locoregional
Metastasis
Patient SUVpeak SUVmax SUVmean Day SUVpeak SUVmax SUVmean TBR Day SUVpeak SUVmax SUVmean TBR r
1 16.4 20.9 7.7 NA NA NA NA NA 7 5.5 7.7 2.7 2.2 NA Cetuximab 0 0
2 15.0 17.1 7.8 4 2.7 2.9 2.1 1.1 7 2.9 3.2 2.0 1.9 0.76 Cetuximab 0 0
3 8.6 10.9 4.3 4 4.7 6.8 2.3 1.9 7 4.2 5.7 2.2 2.4 0.53 Cetuximab 0 0
4 12.0 15.2 6.8 3 6.2 7.9 4.0 1.4 6 6.2 7.5 3.9 2.3 0.86 Cisplatin 0 0
5 8.6 9.7 4.7 4 4.1 5.6 2.5 1.0 7 4.5 6.8 3.0 1.1 0.18 Cisplatin 0 0
6 19.1 22.0 8.8 3 5.7 6.5 3.8 1.2 6 5.4 7.0 3.6 2.3 0.60 Cisplatin 0 1
7 8.4 10.9 3.0 3 2.5 2.8 1.8 0.8 6 2.5 2.9 1.7 1.2 0.50 Cisplatin 0 0
8 13.6 16.5 6.6 3 3.2 3.5 2.5 0.9 6 3.3 3.7 2.6 1.4 0.73 Cetuximab 1 0
9 11.9 16.0 5.5 4 3.1 3.4 1.9 1.3 7 2.7 3.2 1.6 2.6 0.68 Cetuximab 1 0
10 12.0 13.2 5.9 3 3.5 3.8 2.7 0.7 6 3.8 4.1 3.0 1.0 0.66 Cetuximab 0 0
11 9.8 13.4 3.0 4 3.7 4.5 2.0 1.1 7 3.0 3.6 1.9 1.5 0.75 Cetuximab 0 0
12 17.3 21.3 9.1 3 4.4 5.2 3.0 0.9 6 4.3 5.2 2.8 1.3 0.78 Cetuximab 1 1
13 37.9 44.2 14.3 NA NA NA NA NA 7 5.7 6.5 3.4 2.6 NA Cisplatin 0 1
14 12.2 18.1 2.9 4 3.1 3.7 2.0 1.0 7 2.9 3.7 1.8 1.4 0.61 Cisplatin 0 0
15 16.7 19.9 7.5 4 4.2 4.7 2.9 1.2 7 4.2 4.9 2.8 1.7 0.63 Cisplatin 0 0
16 12.1 14.9 5.2 4 2.8 3.4 2.0 0.7 7 3.3 4.0 2.5 1.2 0.20 Cisplatin 0 0
17 11.5 14.5 6.1 4 6.2 7.6 3.5 1.5 7 5.6 6.6 3.1 1.5 0.80 Cisplatin 0 0
Abbreviations: SUV = standardized uptake value; TBR = tumour-to-background ratio; NA = not acquired. For patient 1 and 13 only the second scan was available for analysis.
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Table S3.2. Imaging characteristics for the 89Zr-cetuximab scans and FDG PET/CT scan for the
lymph nodes.
FDG PET/CT 89Zr-cetuximab PET/CT scan 1 89Zr-cetuximab PET/CT scan 2
Patient SUVpeak SUVmax Day SUVpeak SUVmax TBR Day SUVpeak SUVmax TBR
1 4.5 8.5 NA NA NA NA 7 2.4 3.7 0.9
2 4.0 7.3 4 2.1 2.3 0.9 7 1.8 1.9 1.1
3 3.7 5.3 4 2.3 3.1 1.0 7 1.8 2.5 1.0
4 18.9 21.4 3 5.0 5.5 1.1 6 5.4 5.7 2.0
5 8.3 10.9 4 4.1 5.6 1.0 7 4.4 6.5 1.1
6 18.6 20.9 3 5.2 6.4 1.1 6 5.0 6.7 2.2
7 5.5 7.1 3 2.6 2.9 0.8 6 2.1 2.4 1.0
8 - - - - - - - - - -
9 9.1 12.6 4 2.7 3.0 1.1 7 2.7 3.4 2.6
10 6.2 7.7 3 3.3 3.9 0.7 6 3.3 3.8 0.8
11 3.5 5.1 4 2.6 3.1 0.8 7 2.4 2.7 1.2
12 7.9 11.4 3 3.5 4.2 0.8 6 3.3 4.0 1.0
13 13.5 17.2 NA NA NA NA 7 4.5 5.2 2.1
14 2.4 3.2 4 3.0 3.4 1.0 7 2.9 3.4 1.4
15 4.6 6.1 4 3.4 3.8 1.0 7 2.7 2.9 1.1
16 10.3 14.1 4 4.0 4.5 0.9 7 3.7 4.3 1.3
17 12.0 15.0 4 4.8 5.7 1.2 7 5.1 6.3 1.4
Abbreviations: SUV = standardized uptake value; TBR = tumour-to-background ratio; NA = not acquired. For
patient 1 and 13 only the second scan was available for analysis. Patient 8 did not have involved lymph nodes.
Table S3.3. Comparison of the mean uptake in the normal tissues (aorta and trapezius muscle),
and in the primary tumour for the two 89Zr-cetuximab PET/CT scans. The SUVpeak of the
tumour is compared to the uptake in the aorta, to calculate the tumour-to-background ratio
(TBR), and compared to the uptake in the trapezius, to calculate the tumour-to-muscle ratio
(TMR).
89Zr-cetuximab PET/CT scan 1 89Zr-cetuximab PET/CT scan 2
Patient aorta
SUVmean
trapezius
SUVmean
aorta
TBR
trapezius
TMR
tumour
SUVpeak
aorta
SUVmean
trapezius
SUVmean
aorta
TBR
trapezius
TMR
tumour
SUVpeak
1 NA NA NA NA NA 2.5 0.3 2.1 15.9 5.5
2 2.5 0.4 1.1 6.4 2.7 1.6 0.4 1.9 7.4 2.9
3 2.4 0.3 1.9 15.2 4.7 1.8 0.2 2.4 18.7 4.2
4 4.5 0.4 1.4 13.9 6.2 2.7 0.4 2.3 15.8 6.2
5 4.1 0.6 1.0 7.1 4.1 4.0 0.7 1.1 6.3 4.5
6 4.7 0.4 1.2 14.2 5.7 2.3 0.4 2.3 12.4 5.4
7 3.2 0.3 0.8 8.1 2.5 2.1 0.2 1.2 12.1 2.5
8 3.4 0.3 0.9 9.6 3.2 2.4 0.3 1.4 11.3 3.3
9 2.4 0.3 1.3 10.6 3.1 1.1 0.2 2.6 11.6 2.7
10 5.0 0.4 0.7 9.0 3.4 4.0 0.4 1.0 9.9 3.8
11 3.4 0.4 1.1 9.9 3.7 2.0 0.4 1.5 7.3 3.0
12 4.7 0.6 0.9 7.8 4.4 3.3 0.6 1.3 6.6 4.3
13 NA NA NA NA NA 2.2 0.2 2.6 25.5 5.7
14 3.1 0.6 1.0 5.1 3.1 2.1 0.5 1.4 5.5 2.9
15 3.5 0.4 1.2 11.6 4.2 2.4 0.4 1.7 11.8 4.2
16 4.3 0.5 0.7 5.9 2.8 2.8 0.5 1.2 6.0 3.3
27 4.1 0.6 1.5 9.9 6.2 3.7 0.8 1.5 6.8 5.6
Mean 3.7 0.4 1.1 9.6 4.0 2.5 0.4 1.7 11.2 4.1
Stdev 0.9 0.1 0.3 3.1 1.2 0.8 0.2 0.6 5.4 1.2
Abbreviations: SUV = standardized uptake value; TBR = tumour-to-background ratio; TMR = tumour-to-muscle ratio; NA = not
acquired. For patient 1 and 13 only the second scan was available for analysis.
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Abstract
Background Nitroglycerin, a vasodilating drug, is a potential candidate
for targeting treatment resistant hypoxic tumour regions. It has been
hypothesized that nitroglycerin reduces tumour hypoxia and improves
perfusion, however, trials examining the added benefit of nitroglycerin to
(chemo)radiotherapy have been inconclusive. A window-of-opportunity
trial (NCT01210378) was designed to study the effect of nitroglycerin on
hypoxia and tumour vasculature in non-small cell lung cancer (NSCLC)
patients, and to study the potential of functional imaging for patient
selection.
Material and methods Stage IB–IV NSCLC patients treated with curative
intent using (chemo)radiotherapy, received a hypoxia HX4 PET/CT and
a dynamic contrast-enhanced CT (DCE-CT) scan at baseline and after
applying a transdermal nitroglycerin patch (Transiderm Nitro 5 mg).
Patients were stratified based on hypoxia levels (TBR > 1.2), median
tumour blood flow (BF), and blood volume (BV). Differences in
overall survival (OS), locoregional progression-free survival (LRPFS) and
metastasis-free survival (MFS) were assessed using Kaplan Meier curves
and log-rank tests. The survival of patients with a nitroglycerin related
reduction in hypoxia was assessed separately.
Results Hypoxia HX4 PET/CT scans were acquired at baseline and after
nitroglycerin administration for 32 and 25 patients, respectively; DCE-
CT images were acquired for 22 and 13 patients at these time points.
At baseline, significant differences between hypoxic and non-hypoxic
tumours were found for OS (two-year OS: 47 % vs 100 %; p = 0.029) and
MFS (two-year MFS: 52 % vs 100 %; p = 0.045), but not for LRPFS. DCE-CT
derived parameters, at baseline or with nitroglycerin, could not be related
to survival. Four patients showed a significant reduction in hypoxia in the
primary tumour or lymph nodes after nitroglycerin administration. None
of these four patients experienced locoregional failure.
Conclusion Tumour hypoxia assessed with HX4 PET is a prognostic
biomarker for survival, in contrast to DCE-CT or FDG PET. Patients with
hypoxic tumours at baseline had a worse OS compared to non-hypoxic
tumours. The limited number of patients with a reduction in hypoxia,
restricted the validation of predictive imaging biomarkers for nitroglycerin
in this trial.
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Introduction
Tumour hypoxia is an independent negative prognostic factor in most solid cancers.
The poorly regulated neovascularisation in tumours results in underdeveloped leaky
vessels, with a highly irregular infrastructure, resulting in regions with low levels
of oxygenation (i.e. hypoxia) [1]. These hypoxic regions are more resistant to both
chemotherapy and radiotherapy [2]. The lack of oxygen reduces the efficiency of the
DNA damage caused by radiotherapy, and the poor vasculature limits the distribution
of chemotherapy [3]. Furthermore, the hypoxic microenvironment promotes a more
aggressive, metastasis-prone phenotype [4, 5]. All these factors combined, highlight
the potential of hypoxia as a target for anticancer therapy.
Nitric oxide-donating drugs, such as nitroglycerin, are an example of drugs that
have the potential to target hypoxia. Nitroglycerin is a commonly used vasodilator to
treat cardiac diseases such as angina pectoris or heart failure. In addition to the well-
known cardiac effects, it also stimulates processes that may reduce tumour hypoxia.
Nitroglycerin increases tumour blood flow, normalizes blood viscosity, stabilizes p53
and reduces hypoxia-inducible factor-1α (HIF-1α) levels [6–8].
Several clinical trials have been conducted examining the added clinical benefit
of nitroglycerin. Yasuda et al. showed a significant survival benefit for adding
nitroglycerin to chemotherapy in a randomized phase II trial [9]. However, several
other trials examining the combination of chemotherapy with nitroglycerin, including
a large randomized multicentre phase II trial and a phase III trial, could not confirm
these results [10–12]. For chemoradiotherapy combined with nitroglycerin, response
and survival rates comparable to the standard arms of recent randomized trials on
chemoradiation were found [13].
One major limitation of these clinical trials is the lack of patient selection;
none of the patients were screened for tumour hypoxia before inclusion. Since
nitroglycerin is hypothesized to mainly target hypoxia, trials without hypoxia based
patient stratification might not show its full potential [14].
We designed a window-of-opportunity trial to test the possibility to preselect
non-small cell lung cancer (NSCLC) patients that would most likely benefit from the
addition of nitroglycerin to radiotherapy. We hypothesized that tumour hypoxia,
acquired with HX4 PET/CT, and tumour vasculature, assessed with dynamic contrast-
enhanced CT (DCE-CT), are two important prognostic and possibly predictive factors
for the benefit of nitroglycerin addition. In this study we analysed the prognostic value
of hypoxia HX4 PET and DCE-CT imaging at baseline. So far, several studies have
shown that nitroimidazole-based hypoxia PET tracers are prognostic for survival in
NSCLC patients [15–18]. The prognostic value of the newer nitroimidazole hypoxia
PET tracer HX4 [19–21] however, has not yet been assessed. Additionally, we assessed
78 Chapter 4
the effect of the nitroglycerin patch on hypoxia and tumour perfusion by comparing
the baseline and nitroglycerin scans. The changes in imaging parameters between the
two time points are explored as a potential predictive marker.
Materials and Methods
Patient selection and treatment
Stage IB–IV NSCLC patients, receiving radiotherapy with curative intent and with
a WHO performance status 0–2, were eligible for the prospective nitroglycerin
trial (NCT01210378). Patients with recent severe cardiac disease, symptomatic
hypotension, or poor renal function, were not eligible. The trial allowed inclusion
of patients treated with radical radiotherapy, with or without standard chemotherapy
(platinum doublet chemotherapy combined either with etoposide or vinorelbin).
During the course of the trial, several standard radiotherapy regimens were used
at Maastro clinic. Patients treated with stereotactic radiotherapy were treated with
8 fractions of 7.5 Gy delivered 3 days per week with a minimum interfraction
interval of 48 hours. Patients treated without chemotherapy or with sequential
chemoradiotherapy were treated using our individualized accelerated radiotherapy
(INDAR) using twice daily fractions of 1.8 Gy per fraction up to an individual total
tumour dose (TTD) limited by the dose constraints of the organs at risk (OAR). In
concurrent chemoradiation, patients were treated with a different INDAR schedule
consisting of 30 fractions of 1.5 Gy delivered twice daily, followed by an individually
variable number of fractions of 2 Gy delivered once daily up to a TTD determined by
the OAR constraints. Both INDAR schedules have been described in detail [22, 23]. The
last patient included in the trial was treated concurrently with chemotherapy using
30 fractions of 2 Gy because the INDAR approach was abandoned shortly before his
inclusion. Patient characteristics and treatment schedules are listed in Table 4.1.
In addition to the standard (chemo)radiotherapy, patients were asked to apply a
transdermal nitroglycerin patch (Transiderm Nitro 5 mg, Novartis), throughout the
course of radiotherapy, for 12 hours per day. These patches release 0.2 mg nitroglycerin
per hour and contain 25 mg/10 cm2. The trial was approved by the Medical Ethics
Review Committee and all patients gave written informed consent.
Hypoxia and DCE-CT image acquisition and image processing
The imaging protocol consisted of two sets of HX4 PET/CT and DCE-CT images taken
before the start of radiotherapy: one set without a nitroglycerin patch (baseline) and
one with the patch (nitroglycerin scan). The second set of scans was scheduled at least
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Table 4.1. Patient characteristics of the 34 analysed patients.
Patients 34
Gender Male 21
Female 13
Age (mean and range in years) 63 (40–82)
GTV (median and range in cm3) Tumour 23 (1–477)
Nodes 19 (2–251)
Total 64 (6–497)
WHO-PS 0 6
1 28
Treatment Radiotherapy 4
Stereotactic radiotherapy 2
Sequential chemoradiation 1
Concurrent chemoradiation 25
Radiotherapy with neoadjuvant chemotherapy 2
Radiotherapy schedules 60 Gy/2Gy/QD 1
60 Gy/7.5 Gy/3 fractions per week 2
INDAR:1.8 Gy/BID 8
INDAR: 1.5 Gy/BID + 2Gy/QD 23
TNM (T) TX 1
T2 10
T3 10
T4 13
TNM (N) N0 7
N1 1
N2 15
N3 11
TNM (M) M0 24
M1 10
Pathology Adenocarcinoma 12
Squamous cell carcinoma 9
Large-cell carcinoma 6
NSCLC NOS 7
Abbreviations: GTV = gross tumour volume, WHO-PS = World Health Organisation performance
status, INDAR = individualized isotoxic accelerated radiotherapy, BID = twice-daily, NOS = not
otherwise specified.
48 hours after baseline imaging, with the nitroglycerin patch applied at least one hour
before the scan.
Hypoxia HX4 PET/CT scans were acquired according to a previously described
protocol [24]. The scans were acquired 4 hours after injecting 413 MBq ± 80 MBq
HX4 PET tracer for the first scan or 444 MBq ± 27 MBq HX4 PET tracer for the
second scan. The scans were acquired on a Gemini TF64 PET/CT (Philips, Best, the
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Netherlands), in treatment position, on a flat table top, with arm and knee supports.
The PET images were attenuation corrected, using a low-dose CT scan, and corrected
for scatter and random coincidences. A BLOB-OS-TF algorithm (3 iterations and 33
subsets) was applied to reconstruct images of 4 by 4 mm with a slice thickness of
4 mm. The measured uptake was corrected for body weight, injected dose, and decay
to calculate the standardized uptake value (SUV). Tumour-to-background ratios (TBR)
were calculated by dividing the SUV in the tumour by the average SUV in the aortic
arch. The hypoxic volume (HV), in cm3, was determined by summing the volume of
voxels in the tumour with a TBR > 1.2. The fraction of HV (FHV) was calculated by
dividing the HV by its respective tumour volume.
The DCE-CT imaging protocol was described previously [25]. In short,
33 consecutive 80 kVp CT scans were acquired every 1.5 seconds after injecting 60
or 65 ml (7 ml/s) iodine-based contrast material (Iopromide 300, Bayer Healthcare,
Berlin, Germany). The contrast material was followed by a saline chaser of 30 or 40 ml
(7 ml/s). Images were acquired in treatment position on a second or third generation
dual source CT scanner (SOMATOM Definition Flash or SOMATOM Force, Siemens
Healthcare, Erlangen, Germany), and reconstructed using a B20f filter on 0.8× 0.8 mm
voxels with a slice thickness of 5 mm and slice increment of 3 mm. Patients were asked
to perform expiration breath hold and continue shallow breathing if breath hold could
not be maintained. The Siemens noise reduction was applied. To compensate for any
movement, all CT scans were registered to the first CT frame [26]. The aortic arch was
delineated to calculate the aortic input function. A deconvolution algorithm was used
for kinetic modelling to create parametric maps of blood volume (BV), in ml/100 ml,
and blood flow (BF), in ml/100 ml/min (syngo MMWP, version VE40A, Siemens).
The mean tumour BF and BV were calculated for each patient. DCE-CT scans with
incorrect timing, either acquired too early or too late after contrast administration,
missing a part of the uptake curve in the tumour or aorta, were omitted.
Radiotherapy planning and tumour delineation
The majority of patients received a 4D FDG PET/CT on a Siemens Biograph 40
PET/CT scanner (Siemens Healthcare, Erlangen, Germany) one hour after injection
of FDG, for radiotherapy treatment planning purposes. The PET scan was attenuation
corrected using the midventilation phase of the CT image and corrected for scatter
and random coincidences. For two patients, treatment planning was performed
on a dedicated CT scan (Sensation Open, Siemens Healthcare, Erlangen, Germany).
Delineation of the primary gross tumour volume (GTVprim) and involved lymph nodes
(GTVln) was performed by an experienced radiation oncologist on the fused PET and
midventilation CT scan or the dedicated CT scan.
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Coregistration of the images
The CT of the hypoxia PET/CT and the first CT scan of the DCE-CT were registered to
the CT of the FDG PET/CT or the dedicated planning CT using a two-step process; the
scans were aligned using a non-deformable registration and consecutively deformed
using a non-rigid registration (Elastix [27, 28]). The deformation field of the hypoxia
CT was applied on the HX4 PET, and the deformation field of the DCE-CT was applied
on the BV and BF maps.
Survival analysis and response to nitroglycerin
Follow-up for all patients was performed according to the regional standard follow-up
protocol. This includes a CT scan at three months after radiotherapy, repeated yearly
afterwards and whenever clinically indicated. The overall survival (OS), locoregional
progression-free survival (LRPFS) and metastasis-free survival (MFS) were determined
for all patients. The overall survival was defined as the time between the pathology
diagnosis and death from any cause. LRPFS and MFS were defined from the time of
pathology until the first sign of progression on imaging, which was either a recurrence
in the primary tumour or regional lymph nodes, or a distant metastasis.
Kaplan Meier curves were used to analyse OS, LRPFS and MFS for the HX4 PET
and DCE-CT scans at baseline and after applying the nitroglycerin patch. For the
survival analysis, patients were split into hypoxic tumours (TBR > 1.2) and non-
hypoxic tumours (TBR < 1.2). For the DCE-CT scans, the median BF and BV were
used for patient stratification. In addition, baseline median GTV size and median FDG
SUVmax and SUVmean were tested for their prognostic value.
The response to nitroglycerin was assessed by comparing the baseline and
nitroglycerin scans for hypoxia PET and DCE-CT. Changes in hypoxia were marked
as significant, if they exceeded the previously determined coefficient of repeatability
(CR). The absolute CR was 0.30 for the TBR and 14.9 % for the FHV with a threshold of
1.2 times the background [29]. The survival of patients with a significant reduction in
hypoxia were analysed separately.
Statistical analysis
The data were analysed using R: A Language and Environment for Statistical
Computing (v3.3.2, Vienna, Austria; survival package v2.38). For the imaging
parameters, the median and interquartile range (IQR) of the group of patients are
provided. The survival statistics are presented as the median with the 95 % confidence
interval (CI). Survival differences between the several groups were statistically tested
using a log-rank test. A p-value < 0.05 was considered statistically significant.
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Results
In total 42 patients were included in the nitroglycerin clinical trial between December
2011 and June 2016. Of those patients, 34 patients (21 male, 13 female; mean age
63 years ± 11 years) had at least a baseline HX4 PET/CT or baseline DCE-CT scan
and were included in this study. A primary tumour was present in 33 out of 34
patients; involved lymph nodes were detected in 27 out of 34 patients. The patient
details of the analysed patients are given in Table 4.1. The majority of patients
(n = 17) were treated with concurrent chemoradiotherapy of 69 Gy in 42 fractions.
Two patients were treated with stereotactic radiotherapy (60 Gy in 8 fractions of
7.5 Gy). For the other patients (n = 15), the prescribed radiotherapy dose ranged from
53–75 Gy in 30–41 fractions, and patients received either concurrent chemotherapy
(n = 8), neoadjuvant chemotherapy (n = 2), sequential chemotherapy (n = 1) or no
chemotherapy (n = 4). At baseline, of the 34 patients analysed in this study, 32 patients
received a FDG PET/CT, 32 patients a HX4 PET/CT and 22 patients received a DCE-
CT scan. After applying the nitroglycerin patch, HX4 PET/CT scans were acquired for
25 patients and DCE-CT scans for 13 patients. Nitroglycerin scans were only acquired
for patients with a baseline scan. In Figure 4.1, HX4 PET/CT scans, and BF and BV
DCE-CT maps at baseline and after applying the nitroglycerin scans of two example
patients are shown.
For all patients with a baseline scan, the median HX4 TBR was 1.4 (IQR:
1.2–1.7), the median HV 2.9 cm3 (IQR: 0.1–12.1 cm3), BF 63.5 ml/100 ml/min (IQR:
52.0–75.3 ml/100 ml/min), BV 7.1 ml/100 ml (IQR: 5.5–9.7 ml/100 ml), FDG SUVmax
10.9 (IQR: 7.2–14.5), and the median FDG SUVmean 4.2 (IQR: 2.7–5.7). Only weak
correlations were observed between baseline hypoxia features and GTV size, for TBR
(r = 0.49) and FHV (r = 0.27).
For the patients with both scans, the changes in imaging characteristics in the
primary tumour after applying the nitroglycerin patch are shown in Figure 4.2. Both
increases and decreases were observed on a patient level, for all imaging features.
For the 24 patients with HX4 PET imaging available and a primary tumour, the
median TBR remained unchanged between baseline (1.4; IQR: 1.2–1.8) and the
nitroglycerin scan (1.4; IQR: 1.3–1.8). For the other hypoxia features only minor
differences were observed, see Figure 4.2. For the 13 patients with both DCE-CT
scans and a primary tumour, the median BF decreased from 63.6 ml/100 ml/min (IQR:
52.0–81.2 ml/100 ml/min) to 53.8 ml/100 ml/min (IQR: 44.8–78.4 ml/100 ml/min), and
the median BV decreased from 7.5 ml/100 ml (IQR: 5.8–9.4 ml/100 ml) to 7.2 ml/100 ml
(IQR: 6.9–8.6 ml/100 ml), see Figure 4.2.
The median follow-up time was 39 months, with follow-up ranging between 11
and 64 months for the patients alive. The two-year overall survival for the group of
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HX4
BF
BV
0 ml/100 ml/min 80 ml/100 ml/min 
TBR: 0 TBR: 1.8
0 ml/100 ml 12 ml/100 ml
Baseline
TBR: 0 TBR: 2.2
0 ml/100 ml/min 60 ml/100 ml/min 
0 ml/100 ml 8 ml/100 ml
Nitroglycerin Baseline Nitroglycerin
Figure 4.1. HX4 PET/CT scan, and blood flow (BF) and blood volume (BV) DCE-CT maps
of two example patients, at baseline and after applying a nitroglycerin patch. Both patients
had a hypoxic tumour at baseline. In the patient on the left, the hypoxic volume decreases
after administration of nitroglycerin (from 70 cm3 to 64 cm3), while the mean BF (from 37
ml/100 ml/min to 54 ml/100 ml/min) and mean BV (from 5.8 ml/100 ml to 8.6 ml/100 ml)
increase. In the patient on the right, hypoxia and tumour perfusion remain almost unchanged,
with a HV of 61 cm3 and 59 cm3, a BF of 32 ml/100 ml/min and 31 ml/100 ml/min, and a BV of
5.8 ml/100 ml and 5.7 ml/100 ml, at baseline and after nitroglycerin administration respectively.
34 patients described in this paper was 58 % (95 % CI: 44–78 %); the median overall
survival was not yet reached at the time of analysis. Thirteen of the 34 patients
(38 %) developed metastatic disease over time. The two-year metastasis-free survival
was 63 % (95 % CI: 48–83 %). Eight patients (24 %) presented with a locoregional
recurrence. Recurrences inside the original PTV occurred in five patients (15 %). The
two-year locoregional relapse free survival was 75 % (95 % CI: 60–93 %).
The Kaplan Meier curves, assessing the prognostic value of baseline imaging, are
presented in Figure 4.3, for hypoxia PET imaging, and in Supplementary Figure S4.1,
for DCE-CT imaging. A significant difference in OS (p = 0.029) was observed between
patients with hypoxic tumours (two-year OS 47 %; 95 % CI: 31–72 %) and non-hypoxic
tumours (two-year OS 100 %; 95 % CI: 100–100 %). Patients with hypoxic tumours also
suffered from a worse MFS (p = 0.045), with a two-year MFS of 52 % (95 % CI: 34–79 %),
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Figure 4.2. Boxplots of HX4 PET and DCE-CT imaging characteristics for the primary tumour
for the patients with both a baseline and nitroglycerin scan. For the HX4 PET, the mean uptake
(SUVmean), tumour-to-background ratio (TBR), hypoxic volume (HV), and fraction of HV (FHV)
are given. For the DCE-CT images, the average blood flow (BF) and blood volume (BV) are
shown. The observations of a single patient are connected with a line. The HX4 PET imaging
features are shown for 24 patients; the DCE-CT features were available for 13 patients.
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Figure 4.3. Prognostic value of baseline HX4 PET imaging of the primary tumour, with from left
to right the overall survival (OS), metastasis-free survival (MFS), and locoregional progression-
free survival (LRPFS). In total 32 patients received a baseline HX4 PET/CT. The 31 patients with
a primary tumour are displayed in the figure.
compared to 100 % (95 % CI: 100–100 %) for non-hypoxic tumours. LRPFS was not
significantly different between hypoxic and non-hypoxic tumours (p = 0.23). For the
baseline DCE-CT scans, no significant differences were observed between patients
with blood flow or blood volume above or below the median, for OS (BF: p = 0.7; BV:
p = 0.45), MFS (BF: p = 0.58; BV: p = 0.15) and LRPFS (BF: p = 0.49; BV: p = 0.48). The
cumulative GTV of the primary tumour and involved lymph nodes (OS: p = 0.94; MFS:
p = 0.35; LRPFS: p = 0.56), baseline FDG SUVmax (OS: p = 0.72; MFS: p = 0.94; LRPFS:
p = 0.48), and baseline FDG SUVmean (OS: p = 0.62; MFS: p = 0.31; LRPFS: p = 0.74) were
also not prognostic in this patient cohort.
Kaplan Meier curves based on the scans with the nitroglycerin patch are shown in
Figure 4.4 for hypoxia PET imaging, and in Supplementary Figure S4.2 for the DCE-CT
imaging features. For the 24 patients with a nitroglycerin scan and primary tumour,
no significant differences were found between patients with hypoxic and non-hypoxic
tumours for OS (p = 0.14), MFS (p = 0.19), or LRFS (p = 0.99). No survival difference was
found for BF or BV for the 13 patients with a nitroglycerin DCE-CT scan.
A reduction in hypoxia, after applying the nitroglycerin patch, exceeding the
coefficient of repeatability, was found in one GTVprim based on the TBR threshold and
two primary GTVs based on the FHV threshold. In total, two patients had a significant
decrease in hypoxia in the primary tumour. In the first patient, the FHV decreased
from 0.45 to 0.13; in the second patient, the FHV decreased from 0.24 to 0.09. None of
the primary tumours changed from hypoxic into non-hypoxic after the nitroglycerin
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Figure 4.4. Prognostic value of HX4 PET imaging of the primary tumour after administration of
nitroglycerin, with from left to right the overall survival (OS), metastasis-free survival (MFS), and
locoregional progression-free survival (LRPFS). In total 25 patients received a nitroglycerin HX4
PET/CT. The 24 patients with a primary tumour are displayed in the figure.
administration, based on the TBR 1.2 threshold. Of the two patients with a significant
decrease, the first patient developed metastases in the adrenal glands, paraaortic
lymph nodes and longs and had an OS of 6 months. The second patient did not have
any recurrences and was still alive after a follow-up period of 28 months.
In the first patient, in addition to a hypoxia decrease in the GTVprim, also a
significant reduction of hypoxia in the lymph nodes was observed. Two other patients
showed a hypoxia reduction in the lymph nodes only. For one patient, a significant
reduction of the FHV (from 0.20 to 0.03) was found. In the other patient, the lymph
nodes were hypoxic at baseline (TBR = 1.3) and non-hypoxic after nitroglycerin
administration (TBR = 1.1). These last two patients were alive at the last follow-up, with
a follow-up of 39 and 42 months respectively. No locoregional progression was found
in the two patients. The last patient developed metastatic disease after 17 months.
Discussion
Despite several hypoxia reducing properties that have been attributed to the
vasodilating drug nitroglycerin, the added value of nitroglycerin in oncology is still
inconclusive. The only other trial, to our knowledge, that has studied the benefit
of adding nitroglycerin to (chemo)radiotherapy in NSCLC patients found an average
response rate and acceptable toxicity levels [13]. For the 34 patients studied in this
manuscript, a two-year OS of 58 % (95 % CI: 44–78 %) was found. The survival of
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this heterogeneous stage IB–IV patient group was comparable to standard treatment
in stage III NSCLC patients [30].
Mixed responses to nitroglycerin were observed between patients, which both
increases and decreases in hypoxic levels, blood flow, and blood volume. Highlighting
the need for patient stratification and selection. We hypothesized that nitroglycerin-
induced differences in hypoxia levels, as measured on HX4 PET/CT scans, could aid
selection of patients for nitroglycerin treatment. However, due to the limited number
of patients and the heterogeneous patient group, we could not confirm this hypothesis.
Of all 42 patients included in the clinical trial, a baseline hypoxia PET scan was
acquired for 32 patients, and only 25 of those patients received a nitroglycerin hypoxia
PET. Most of the scans were not performed due to logistic reasons, or patients were not
willing or able to undergo the scans. Of the 32 patients scanned at baseline, 25 patients
had a hypoxic tumour at baseline and only two patients showed a significant reduction
in hypoxia in the primary tumour and two patients in the lymph nodes. For one
patient, the lymph nodes were hypoxic at baseline and non-hypoxic after nitroglycerin
administration. Although none of these patients experienced locoregional failure, the
patient number was insufficient for any statistical analysis on survival differences.
Patient stratification based on imaging characteristics can be a powerful method for
treatment personalization, yet it should be recognized that it rapidly decreases the
number of patients available for analysis [31].
The threshold used to divide the patients in nitroglycerin responders and non-
responders based on their hypoxia status may have been too strict for this study and
may have limited the number of detectable responders. The HX4 PET scans that
were used to calculate the coefficients of repeatability were acquired shortly after
injection of the PET tracer (90 minutes postinjection) and with short acquisition times
(3 minutes per bed position) [29]. These scans will have suboptimal contrast to noise
ratios compared to the scans used in this study (acquired at 4 hours postinjection, with
20 minutes per bed position) [24]. The expected lower noise levels in this study will
arguably yield a higher reproducibility, thus smaller changes in hypoxia levels could
be ascribed to the nitroglycerin administration.
This study showed the prognostic value of baseline HX4 PET/CT imaging for
OS in NSCLC patients. Other nitroimidazole based PET tracers, FMISO, FAZA and
FETNIM [15–18], already showed to be prognostic in NSCLC, however, no survival
data was available until now for HX4 PET imaging. In this study we used a threshold
of TBR > 1.2 to distinguish between hypoxic and non-hypoxic tumours. However, a
formally established threshold is missing and several thresholds have been proposed
for nitroimidazole-based PET tracers [24]. The Kaplan Meier curves for another
commonly applied threshold, TBR > 1.4, are shown in Supplementary Figure S4.3 and
Supplementary Figure S4.4. These thresholds should be further validated in a larger
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patient cohort.
For tumour size, FDG PET features, and DCE-CT imaging parameters, no survival
differences were observed. This is in contradiction to other research showing the
prognostic value of tumour volume [32, 33] and FDG PET [34]. It has to be noted
though, that the studied group of patients is possibly too small and too heterogeneous
to show survival differences based on these features. NSCLC patients stage IB–IV were
included, receiving a wide range of (combined) treatments. Multiple factors could
have influenced survival, but further subgroup analysis is restricted due to the limited
number of patients. DCE-CT scans were, similar to the HX4 PET scans, missing due
to logistic reasons, or patients refused additional scans, or the timing of the scans was
incorrect.
A final limitation of this study is the averaging of all imaging features over
the whole tumour. It is well established that the tumour vasculature is highly
irregular, and differences in tumour perfusion and hypoxia levels can be very local
and heterogeneous [1, 35]. By averaging the imaging features over a large region,
subtle regional nitroglycerin effects might be unappreciated. It is possible that
the distribution or redistribution of the blood flow, and not the average, may be
more relevant for reducing hypoxia and improving chemotherapy accessibility [1].
Subregional tumour analysis could yield valuable information on local differences,
however, the small patients group limits this more advanced image analysis. In a larger
study cohort, more advanced imaging analysis methods may provide more insight
[36, 37].
In conclusion, we presented the results of a window-of-opportunity trial on
nitroglycerin. Patients with a hypoxic tumour at baseline, as determined on HX4
PET/CT, had a worse overall survival, compared to non-hypoxic tumours. In contrast,
DCE-CT and FDG PET imaging features, and tumour volume could not be linked to
patient prognosis. Confirmation of the prognostic value of HX4 PET is needed in a
larger patient cohort.
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Figure S4.1. Prognostic value of baseline DCE-CT imaging of the primary tumour, with from left
to right the overall survival (OS), metastasis-free survival (MFS), and locoregional progression-
free survival (LRPFS). The top row is tumour blood flow (> median), the bottom row is blood
volume (>median).
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Figure S4.2. Prognostic value of DCE-CT imaging of the primary tumour after administration of
nitroglycerin, with from left to right the overall survival (OS), metastasis-free survival (MFS), and
locoregional progression-free survival (LRPFS). The top row is tumour blood flow (> median),
the bottom row is blood volume (>median).
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Figure S4.3. Prognostic value of baseline HX4 PET imaging of the primary tumour. Tumours
with a tumour-to-background ratio > 1.4 where categorized as hypoxic. From left to right
the graphs show the overall survival (OS), metastasis-free survival (MFS), and locoregional
progression-free survival (LRPFS).
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Abstract
Background and purpose We compared two imaging biomarkers for
dose escalation in patients with advanced non-small cell lung cancer
(NSCLC). Treatment plans boosting metabolically active subvolumes
defined by FDG PET or hypoxic subvolumes defined by HX4 PET were
compared with boosting the entire tumour.
Materials and methods Ten NSCLC patients underwent FDG and HX4
PET/CT scans prior to radiotherapy. Three isotoxic dose escalation
plans were compared per patient: plan A, boosting the primary tumour
(PTVprim); plan B, boosting the subvolume with FDG PET uptake > 50 %
SUVmax (PTVFDG); plan C, boosting the hypoxic volume with HX4 tumour-
to-background ratio > 1.4 (PTVHX4).
Results Average boost volumes were 507 cm3 ± 466 cm3 for PTVprim,
173 cm3 ± 127 cm3 for PTVFDG and 114 cm3 ± 73 cm3 for PTVHX4.
The smaller PTVHX4 overlapped on average 87 % ± 16 % with PTVFDG.
Prescribed dose was escalated to 87 Gy± 10 Gy for PTVprim, 107 Gy± 20 Gy
for PTVFDG, and 117 Gy ± 15 Gy for PTVHX4, with comparable doses to
the relevant organs at risk (OAR). Treatment plans are available online
(https://www.cancerdata.org).
Conclusions Dose escalation based on metabolic subvolumes, hypoxic
subvolumes and the entire tumour is feasible. The highest dose was
achieved for hypoxia plans, without increasing dose to OAR. For most
patients, boosting the metabolic subvolume also resulted in boosting the
hypoxic volume, although to a lower dose, but not vice versa.
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Introduction
The prognosis of patients with advanced stage non-small cell lung cancer (NSCLC) re-
mains poor despite the use of new radiation techniques and addition of chemotherapy
to radiotherapy [1]. Poor overall survival of patients treated with chemoradiotherapy
is, besides distant metastases, negatively related to insufficient local tumour control.
Increasing the dose to the tumour may improve local control, but escalating the dose
to the whole tumour is currently limited by normal tissue toxicity [2, 3].
Instead of escalating the dose to the whole tumour, a more sophisticated approach
may selectively increase dose to treatment resistant areas while maintaining the dose
to other parts of the target volume: a concept called dose painting [4]. Tumours are
known to be heterogeneous and biological properties, such as hypoxia, cell density,
proliferation and vascularisation, vary throughout the tumour. As a consequence,
some parts of the tumour are more treatment resistant than others [5, 6]. This
biological knowledge is integrated in dose painting to create highly personalized
treatment plans. Dose can be prescribed to individual voxels (i.e. dose painting by
numbers [7]) or to tumour subvolumes (i.e. dose painting by contours [4]). Dose
painting by contours has the advantage that clinical treatment planning software can
be used and a robust plan can be created by using margins to account for uncertainties.
This latter approach is currently being tested in several clinical trials [8, 9].
Dose painting requires an imaging biomarker to determine subvolumes that are
more treatment resistant and should therefore receive a higher dose. By selecting
the appropriate positron emission tomography (PET) tracer, biological processes like
hypoxia and glycolytic metabolism can be imaged. Hypoxia is a tumour characteristic
that is known to be correlated with tumour aggressiveness and radioresistance [10, 11].
The 2-nitroimidazole tracer 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-
1H-1,2,3-triazol-1-yl)propan-1-ol (HX4) is an example of a PET tracer whose ability to
assess tumour hypoxia non-invasively has been validated [12–15]. Another biological
process that can be assessed is tumour glucose metabolism, which is imaged with the
commonly used tracer 18F-fluorodeoxyglucose (FDG). For FDG PET, it has been shown
that volumes of local relapse are correlated with high uptake regions on pretreatment
images and are stable over time [16–19].
The question of which imaging surrogate should be used for dose painting is still
under debate, but several surrogates have been and are being used in clinical trials
[8, 9, 20, 21]. FDG is commonly used and widely available; its high pretreatment
uptake is related to local relapses. However, spatial correlation between uptake and
local recurrences is not perfect. Aerts et al. [18] found that 30% of relapses were outside
the high FDG region. On the other hand, hypoxia is known to be an important factor in
chemotherapy and radiotherapy resistance. Although hypoxia imaging has only been
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used in clinical trials so far, these tracers are receiving more attention for dose painting
purposes.
Zegers et al. [22] compared metabolic and hypoxic uptake patterns and found a
good correlation between high uptake volumes of both tracers for most patients. For
frequently used thresholds, the hypoxic volumes were generally smaller than the high
metabolic uptake volumes. Consequently, creating a boost plan based on hypoxia
imaging may reduce the boost volume and increase dose escalation levels even further.
However, since margins have to be added in dose painting by contours to account
for treatment delivery uncertainties, smaller high uptake subvolumes on PET do not
automatically result in smaller planning boost volumes. Furthermore, Zegers et al.
[22] described a partial mismatch between hypoxic and metabolic volumes in some
patients. For those patients, it is a priori unknown what effect the selected boost
volume with appropriate margins will have on the dose distributions of different dose
painting plans.
Therefore, we compared different dose escalation strategies to determine the
influence of the used imaging biomarker on achieved tumour dose levels. For each
patient, we created an isotoxic dose painting plan boosting the FDG high uptake
volume and a plan boosting the hypoxic volume. For comparison, a plan with a boost
to the whole tumour was created. We evaluated the feasibility of these treatment plans
together with dosimetrically achieved parameters for organs at risk dose and target
volume. Furthermore, we evaluated the accuracy of a particular imaging surrogate for
dose boosting on the coverage of the other biological subvolumes.
Materials and methods
Patients
NSCLC patients who were inoperable or had irresectable disease (cT2–T4, stage IB–III)
were included in an ongoing phase II randomized clinical trial (NCT01024829). To be
eligible, the primary tumour had to have a minimum diameter of 4 cm and maximum
standardized uptake value (SUVmax) ≥ 5 on pretreatment FDG PET [8]. The study
was approved by the Medical Ethics Review Committee and all patients gave written
informed consent. A dummy treatment plan was generated and a minimal dose of
72 Gy in 24 fractions (i.e. 3 Gy / fraction) to the planning target of the primary tumour
(PTVprim) ought to be feasible before randomisation was performed. We selected
patients with hypoxic subvolumes as detected on HX4 PET for this study.
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Image acquisition
Patients were scheduled for FDG PET/CT and hypoxia HX4 PET/CT scans on different
days, within the same week before radiotherapy. A pretreatment respiratory gated 4D
FDG PET/CT was acquired using a Siemens Biograph 40 PET/CT scanner (Siemens
Healthcare, Erlangen, Germany), according to the NEDPAS protocol [23]. HX4 PET/CT
acquisition was performed four hours after injection of the hypoxia tracer on a Philips
Gemini TF 64 scanner (Philips Healthcare, Best, the Netherlands) [13]. Patients were
scanned in treatment position on a flat table top using the same fixation devices.
Boost volumes
Gross tumour volumes of the primary tumour (GTVprim) and involved lymph nodes
(GTVln) were delineated on the midventilation phase of the 4D FDG PET/CT scan by an
experienced radiation oncologist. A 5 mm margin was added to the GTVprim to include
microscopic disease extension and create the clinical target volume (CTVprim). An
individualized margin, depending on the movement of the tumour on the 4D planning
CT, was added to the CTVprim to create the planning target volume (PTVprim) [24]. For
the lymph nodes, we used a 5 mm CTV and 5 mm PTV margin irrespective of the
motion of the nodes.
The PTVprim was used as uniform boost planning target for plan A; additional
structures were created to boost the metabolic and hypoxic subvolumes. Boosting
the metabolic target (GTVFDG) was based on FDG PET/CT and defined as the region
within GTVprim with an SUV above 50 % of SUVmax (Plan B). Since the FDG PET/CT
scan was used as planning CT, no additional registration of the PET to the CT had to be
performed. Boosting the hypoxic volumes (GTVHX4) was based on HX4 PET/CT (plan
C). The HX4 PET/CT scan was registered rigidly to the planning FDG PET/CT scan
using the treatment planning system (Eclipse version 11.0, Varian Medical Systems,
Palo Alto, CA). We applied a bony anatomy match, followed by a soft tissue match
with the primary tumour as region of interest. Background was defined as mean
uptake in the aortic arch. Voxels with a tumour-to-background ratio (TBR) > 1.4
within the GTVprim were classified as GTVHX4. The TBR > 1.4 cutoff value was chosen
based on published research [12, 25–27]. For GTVFDG and GTVHX4, we used the same
individualized GTV–PTV margins to create PTVFDG and PTVHX4 [8].
Organs at risk
Organs at risk (OAR) were delineated on the planning FDG PET/CT. Dose constraints
were chosen according to the ongoing clinical trial protocol [8, 28]: lungs Dmean
< 20 Gy (corrected to EQD2); spinal cord D0.1 < 51 Gy (EQD2< 52 Gy); oesophagus V36
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< 80 % [29]; brachial plexus D0.1 < 66 Gy (EQD2 < 66 Gy); whole heart Dmean < 46 Gy
(EQD2 Dmean < 46 Gy); planning organ at risk volume mediastinal structures (OAR +
5 mm margin) D0.1 < 76 Gy (EQD2 < 94 Gy), where Dmean is the mean dose, D0.1 the
dose delivered to 0.1 % of the OAR, V36 the volume receiving 36 Gy, and EQD2 the
equivalent 2 Gy dose. For the biological dose calculation, we used an α / β value of 3 Gy
for the lungs, heart and mediastinal structures, 2 Gy for the spinal cord, and 10 Gy for
the oesophagus.
Treatment planning
Experienced radiation technicians created three volumetric modulated arc therapy
plans (VMAT; typically two half arcs for lateral tumours and two full arcs for medial
tumours) for each patient using RapidArc (Eclipse version 11.0). Plans were created
using a simultaneous integrated boost in 24 fractions. Doses were calculated with a
type B dose calculation algorithm (AcurosXB-10.0). The prescribed dose was escalated
until one or more of the OAR constraints was reached, or when a maximum dose of
129.6 Gy in 24 fractions in the PTVboost volume (PTVprim for plan A; PTVFDG for plan B;
PTVHX4 for plan C) was achieved. An isotoxic planning strategy was applied to ensure
equal lung toxicity. The target maximum mean lung dose difference between plans was
0.5 Gy. Plans with a higher mean lung dose were downscaled and reoptimized. This
normalisation strategy has been shown to lead to similar mean doses in the PTVprim
[8].
The PTVboost was planned to have 99 % of the volume covered by 90–115 % of the
prescribed dose. If there was overlap of less than 15 % between PTVboost and OAR, a
partial underdosage was accepted: 85 % of PTVboost was required to receive at least
90 % of the prescribed dose where the dose in the overlap volume was escalated to
90 % of the allowed OAR dose constraint. If this overlap was more than 15 %, no
underdosing was accepted and 90 % of the prescribed dose should cover 99 % of the
target, equal to the non-overlapping scenario. Lymph nodes were planned to receive
90–115 % of 66 Gy. If PTVln overlapped with PTVprim, the PTVprim was prioritized.
Created treatment plans are available online at https://www.cancerdata.org.
Analysis of the plans
We calculated dose distributions and generated dose-volume histograms for the three
treatment strategies. We compared prescribed and mean doses in the PTVprim between
plans and calculated appropriate dose metrics for the OAR. We used a Wilcoxon signed
rank test in SPSS (IBM Corp., Version 22.0, Armonk, NY) to compare prescribed doses
and OAR doses between plan A, B and C. The significance level was adjusted for
multiple comparisons (Bonferroni correction): a p-value < 0.017 was assumed to be
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statistical significant. Finally, we calculated the overlap between PTVHX4 and PTVHX4
to evaluate how boosting one of the two subvolumes affected the other subvolume.
Results
Between September 2011 and August 2014, 35 NSCLC patients were included in the
PET-boost clinical trial at our institute. Fourteen patients were not eligible because
they did not receive a HX4 PET/CT which was part of the translational research of the
trial and not mandatory for inclusion in the study, eight patients did not have a hypoxic
tumour and in three patients dose escalation up to more than 72 Gy was not feasible.
In total, ten patients were selected for this study. Patient and tumour characteristics
are listed in Table 5.2.
The mean GTVprim was 199 cm3 (range: 32–853 cm3), mean GTVFDG 48 cm3
(range: 15–85 cm3) and mean GTVHX4 30 cm3 (range: 5–58 cm3); see Supplementary
Table S5.1. The respective mean planning target volumes were 507 cm3 (range: 149–
1749 cm3), 173 cm3 (range: 53–484 cm3) and 114 cm3 (range: 32–273 cm3). Table
5.2 presents the boost volumes and overlap between those volumes. The volume
encompassing both PTVFDG and PTVHX4 overlapped for 61 % with PTVFDG and for 87 %
with PTVHX4. As shown in Table 5.2, PTVHX4 was smaller than PTVFDG for nine of the
ten patients; PTVHX4 was almost completely within PTVFDG for eight patients. Patient
3 is an example of such a patient. In Figure 5.1 both PET scans and the delineated
planning target volumes of patient 3 are shown. Patient 7 (also shown in Figure 5.1) is
the only patient with a spatial mismatch between FDG and HX4 high uptake volumes.
It was feasible to generate plans with a boost to PTVprim, PTVFDG and PTVHX4 for all
patients. The dose distributions of two patients, patient 3 and 7, are shown in Figure
5.1. The corresponding dose-volume histograms are displayed in Figure 5.2. For both
patients, the histograms show that boosting the FDG volume also resulted in a boost
to almost the entire hypoxic volume, while boosting hypoxia only increased the dose
in part of the FDG high uptake volume.
For nine patients the highest dose was prescribed for plan C (see Supplementary
Figure S5.1); the tenth patient had a larger PTVHX4 than PTVFDG. The average pre-
scribed doses to the boost volume were 87.1 Gy ± 10.1 Gy (plan A), 107.3 Gy ± 20.6 Gy
(plan B) and 117.6 Gy ± 15.2 Gy (plan C). The prescribed doses for plans B (p = 0.005)
and C (p = 0.005) were statistically significantly higher than for plan A. Prescribed doses
and boost volumes per patient are listed in Table 5.1. Comparing prescribed doses
with respect to boost volumes, Figure 5.3, shows that it is generally more difficult to
prescribe a high dose to large boost volumes.
The isotoxic planning approach resulted in no significant differences in OAR doses
(see Supplementary Table S5.2). Two examples of OAR dose-volume histograms are
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Figure 5.1. Example of pretreatment FDG and HX4 PET/CT scans. For patient 3 (top row) the
GTVHX4 is smaller than the GTVFDG and the hypoxic volume is within the high FDG volume,
which is the case for most patients. Patient 7 (bottom row) is the only patient with a spatial
mismatch between FDG and HX4 uptake. The dose distributions of plans A, B and C are shown
for the same patients. The red region is GTVprim, the magenta region GTVFDG, and the cyan
region GTVHX4. The line with corresponding colour represents PTVprim, PTVFDG, and PTVHX4,
respectively. The isodose line of 90% of the prescribed dose to the lymph nodes is shown in
yellow and 90 % of the prescribed dose to the boost region is shown in white.
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Figure 5.2. Dose-volume histograms for the planning target volumes for the primary tumour
(PTVprim), the high FDG volume (PTVFDG) and the hypoxic volume (PTVHX4). In addition, the
DVHs for the organs at risk are plotted. Plan A is displayed as a solid line, plan B as a dashed line
and plan C as a dotted line for the organs at risk. The top row, patient 3, and bottom row, patient
7, are the same patients as depicted in Figure 5.1.
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Table 5.1. Prescribed dose and mean dose to the planning target volume in the primary tumour
(PTVprim) for plan A (boost PTVprim), plan B (boost PTVFDG) and plan C (boost PTVHX4). Doses
were compared using a Wilcoxon signed rank test.
Patient Prescribed dose boost volumes (Gy) PTVprim Dmean (Gy)
A B C A B C
1 83.0 110.0 129.6 81.8 85.9 87.1
2 105.6 128.4 128.4 101.5 104.9 93.0
3 82.1 93.1 129.6 78.4 78.2 92.0
4 90.3 129.6 129.6 86.0 93.4 81.3
5 78.0 90.7 101.0 76.5 80.2 86.9
6 96.5 129.6 129.6 94.5 96.0 87.5
7 75.3 81.2 95.4 75.6 71.6 78.9
8 78.2 82.4 104.0 77.7 74.2 79.2
9 83.9 98.3 99.8 82.4 86.9 85.1
10 98.2 129.6 129.0 94.8 94.1 100.4
mean 87±10 107±21 118±15 85±9 87±11 87±7
p-value compared to plan A - 0.005 0.005 - 0.203 0.386
p-value compared to plan B 0.005 - 0.028 0.203 - 0.878
p-value compared to plan C 0.005 0.028 - 0.386 0.878 -
Abbreviations: PTVprim = planning target volume of the primary tumour; Dmean = mean dose.
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Figure 5.3. Prescribed dose to the boost region plotted as a function of the boost volume.
Analysis for plan A (boost PTVprim), plan B (boost PTVFDG) and plan C (boost PTVHX4).
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Table 5.2. Patient and tumour characteristics. Volumes of boost planning target for plan A (PTVprim), plan B (PTVFDG) and plan C (PTVHX4), and the overlap between
the planning volumes.
Patient Gender Age (years) cTNM Stage Pathology Planning boost volume (cm3) Overlap PTVFDG and PTVHX4
A B C (cm3) (% of PTVFDG) (% of PTVHX4)
1 M 64 T4N2M0 IIIb Squamous cell carcinoma 558.4 188.4 129.5 124.1 65.9 95.8
2 F 65 T2N2M0 IIIa Adenocarcinoma 148.6 61.6 40.7 38.7 62.8 95.2
3 M 77 T3N2M0 IIIa Large cell carcinoma 651.0 246.4 139.7 122.0 49.5 87.3
4 M 82 T3N0M0 IIb Adenocarcinoma 259.4 80.2 32.3 31.7 39.5 98.2
5 M 66 T2N3M0 IIIb Unknown 300.0 136.2 131.2 118.8 87.3 90.6
6 M 71 T2N3M0 IIIb Adenocarcinoma 173.3 53.2 36.8 35.8 67.3 97.2
7 M 60 T4N1M0 IIIb Adenocarcinoma 1749.4 483.6 272.6 127.2 26.3 46.7
8 M 65 T3N2M0 IIIa Squamous cell carcinoma 484.2 194.8 77.0 75.9 39.0 98.6
9 F 46 T3N2M0 IIIa Adenocarcinoma 432.2 194.5 151.2 137.6 70.8 91.0
10 M 66 T3N2M0 IIIa Adenocarcinoma 313.3 95.8 133.3 94.3 98.4 70.7
mean 66±10 507±466 173±127 114±73 91±42 61±22 87±16
Abbreviations: PTVprim = planning target volume of the primary tumour; PTVFDG = planning target volume of the high FDG subvolume, PTVHX4 = PTV of the
hypoxic subvolume.
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shown in Figure 5.2. Prescribed dose was limited either by the mediastinal structures
(seven patients), or mean lung dose (three patients).
Discussion
We performed a dosimetric comparison of three clinically feasible dose escalation
plans for ten NSCLC patients: boosting FDG and HX4 high uptake volumes was
compared with boosting the entire tumour. The size of the boost volume appears to
be an important factor for the dose level that can be prescribed. Hypoxia planning
volumes were generally smaller than FDG boost volumes, resulting in less overlap
between target and surrounding OAR. In two cases, underdosage of the boost volumes
was allowed in the hypoxia plan because overlap with the OAR was less than the
predefined threshold (i.e. 15 % of the volume), but it was not tolerated for the other
two plans. This facilitated further dose escalation in the hypoxia boost plan.
To our knowledge, this is the first study showing the feasibility of boosting hypoxia
in NSCLC. This approach was already proven feasible in head and neck cancer [30–33].
It is important to note that not all patients were eligible for hypoxia boosting; 50 % of
the patients had hypoxic tumours. We do not expect that this approach is suitable
for all patients; patient selection is essential and treatment should be adapted for
every patient. Patients with non-hypoxic tumours have generally a better prognosis
[34–38] and probably do not need an aggressive treatment as presented. Based on
pretreatment hypoxia and FDG PET/CT scans it can be decided to boost hypoxic or
FDG subvolumes, or a combination. For most patients the largest part of the hypoxic
volume was located inside the high FDG volume. As a consequence, boosting FDG
will also boost the hypoxia, but a boost to the hypoxic volume will not escalate the
dose in the entire FDG volume. For patients without a hypoxia scan, FDG PET imaging
can be used as a surrogate for boosting hypoxia; however, less dose escalation can be
achieved.
We used commonly applied thresholds to determine FDG and HX4 high uptake
subvolumes, although these thresholds are arbitrarily defined. The FDG threshold is
already used in a clinical trial [8], whereas the HX4 threshold is based on literature
[12, 25–27]. Zegers et al. [22] showed that the proportional overlap of the tracers is
rather stable for varying thresholds. That suggests that the FDG plan will still boost the
hypoxia volume with different thresholds, but not vice versa. The different thresholds
are likely to have the greatest impact on the height of the prescribed dose levels, as
these are linked to boost volume (Figure 5.3).
An important aspect that has to be considered in hypoxia dose painting is stability
of the target over time. Small studies testing temporal stability of hypoxia in NSCLC
have so far found inconclusive results. Some studies have observed stable hypoxia
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[39, 40], whereas others have reported a decrease in hypoxia [26, 41], or a mix of stable
and dynamic hypoxia [42]. Lin et al. [43] showed in head and neck cancer that when
there is a spatial shift, dose painting of the initial subvolume still results in improved
equivalent uniform dose on a later scan. For pretreatment FDG PET/CT imaging, it is
known that most local relapses were within the FDG high uptake region. However, it is
still unknown whether pretreatment hypoxic regions also correlate with the locations
of local relapses. Because high correlations are observed between FDG high uptake
areas and hypoxic areas on pretreatment scans, we hypothesize that local recurrences
will primarily occur in these hypoxic regions. It is essential to confirm this hypothesis
before applying hypoxia boosting in clinical practice. This will in the future be assessed
in the PET-boost clinical trial.
This study used a dose painting by contours approach. Compared to dose painting
by numbers, this approach is easier to implement in clinical treatment planning
software. Furthermore, it includes a safety PTV margin to tackle small deviations in
target subvolume definition.
Finally, there is still debate about the applicability and safety of dose escalation
in NSCLC. Although multiple clinical trials suggest dose escalations could improve
overall survival [44–46], a large randomized phase III trial showed an unexpected lower
survival for the group that received a higher dose [47]. This unexpected outcome may
result from various causes including longer overall treatment time, increased cardiac
toxicity, or compromises in defining the PTV for the high dose group [48]. Alternatively,
the results may suggest that standard dose escalation is not the way forward and more
sophisticated dose redistribution techniques are necessary to improve local survival.
In conclusion, selective boosting of subvolumes based on FDG or hypoxia is
feasible and increases the prescribed dose compared to whole tumour boosting,
without increasing the dose to the organs at risk.
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Figure S5.1. Prescribed dose to the boost volume per patient for plan A (boost PTVprim) plan B
(boost PTVFDG) and plan C (boost PTVHX4). The dose is escalated up to a maximum of 129.6 Gy.
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Table S5.1. Gross tumour volume of the primary tumour (GTVprim), the FDG high uptake volume (GTVFDG) and the hypoxic
volume (GTVHX4). The overlap between GTVFDG and GTVHX4 is also listed.
Patient GTVprim GTVFDG GTVHX4 Overlap GTVFDG and GTVHX4
(cm3) (cm3) (% of GTVprim) (cm
3) (% of GTVprim) (cm
3) (% of GTVprim) (OFFDG) (OFHX4)
1 213.6 76.8 35.9 36.4 17.1 32.1 15.0 0.4 0.9
2 32.5 15.5 47.6 7.7 23.6 7.0 21.6 0.5 0.9
3 295.2 74.2 25.1 19.7 6.7 14.8 5.0 0.2 0.8
4 62.9 19.4 30.8 5.0 8.0 4.7 7.5 0.2 0.9
5 78.0 44.2 56.7 47.9 61.4 37.4 48.0 0.8 0.8
6 42.4 15.9 37.6 7.0 16.4 6.9 16.2 0.4 1.0
7 853.1 85.2 10.0 44.1 5.2 6.1 0.7 0.1 0.1
8 148.7 47.9 32.2 19.4 13.1 13.0 8.7 0.3 0.7
9 168.2 65.8 39.1 57.7 34.3 29.7 17.6 0.5 0.5
10 94.7 34.3 36.2 51.4 54.3 32.2 34.0 0.9 0.6
mean 199±244 48±27 35±12 30±20 24±20 18±13 17±14 0.4±0.3 0.8±0.3
Abbreviations: GTVprim = primary gross tumour volume; GTVFDG = volume of GTVprim with FDG uptake > 50 % SUVmax;
GTVHX4 = volume of GTVprim with a tumour-to-background ratio > 1.4; OF = overlapping fraction; OFFDG = overlapping
volume divided by FDG volume; OFHX4 = overlapping volume divided by HX4 volume.
Table S5.2. Dose to organs at risk for plan A (boost PTVprim), plan B (boost PTVFDG) and plan C (boost PTVHX4). Doses were compared using a Wilcoxon signed rank test.
Patient dose (Gy)
Mean lung
dose (Gy)
EQD2 mean lung
structures D0.1 (Gy)
PRV mediastinal
D0.1 (Gy)
Spinal cord
V36 (%)
Oesophagus
D0.1 (Gy)
Oesophagus
Dmean (Gy)
Oesophagus
A B C A B C A B C A B C A B C A B C A B C
1 18.4 17.9 17.8 17.9 20.0 19.1 75.9 76.3 74.1 32.2 22.9 23.3 0.3 0.0 0.0 36.9 24.6 25.0 13.2 10.5 10.0
2 20.8 21.1 21.3 13.4 20.1 19.8 75.2 74.0 74.4 48.5 46.9 48.7 46.3 36.0 37.6 71.7 73.2 74.1 32.9 32.9 34.0
3 19.5 20.2 20.4 17.8 15.2 20.1 74.8 76.1 75.4 43.8 47.5 50.0 28.1 29.5 32.9 70.9 73.0 71.8 22.0 25.5 25.9
4 13.8 13.9 14.0 18.5 17.7 20.0 70.4 66.8 66.2 38.7 34.7 32.9 5.1 9.7 9.6 49.7 52.2 53.6 12.6 14.0 14.0
5 21.3 21.3 20.8 19.0 13.3 20.2 71.9 75.0 75.2 47.1 45.5 49.8 52.3 52.7 52.0 71.9 75.4 75.1 35.7 37.7 38.2
6 20.5 20.6 20.9 19.4 17.3 14.6 76.1 74.0 71.6 50.9 49.1 49.1 45.2 43.2 45.3 69.5 72.7 71.2 31.8 31.9 32.8
7 18.5 18.4 17.7 20.0 18.0 17.6 75.4 76.0 76.1 49.1 50.2 49.4 54.2 59.0 52.7 77.5 77.4 75.9 39.8 40.3 37.0
8 15.6 15.5 15.5 19.7 19.4 12.9 76.0 76.0 75.3 43.4 39.4 50.4 29.9 22.4 27.9 72.1 68.7 71.6 22.1 20.2 20.8
9 20.2 20.6 20.3 20.1 19.2 16.8 73.5 76.3 76.0 44.1 31.5 31.2 22.3 31.6 24.3 67.9 71.1 69.9 19.5 23.0 20.2
10 19.1 18.9 19.2 15.1 20.0 18.5 75.7 74.7 74.3 41.0 39.0 39.2 15.3 18.2 18.6 63.9 62.2 67.9 18.8 18.8 18.9
mean 19±2 19±3 19±2 18±2 18±2 18±2 74±2 75±3 74±3 44±6 41±9 42±10 30±19 30±18 30±18 65±12 65±16 66±17 25±10 25±10 25±10
vs plan A (p-value) - 0.508 0.799 - 0.721 0.878 - 0.878 0.386 - 0.037 0.646 - 0.646 0.799 - 0.575 0.169 - 0.262 0.575
vs plan B (p-value) 0.508 - 0.878 0.721 - 0.646 0.878 - 0.037 0.037 - 0.169 0.646 - 0.859 0.575 - 0.799 0.262 - 0.813
vs plan C (p-value) 0.799 0.878 - 0.878 0.646 - 0.386 0.037 - 0.646 0.169 - 0.799 0.859 - 0.169 0.799 - 0.575 0.813 -
Abbreviations: EQD2 = equivalent 2 Gy dose; PRV = planning risk volume; D0.1 = dose received by maximal 0.1 % of the organ; V36 = volume receiving at least 36 Gy; Dmean is the mean dose.
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Abstract
Background Most solid tumours contain inadequately oxygenated (i.e.
hypoxic) regions, which tend to be more aggressive and treatment
resistant. Hypoxia PET allows visualization of hypoxia and may enable
treatment adaptation. However, hypoxia PET imaging is expensive, time-
consuming, and not widely available. We aimed to predict hypoxia levels
in non-small cell lung cancer (NSCLC) using more easily available imaging
modalities: FDG PET/CT and dynamic contrast-enhanced CT (DCE-CT).
Material and methods For 34 NSCLC patients, included in two clinical
trials, hypoxia HX4 PET/CT, planning FDG PET/CT, and DCE-CT scans
were acquired before radiotherapy. Scans were non-rigidly registered to
the planning CT. Tumour blood flow (BF) and blood volume (BV) were
calculated by kinetic analysis of DCE-CT images. Within the gross tumour
volume, independent clusters, i.e. supervoxels, were created based on
FDG PET/CT. For each supervoxel, tumour-to-background ratios (TBR)
were calculated (median SUV / aorta SUVmean) for HX4 PET/CT, and
supervoxel features (median, SD, entropy) for the other modalities. Two
random forest models (cross-validated: ten folds, five repeats) were
trained to predict the hypoxia TBR; one based on CT, FDG, BF and BV,
and one with only CT and FDG features. Patients were split in a training
(trial NCT01024829) and independent test set (trial NCT01210378). For
each patient, predicted, and observed hypoxic volumes (TBR > 1.2) were
compared.
Results Fifteen patients (3291 supervoxels) were used for training and
19 patients (1502 supervoxels) for testing. The model with all features
(RMSE training: 0.19 ± 0.01, test: 0.27) outperformed the model with only
CT and FDG PET features (RMSE training: 0.20 ± 0.01, test: 0.29). All
tumours of the test set were correctly classified as normoxic or hypoxic
(hypoxic volume > 1 cm3) by the best performing model.
Conclusion We created a data-driven methodology to predict hypoxia
levels and hypoxia spatial patterns using CT, FDG PET, and DCE-CT
features in NSCLC. The model correctly classifies all tumours, and could
therefore, aid tumour hypoxia classification and patient stratification.
6Predicting tumour hypoxia in NSCLC by combining FDG PET/CT and DCE-CT 125
Introduction
Hypoxia is one of the important factors influencing treatment outcome in cancer
patients. Most solid tumours contain hypoxic, poorly oxygenated, regions, which
are prone to be more radioresistant, chemoresistant, and aggressive. This is due to
multiple features such as an altered metabolism, increased resistance to cell death,
increased angiogenesis and invasiveness, and tendency to metastasize [1–3].
Although hypoxic tumours are less sensitive to conventional treatments, they
might benefit from specially designed targeted treatments such as hypoxia activated
prodrugs or the inhibition of molecular targets in hypoxic cells [1–4]. Other
approaches include increasing the radiotherapy dose in the hypoxic areas to overcome
radioresistance [5, 6], or adding radiosensitizers to radiotherapy treatment [7]. To
select patients that will benefit the most from these targeted strategies, in clinical
routine, as well as in clinical trials, there is a need for non-invasive techniques that can
reliably detect hypoxia. In most clinical trials, patients are not stratified by hypoxia
status and therefore these trials most likely do not demonstrate the full potential of
hypoxia targeting strategies.
The most studied non-invasive techniques to visualize hypoxia make use of PET
tracers based on 2-nitroimidazoles labelled with Fluorine-18, for example 18F-MISO,
18F-FAZA and 18F-HX4 [8]. In the absence of oxygen, the reduction of nitroimidazoles
cannot be reversed and the reactive product gets trapped in the hypoxic cell. Other
studied imaging techniques make use of more indirect ways of assessing hypoxia.
Perfusion and diffusion based approaches, for example, have been suggested as
surrogates for hypoxia, since the delivery of oxygen to tumours is regulated by blood
supply. CT-based perfusion techniques, dynamic contrast-enhanced CT (DCE-CT), as
well as MRI-based modalities, DCE-MRI or diffusion weighted MRI (DW-MRI), have
been proposed. However, hypoxia is not only influenced by perfusion; perfusion
markers cannot visualize the ability of blood to carry and release oxygen or the oxygen
consumption rate of cells. 18F-FDG PET has been suggested as another indirect marker
of hypoxia [9]. Hypoxic cells have to resort to the less efficient glycolysis for their energy
production resulting in an upregulated metabolism that can be visualized with the
commonly used FDG PET tracer. Unfortunately, cancer cells tend to predominately
rely on glycolysis even under well oxygenated conditions, hindering the distinction
between hypoxic and non-hypoxic tumour cells [10].
PET tracers based on 2-nitroimidazoles are the most studied and most direct way of
in vivo visualizing of hypoxia. However, so far, these PET images have only been used in
research or clinical trial setting, as they are not widely available, expensive, and time-
consuming. In this study we investigated the possibility of replacing a 2-nitroimidazole
PET tracer by alternative indirect hypoxia markers that are more accessible. We aimed
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to predict hypoxia levels in patients with non-small cell lung cancer (NSCLC) tumours,
assessed with HX4 PET, by using FDG PET/CT and dynamic contrast-enhanced CT
imaging.
Materials and Methods
Patient selection
Stage IB–IV NSCLC patients were included in two prospective clinical trials (PET-
boost trial: NCT01024829 [11]; Nitroglycerin trial: NCT01210378). The pretreatment
imaging protocol was identical for both clinical studies, including a planning FDG
PET/CT, hypoxia HX4 PET/CT, and dynamic contrast-enhanced CT (DCE-CT). The
HX4 PET/CT and DCE-CT scans were preferably scheduled on the same day; FDG
and HX4 PET/CT scans were always planned on different days. The three scans were
planned within the same week before radiotherapy for all except one patient. The time
between scans ranged from 1 to 11 days. All patients gave written informed consent
and both studies were approved by the Medical Ethics Review Committee. For our
analysis, we selected all patients with images of all treatment modalities available.
Image acquisition and preprocessing
All scans were performed in treatment position on a flat table top with the same arm
and knee supports used during radiotherapy treatment.
Planning FDG PET/CT
A 4D respiratory gated FDG PET/CT was acquired one hour after injection of
approximately 197±43 MBq FDG tracer, according to the NEDPAS protocol [12], on
a Siemens Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany).
The midventilation phase of the 4D CT scan was used for attenuation correction.
PET scans were also corrected for scatter and random coincidences. The PET images
were reconstructed in voxels of 4 by 4 mm in-plane with a slice thickness of 3 mm
using an OSEM or PSF algorithm. The voxels of the CT were 1 by 1 by 3 mm. The
gross tumour volume (GTV) was delineated on the fused PET/CT by an experienced
radiation oncologist. Finally, standardized uptake values (SUV) were calculated by
correcting the measured uptake for body weight, injected dose, and decay.
Hypoxia HX4 PET/CT
A 2-nitroimidazole-based PET tracer, [18F]HX4 (3-[18F]fluoro-2-(4-((2-nitro-1H-
imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol), from here on referred to as
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HX4 [13–15], was used to acquire hypoxia PET images. The patients were scanned four
hours postinjection of approximately 417±77 MBq of HX4 on a Gemini TF64 PET/CT
scanner (Philips, the Netherlands). Scans were corrected for attenuation using a low-
dose CT scan, and corrected for scatter and random coincidences. The voxels of the
reconstructed PET images (BLOB-OS-TF with 3 iterations and 33 subsets) had an in-
plane size of 4 by 4 mm and slice thickness of 4 mm. The PET uptake in the aortic arch
was measured to calculate the tumour-to-background ratio (TBR), which was defined
as the SUV in the tumour divided by the SUVmean in the aortic arch.
Dynamic contrast-enhanced CT
For the DCE-CT images, patients were injected with 60 or 65 ml of an iodine-based
contrast material (Iopromide 300, Bayer Healthcare, Berlin, Germany), followed by a
saline chaser of 30 ml or 40 ml. Both at a flow rate of 7 ml/s. The patients were scanned
on a second or third generation dual source scanner (SOMATOM Definition Flash or
SOMATOM Force, Siemens Healthcare, Erlangen, Germany). Every 1.5 second 80 kVp
CT scans of primary tumour were acquired for 33 consecutive frames. Patients were
asked to hold their breath in expiration breath-hold as long as possible and otherwise
continue shallow breathing. Scans were reconstructed with a B20f filter with a slice
thickness of 5 mm. All 33 frames were aligned to the first slice using a deformable
fluid-based registration algorithm (syngo MMWP, version VE40A; Siemens).
Next, kinetic analysis was performed on the DCE-CT scans, using a deconvolution
approach (adiabatic approximation to the tissue homogeneity model; ATH) [16, 17].
The images were smoothed with a median 5 filter and resampled to a 256 × 256
grid. A region of interest was delineated in the aortic arch to determine the arterial
input function. Finally, parametric maps were calculated for tumour blood flow (BF;
ml/100 g/min) and blood volume (BV; ml/100 g).
Image registration and supervoxels
The images of all modalities were mapped onto the planning CT scan using a rigid
alignment followed by a non-rigid registration using the open source software Elastix
[18, 19]. Voxels were resampled to the in-plane dimensions of the CT to create isotropic
voxels. Next, homogeneous patches, preserving local image boundaries, were created
by grouping voxels based on their CT Hounsfield units and FDG SUV, see Figure 6.1.
These clusters of voxels, i.e. supervoxels, were introduced to reduce noise, reduce the
amount of data, and to minimize the effect of registration uncertainties. Supervoxels
were generated using an adapted k-means clustering algorithm called Simple Linear
Iterative Clustering (SLIC [20]). This freely available algorithm was tuned to create
supervoxels with a size of 400 voxels (typically 0.4 cm3) and compactness of 20. For
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Figure 6.1. An example patient from the test set with the different imaging modalities, the
supervoxel preprocessing, and hypoxia images. On the top row, the images that are used as
model input: CT, FDG PET, DCE-CT blood flow and blood volume, overlaid on the planning CT.
Clustering is performed on the CT and FDG PET data to create supervoxels (solid line). For each
supervoxel, the mean, standard deviation and entropy are calculated for each input imaging
modality (dashed line). These features are combined in a random forest model to predict
hypoxia TBR for every supervoxel. The missing values at the top of the GTV (the contoured
structure) in the prediction image are supervoxels with high DCE-CT residuals (e.g. motion) and
therefore excluded from analysis.
further analysis we included all supervoxels with at least 90 % of their voxels in the GTV.
Supervoxels with high residuals in the DCE-CT kinetic analysis (> 100× 33 (number of
DCE-CT frames)) were excluded from the analysis.
For every supervoxel, the median, standard deviation, and entropy of all voxels in
the supervoxels were calculated for the CT (HU), FDG PET (SUV), BF (ml/100 g/min),
and BV (ml/100 g). In addition the median HX4 TBR was determined in every
supervoxel.
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Building a random forest
Random forest models were trained in R (version 3.3.2) to predict hypoxia TBR
inside a supervoxel based on CT, FDG PET, BF and BV features. For this purpose,
patients were split in a training set (trial NCT01024829) and independent test set
(trial NCT01210378). All supervoxels of the tumours in the training set were grouped,
likewise for the supervoxels in the test set. The numbers of trees in the random
forest were fixed to 500. Cross validation of ten folds and five repeats was applied to
tune one model parameter, i.e. number of variables randomly sampled at each split,
and to evaluate the performance of the final model. Two models were trained: one
containing all features of the CT, FDG PET, BF and BV, and one with only the CT and
FDG PET features. Finally, a multivariable linear regression model was trained to serve
as benchmark for the random forest models.
Predicting tumour hypoxic volume
The predicted hypoxia TBR values for all supervoxels for each patient in the test set
were used to determine the hypoxic volume (HV). First, the outputs of the random
forest models were calibrated by refitting the prediction of the training set with a
linear regression and applying the fit to the prediction of the supervoxels in the test
set. Next, all supervoxels with a predicted TBR > 1.2 were defined as hypoxic and
summed for the patients in the test set. We chose a threshold of 1.2 in the absence of
a standardized threshold. Predicted hypoxic volumes were compared to the observed
hypoxic volumes based on the HX4 PET/CT scans. Tumours with a hypoxic volume
larger than 1 cm3 were classified as hypoxic. The 1 cm3 threshold was introduced to
have a robust metric that takes into account the imaging noise and limited resolution
of the imaging modalities.
Evaluating supervoxels
One extra random forest was trained to quantify the influence of the supervoxel over-
segmentation on model performance and to evaluate the need for this preprocessing
step. For this, no supervoxels were calculated and the FDG PET and DCE-CT param-
eter maps were rescaled to the planning CT scan resolution. Voxels with high DCE-
CT residuals were again excluded; all other voxels were used to train and validate the
model.
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Table 6.1. Patient and tumour characteristics for all patients together, for the training patients,
and the test patients.
Total Training Test
Patients 34 15 19
Gender Male 25 12 13
Female 9 3 6
GTV Median volume (cm3) 49 65 42
Volume interquartile range (cm3) 25–91 41–122 10–74
Median number of supervoxels 92 117 66
Supervoxel interquartile range 41–174 71–234 12–143
TNM (T) T2 12 6 6
T3 12 4 8
T4 10 5 5
TNM (N) N0 3 1 2
N1 2 1 1
N2 19 9 10
N3 10 4 6
TNM (M) M0 28 15 13
M1 6 0 6
Pathology Adenocarcinoma 13 6 7
Squamous cell carcinoma 11 6 5
Large-cell carcinoma 6 2 4
Not otherwise specified 4 1 3
Results
In total, we included 34 NSCLC patients (age 65 years ± 8 years) who all received an
FDG and an HX4 PET/CT as well as a DCE-CT scan. The median GTV was 49 cm3
(interquartile range (IQR): 25–91 cm3). More patient and tumour characteristics are
provided in Table 6.1. The gross tumour volumes were subdivided in a median 92
(IQR: 41–174) supervoxels per patient. The training set contained 15 patients, with
a total of 3291 supervoxels, while the test cohort consisted of 19 patients with a
total of 1502 supervoxels, see Table 6.1. The supervoxels contained on average
405 voxels ± 76 voxels (0.4 cm3 ± 0.1 cm3). An example patient, with the different
imaging modalities and the supervoxel segmentation is shown in Figure 6.1.
The supervoxel approach retains spatial information, while improving the signal-
to-noise ratio. From the predicted TBR values for each supervoxel, hypoxia parameter
maps can be reconstructed for a tumour. In Figure 6.1 such a hypoxia map is shown
for the best performing random forest model using all imaging features. The predicted
hypoxia map shows a visually similar pattern compared to the hypoxia PET/CT scan.
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Figure 6.2. Boxplots comparing the root mean square error (RMSE) of the three different models.
The models are ranked from worst to best performance on the training set based on cross-
validation (10 folds, five repeats).
The random forest model with all features (n = 12) gave the best performance
with a root-mean-square error (RMSE) in hypoxia TBR prediction of 0.19 ± 0.01 for
the training set, and 0.27 for the test set. The random forest with only CT and FDG
features (n = 6) had a slightly worse performance with a RMSE of 0.20 ± 0.01 for
training and 0.29 for the test set. The restricted random forest model still outperformed
the multivariable linear regression with all features (training RMSE: 0.30 ± 0.02; test
RMSE: 0.43). In Figure 6.2 the RMSE of the models are compared. The random forest
directly trained on voxel values, i.e. without using supervoxel preprocessing, had a
higher RMSE compared to both supervoxel random forest models with 0.26 ± 0.00 on
the training data and 0.30 on validation.
The hypoxic areas based on the HX4 PET measurements had a median volume of
1.4 cm3 (IQR: 0–10.6 cm3) for the 18 patients in the test set. For one of the patients,
all supervoxels had a high DCE-CT residual and were excluded from the analysis. The
measured hypoxic volumes and predicted volumes had an absolute median difference
of 1.1 cm3 (IQR: 0.1–4.9 cm3) for the random forest with all features, 0.8 cm3 (IQR:
0.0–6.6 cm3) for the restricted random forest model and 1.7 cm3 (IQR: 0.3–11.8 cm3)
for the multivariable linear regression model. All models underestimated the hypoxic
volumes for tumours with large hypoxic volumes, see Figure 6.3.
All tumours in the test set were correctly classified as hypoxic (hypoxic volume
> 1 cm3) or not-hypoxic by the random forest with features of all image modalities.
Both the random forest with CT and FDG features, and the multivariable linear
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Figure 6.3. Hypoxic volumes (HV) for the patients in the test set: measured HV versus predicted
HV for the two random forest models and multivariable linear regression.
regression model misclassified 3 out of 18 patients, of which two patients were
misclassified by both, Figure 6.3.
Discussion
To our knowledge, the present study is the first data-driven approach to predict
baseline hypoxia levels and to create a virtual hypoxia PET image for non-small cell
lung cancer patients. Other published approaches to simulate tumour oxygenation
have been fully based on mathematical models [21, 22], or a combination of a
mathematical model and anatomical input, using for example histology [22] or MRI
[23]. None of the published methods are solely based on patient specific non-invasive
imaging.
The best performance was achieved by training a random forest combining an
indirect hypoxia marker linked to perfusion (DCE-CT), a marker related to tumour
metabolism (FDG PET), and CT image features. The random forest outperformed a
multivariable linear regression using the same features. We managed to validate our
random forest in an independent test set of patients of a second clinical trial.
The introduction of supervoxels, instead of creating voxel-based models, tremen-
dously decreased the memory and calculation costs. More importantly, the super-
voxel model, with all features, outperformed the voxel-based approach, with a training
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RMSE difference of 0.19 versus 0.26, and test difference of 0.27 versus 0.30, respec-
tively. The supervoxel approach provides the additional benefit of being able to cal-
culate multiple features per supervoxel, such as the median, standard deviation, and
entropy we investigated. We decided to limit our research to these three commonly
used features and did not study other metrics due to the limited number of patients.
Other features could potentially further optimize the models.
The random forest model with features of all image modalities outperformed
the model with only CT and FDG PET features. However, if DCE-CT imaging is
not available, the restricted model could still provide valuable information because
the observed performance difference was minimal. FDG PET appears to be the
strongest indicator of hypoxia in NSCLC tumours and the most important predictor
in our models. Hypoxia levels increase with increasing FDG PET SUV non-
linearly and plateau around a SUV of nine; see Supplementary Figure S6.1 for the
individual contributions of all features to the best performing random forest model.
Interestingly, voxelwise comparison studies between FDG and hypoxia PET have
provided contradicting results regarding their correlation [9, 24]. All other features,
show a less pronounced effect on the predicted hypoxia levels and their contributions
have larger variations (Supplementary Figure S6.1). The first four most important
parameters are based on either FDG PET or CT, and do not include any DCE-CT
features. This, in combination with the limited increase in model performance
between the random forest based on FDG PET/CT or all image features, questions
the potential of perfusion imaging as a hypoxia marker in NSCLC. The relationship
between DCE-CT and hypoxia PET has not been studied intensively. On a tumour
level, negative correlations between perfusion parameters and hypoxia have been
shown [25]. Between immunohistochemical hypoxia markers and DCE-CT parameters
also moderate negative correlations have been found [26]. One hypothesis that could
explain the limited influence of DCE-CT on our hypoxia prediction is the difference
in signal generation between hypoxia PET and DCE-CT imaging. Hypoxia PET tracers
are trapped at the cellular level and only require a relatively small amount of positron
emitters to generate a signal, while DCE-CT analysis compares differences in contrast
uptake over time and averages the signal within every voxel.
The prediction of the hypoxic volumes is correct for NSCLC tumours with small
hypoxic regions, however, the larger hypoxic volumes were all underestimated. One
possible explanation would be that the training set does not represent the test set
well enough. We decided to separate the data of the two clinical trials in a training
and independent test set. The inclusion criteria of the trials are however different,
and therefore also the characteristics of the tumours. In our training data set
(NCT01024829, a dose escalation trial based on FDG PET/CT imaging), only patients
were included with a minimal tumour diameter of 4 cm, a pretreatment FDG SUVmax
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of 5.0, and no distant metastases. While in the test cohort (NCT01210378, standard
(chemo)radiotherapy with the addition of a vasodilating drug), inclusion criteria were
less rigid and almost all stage IB–IV NSCLC with curative intent were eligible, typically
including also smaller size lesions, see also Table 6.1. It is possible that not all
characteristics of the tumours in the test set are provided in the training data. We
decided to keep the two clinical trials separate and to train the models on the data
set with the most supervoxels. Mixing both datasets would most likely yield a better
result, however, the test and training set will no longer be independent and it is
more difficult to determine the generalizability of the model. Although it is rather
unique to have multimodality pretreatment imaging of this many patients, more as
well as more diverse patients are needed to further optimize the model. Furthermore,
the generalizability of the model should be tested in external data sets, possibly by
including also other 2-nitroimidazole PET tracers working with the same mechanism
such as FAZA or FMISO.
The extended random forest model correctly classified all tumours as hypoxic
or normoxic. Such a model could be applied to select NSCLC patients for hypoxia
targeting therapies (e.g. hypoxia targeted prodrugs), if hypoxia PET imaging is not
available. Preferably, the model would be based solely on FDG PET and CT as
these images are already available in clinical routine and the DCE-CT scan adds
an extra radiation and time burden to the patient. The random forest model
without the DCE-CT features, however, misclassified 3 out of 18 patients. The
performance of this restricted model is not sufficient enough for patient stratification
and should be further improved before implementing in clinical practise. Our
described modelling approach provides not only information on the total hypoxic
volume of the tumour, but also gives spatial information which could be used to
further personalize treatment. The described models, however, underestimate, the
larger hypoxic volumes. This should be improved in further research, possibly by using
more (diverse) patients to train the models on.
In conclusion, we created a methodology to predict hypoxia levels and hypoxia
spatial patterns in non-small cell lung cancer using multiparametric imaging. This
data-driven strategy can aid tumour hypoxia classification and patient stratification.
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Figure S6.1. Partial dependence plots of all features in the best performing random forest model.
The plots indicate the partial relationship between the individual features and the modelled
outcome, while keeping all other features constant. The features are ordered by importance, in
reading direction. The grey area depicts the interquartile range and the black line the median
partial dependence.
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Abstract
Background and purpose We aimed to identify tumour subregions
with characteristic phenotypes based on pretreatment multiparametric
functional imaging and to correlate these subregions to treatment
outcome. The subregions were created using imaging of metabolic activity
(FDG PET/CT), hypoxia (HX4 PET/CT) and tumour vasculature (DCE-CT).
Materials and methods Thirty-six non-small cell lung cancer (NSCLC)
patients underwent functional imaging prior to radical radiotherapy.
Kinetic analysis was performed on DCE-CT scans to acquire blood flow
(BF) and volume (BV) maps. HX4 PET/CT and DCE-CT scans were non-
rigidly coregistered to the planning FDG PET/CT. Two clustering steps
were performed on multiparametric images: first to segment each tumour
into homogeneous subregions (i.e. supervoxels) and second to group the
supervoxels of all tumours into phenotypic clusters. Patients were split
based on the absolute or relative volume of supervoxels in each cluster.
Overall survival was compared using a log-rank test.
Results Unsupervised clustering of supervoxels yielded four indepen-
dent clusters. One cluster (high hypoxia, high FDG, intermediate BF/BV)
related to a high-risk tumour type: patients assigned to this cluster
had significantly worse survival compared to patients not in this cluster
(p = 0.035).
Conclusions We designed a subregional analysis for multiparametric
imaging in NSCLC, and showed the potential of subregion classification as
a biomarker for prognosis. This methodology allows for a comprehensive
data-driven analysis of multiparametric functional images.
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Introduction
Tumours often display significant intratumour heterogeneity at the time of diagnosis.
Genetic differences, in combination with regional variation in the tumour microen-
vironment, result in phenotypically distinct tumour subregions [1, 2]. Characteristics
such as metabolic activity, proliferation, cell death, and vasculature vary throughout
the tumour, influencing the sensitivity to (radio)therapy [3]. Identifying therapy re-
sistant subvolumes could give greater insight into the underlying biological processes
that adversely affect patient outcome, and could propel development of personalized
therapies [4] by, for example, escalating radiation dose in treatment resistant areas
[5, 6] or by combining targeted drugs and dose modifications [7].
Imaging provides a minimally invasive way to quantify both anatomical and
functional spatial variations in the tumour and tumour microenvironment. For
instance, different PET and SPECT tracers allow visualization of a range of biological
processes (e.g. metabolic activity, proliferation, and hypoxia), and dynamic contrast-
enhanced CT or MRI scans can demarcate vasculature of the tumour. Most imaging
based features used in clinical practice neglect spatial differences; they only consider
simple characteristics, such as maximum or average tumour values. Voxelwise
approaches, on the other hand, use all available data, but are sensitive to noise.
Subvolume analysis could combine the advantages of both strategies by reducing the
influence of noise without neglecting intratumour heterogeneities.
Current methods to calculate regional imaging features to identify subvolumes
are based on binary classifiers (i.e. presence or absence of a feature), threshold
values [8, 9], geographical location (e.g. tumour rim versus core [9, 10]), or data-driven
approaches [11, 12]. The first three methods all require a priori knowledge about the
appropriate imaging features or thresholds, which needs to be derived from previously
acquired data or biological insights [2]. These strategies can validate the utility of
previously determined thresholds, however, they are limited in their ability to derive
information from the images. Data-driven approaches, in contrast, do not require
any prior knowledge and directly depend on the input images. Wu et al. showed the
feasibility of data-driven approaches in lung cancer to determine tumour subregions
based on CT and FDG PET [11]. However, a methodology to comprehensively assess
subregions based on anatomical imaging in combination with multiple functional
imaging modalities, including hypoxia and tumour vasculature, is still lacking.
Our aim was to derive a methodology to combine multiple functional imaging
techniques to identify high-risk tumour subregions in NSCLC patients treated with
(chemo)radiotherapy. We developed a data-driven clustering approach to correlate the
subregions to patient prognosis using FDG PET/CT (metabolic activity), HX4 PET/CT
(hypoxia), and dynamic contract-enhanced CT (DCE-CT; tumour vasculature).
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Materials and methods
Patient selection and treatment
We analysed 36 stage IB–IV NSCLC patients included in two prospective clinical trials
(NCT01024829 [13] and NCT01210378). Both trials were approved by the Medical
Ethics Review Committee and all patients gave written informed consent. The first
trial was designed to improve local control by uniformly boosting the tumour or
by boosting the high uptake area on FDG PET/CT. The patients received 66 Gy
in 24 fractions with an integrated boost, with or without concurrent or sequential
chemotherapy. The boost dose was maximized until normal tissue constraints were
met. Patients that could not receive dose escalation were treated with the standard
66 Gy or lower in 24 fractions. The second clinical trial was designed to increase overall
survival by adding a vasodilating drug to standard (chemo)radiotherapy. All curative
radiotherapy schedules were allowed. One patient received stereotactic radiotherapy
(60 Gy in 8 fractions). The other patients received 53–70.2 Gy in 30–42 fractions. The
majority of the patients of both trials received concurrent chemotherapy; one patient
received neoadjuvant chemotherapy, one patient sequential chemotherapy, and two
patients were treated by radiotherapy only.
Image acquisition
The pretreatment imaging protocol was identical for the two clinical trials. All patients
included in our analysis received a planning FDG PET/CT, HX4 PET/CT and DCE-CT
scan, within a week before the start of radiotherapy. For one patient only, the time
between the imaging exceeded one week (11 days). For all scans, the patients were
placed in treatment position: on a flat table with a headrest, arm and knee supports.
A 4D respiratory gated FDG PET/CT was acquired for treatment planning purposes.
One hour after injecting 201 MBq± 49 MBq FDG tracer, the patients were scanned on a
Siemens Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany). The
PET scans were corrected for attenuation using the midventilation phase of the 4D CT
scan, scatter, and random coincidences. The PET images were reconstructed (OSEM or
PSF algorithm) to 4 by 4 mm voxels, with a slice spacing of 3 mm. The CT image had the
same slice spacing with 1 by 1 mm voxels. PET standardized uptake values (SUV) were
calculated by correcting for body weight, injected dose, and decay. The PET and the
midventilation CT image were fused and used for the delineation of the gross tumour
volume (GTV) of the primary tumour by an experienced radiation oncologist.
Hypoxia HX4 PET/CT scans and DCE-CT scans were acquired as part of a
translational research programme of both clinical trials. For the hypoxia PET, patients
were scanned 4 hours after injecting 418 MBq ± 75 MBq of the HX4 PET tracer on a
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Gemini TF64 PET/CT scanner (Philips, Best, the Netherlands) [14, 15]. PET images
were corrected for attenuation, using a low-dose CT scan, and for scatter and random
coincidences. A BLOB-OS-TF algorithm (3 iterations and 33 subsets) was used to
reconstruct PET voxels of 4 by 4 mm with a slice spacing of 4 mm. Tumour-to-
background ratios (TBR) were calculated by dividing tumour SUV by the mean SUV
in the aortic arch.
DCE-CT scans were acquired on a second or third generation dual source CT
scanner (SOMATOM Definition Flash or SOMATOM Force, Siemens Healthcare,
Erlangen, Germany). An 80 kVp CT scan was acquired of the primary tumour every
1.5 seconds for 33 consecutive frames, after injecting 60 or 65 ml iodine-based contrast
material (Iopromide 300, Bayer Healthcare, Berlin, Germany). The contrast material
(7 ml/s) was followed by injection of a saline chaser of 30 or 40 ml (7 ml/s). The
scans were reconstructed to 0.8 × 0.8 mm voxels with a slice thickness of 5 mm,
using a B20f filter. Acquisition was performed in expiration breath hold. If breath
hold could not be maintained, patients were asked to continue shallow breathing. All
33 scans were aligned to the first scan using a fluid-based registration to compensate
for possible movement artefacts. Next, a noise reduction was performed (syngo
MMWP, version VE40A; Siemens [16]). The registered images were smoothed with a
median 5 voxel filter and resampled to a 256× 256 grid (1.6× 1.6 mm). Kinetic analysis
was performed on the preprocessed images, using an adiabatic approximation to the
tissue homogeneity model (ATH) [17, 18]. The arterial input function was determined
by delineating a region of interest in the aortic arch. Finally, parametric maps were
calculated for tumour blood flow (BF), in ml/100 g/min, and tumour blood volume
(BV), in ml/100 g.
Image registration and supervoxel segmentation
All image modalities were registered to the planning CT scan. The CT scan of
the HX4 PET/CT and the first frame of the DCE-CT scan were first aligned to the
planning CT scan, and thereafter, deformed using a non-rigid registration using the
Elastix toolbox [19, 20]. The HX4 PET scan, and the BF and BV maps were deformed
accordingly. The voxels were resampled to create isotropic voxels of the inplane
dimensions of the planning CT scan (1 × 1 × 1 mm). A weighted average image was
constructed by normalizing each image, by calculating z-scores, and summing these
z-score maps. The weighted average image was used to subdivide the GTV using
so-called supervoxels; similar voxels were clustered into homogeneous 3D patches
preserving local boundaries. This strategy was chosen to minimize the effect of
registration uncertainties, reduce the amount of data, and reduce noise. An adapted k-
means clustering algorithm called Simple Linear Iterative Clustering (SLIC [21]), with
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a compactness of 20 and size of 400 voxels (typically 0.4 cm3), was used to create
supervoxels. Only supervoxels with at least 90 % of their voxels in the GTV of the
primary tumour and CT Hounsfield units larger than 100 HU, to exclude partial volume
effects of lung tissue, were used for further analysis. Furthermore, supervoxels with
a high residual in the DCE-CT kinetic analysis (> 100 × 33), i.e. squared-difference
of the calculated and measured tumour enhancement, were excluded from analysis.
Meaning that at each time point, a maximum difference between the fitted and
observed enhancement of 10 HU was allowed. For voxels exceeding this empirical
threshold, no accurate fit was expected to be achieved either because of the model
assumptions were violated or because the signal was too low in that voxel. The
uncertainty of the model strongly depends on noise levels and increases as the signal-
to-noise ratio drops (SNR < 5) [22]. For each supervoxel, the median image values
of the voxels within that supervoxel were calculated for the midventilation scan of
the planning CT (HU), FDG PET (SUV), HX4 PET (TBR), BV (ml/100 g) and BF
(ml/100 g/min).
Clustering of the supervoxels and linking to overall survival
The median supervoxel image values were normalized by calculating z-scores. Next,
the normalized image values of all patients were grouped using a hybrid hierarchical
clustering. This unsupervised clustering approach first creates mutual clusters, i.e.
points closely related to each other that cannot be separated, and then performs a top-
down clustering based on those small basic elements [23]. To determine the number of
clusters to use for further analysis we optimized the between and within cluster sum
of squares (Calinski and Harabasz index [24]) and visually assessed the dendrogram.
Clusters were assigned to all supervoxels of all patients. Thereafter, the tumours were
assigned to one or more clusters depending on the absolute or relative volume of
supervoxels present from each cluster. We assigned a tumour to a cluster if it contained
a significant amount of supervoxels of that cluster: i.e. more than 50 % of the tumour
or more than the median volume over all patients.
Finally, a log-rank test was used for each cluster to assess overall survival
differences between the patients assigned to the clusters versus patients not belonging
to those clusters. The overall survival time was defined as the time between pathologic
diagnosis and death from any cause. A graphical representation of the workflow is
shown in Figure 7.1. The clustering and survival analysis was performed using R: A
Language and Environment for Statistical Computing (v3.3.2, Vienna, Austria).
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Cluster the supervoxels
CT BV
Multiparametric functional imaging Sum normalized images
and create supervoxels
Combine image data 
of all supervoxels 
of all patients
Link clusters to outcome
FDG PET HX4 PET BF
Figure 7.1. The processing workflow. For each patient, the multiparametric images are
normalized and summed, and used to create supervoxels (top row). For each supervoxel, the
median of all image features are calculated. Next, the supervoxels of all patients are combined
and clustered based on their image features. Patients are assigned to the different clusters and
differences in overall survival between the groups can be assessed.
Results
The GTV ranged from 3 to 1449 cm3 (median 53 cm3). For all patients, supervoxels
could be created, ranging from 4 to 2028 (median 89) supervoxels per tumour. After
removing the supervoxels with high DCE-CT residuals or low CT HU, one patient had
zero supervoxels and was excluded from further analysis. This tumour was relatively
small (6.9 cm3) and had initially only 4 supervoxels. The number of supervoxels for the
remaining 35 patients ranged from 1 to 1744 (median 60). More patient and tumour
details for these 35 patients and the analysed supervoxels are listed in Table 7.1.
The unsupervised clustering of all supervoxels over all patients provided four
independent groups see Figure 7.2, determined by the local maximum of the Calinski
and Harabasz index. The first cluster (purple) was characterized by low blood flow
and blood volume, and low PET uptake values. The second cluster (turquoise) had low
perfusion values and intermediate PET uptake values; the third cluster (olive green)
had intermediate perfusion values and the highest HX4 SUV and FDG SUV; the fourth
cluster (pink) had a relatively high blood flow and blood volume with intermediate PET
uptake values. The CT values were relatively heterogeneous in each cluster. See also
Table 7.2 for the average values and standard deviations per cluster. The first cluster
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Table 7.1. Patient and tumour characteristics of the 35 patients used for the cluster analysis.
Patients 35
Gender Male 26
Female 9
GTV Median volume (cm3) 53
Volume interquartile range (cm3) 33–113
Median number of supervoxels 60
Supervoxel interquartile range 19–135
TNM (T) T2 11
T3 12
T4 12
TNM (N) N0 3
N1 2
N2 20
N3 10
TNM (M) M0 28
M1 7
Pathology Adenocarcinoma 13
Squamous cell carcinoma 11
Large-cell carcinoma 6
NSCLC not otherwise specified 5
Table 7.2. Image feature averages and standard deviations over the supervoxels per cluster.
Cluster
CT BF BV HX4 FDG
(HU) (ml/100 g/min) (ml/100 g) (TBR) (SUV)
1 32.3 ± 8.5 15.6 ± 7.4 1.2 ± 0.6 0.4 ± 0.2 1.4 ± 1.1
2 18.3 ± 22.0 24.3 ± 12.5 2.6 ± 1.5 1.1 ± 0.2 4.4 ± 2.2
3 28.9 ± 12.7 45.4 ± 15.1 5.3 ± 1.8 1.4 ± 0.3 8.4 ± 3.7
4 29.0 ± 19.3 78.7 ± 30.4 8.9 ± 3.3 1.0 ± 0.2 4.4 ± 2.0
(purple) is mainly dominated by one patient (717/808 supervoxels: 89 %), which is
shown in green in Figure 7.2. This patient had the largest number of supervoxels (1744;
854 cm3) (third patient in Figure 7.3). In the other clusters, there was a more even
contribution of a mix of patients.
With all supervoxels assigned to a cluster, we could evaluate the contribution of
each cluster to each tumour. In Figure 7.3, three example patients are shown with
the supervoxel segmentation and assignment of the supervoxels to one of the four
clusters. Four patients had supervoxels only belonging to one supervoxel cluster. For
the other 31 patients, a mix of two, three or four clusters was identified; see Figure 7.3
and Supplementary Table S7.1.
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Figure 7.2. Heatmap and dendrogram of all supervoxels of all patients. Each row is one
supervoxel. The imaging values are normalized z-scores of the median of the voxels in one
supervoxel. The histogram and colour range of all normalized values is show in the top left.
The dendrogram is divided in four clusters, indicated by the four colours of the dendrogram
(cluster 1: purple; cluster 2: turquoise; cluster 3: olive green; cluster 4: pink). The first coloured
bar indicates the patient the supervoxel belongs to: every colour is a different patient.
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FDG HX4
BF BV
FDG HX4
BF BV
FDG HX4
BF BV
Figure 7.3. Three example patients of the clustered supervoxels. The two top rows show
the functional images (FDG PET, HX4 PET, blood flow, and blood volume) overlaid on the
CT image. The same scaling is applied for each imaging modality for all three patients. The
multiparametric images are used as input to create the four supervoxel clusters as shown in the
bottom row. One tumour can consist of only one type of supervoxels (left), or a mix of two, three
or four clusters. In this example, the first patient belongs to the pink cluster, the second patient
to the turquoise and olive green cluster, and the third patient to all four clusters.
Based on the supervoxel distributions, patients were assigned to the different
clusters. For one of the clusters (cluster 3; olive green), a significant survival difference
was observed. Patients (n = 17) with a high relative or absolute volume of cluster 3 had
a significant worse survival compared to patients not assigned to this cluster (n = 18)
(p = 0.035). This cluster was mainly characterized by a high HX4 uptake (average TBR
of 1.4), and a high FDG SUV (average SUV of 8.4). At two years, the patients not in this
cluster had a 2.6 times higher survival probability (67 %), compared to patients with
a significant amount of supervoxels of this high-risk subgroup (26 %). For the other
three clusters, no survival difference was found with a log-rank p-value of 0.935, 0.730
and 0.465 for respectively, cluster 1 (purple), cluster 2 (turquoise) and cluster 4 (pink).
Discussion
We explored a data-driven approach to identify tumour subregions with characteristic
phenotypes based on pretreatment multiparametric imaging, and related these sub-
regions to overall survival of NSCLC patients treated with definitive (chemo)radiation.
Our method was designed to reduce the influence of registration uncertainties and
of noise, while maintaining subregional information, by clustering the voxels into su-
pervoxels. The methodology allowed for combining data of the whole population by
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clustering the supervoxels of all patients, in order to generate population based phe-
notypical subtypes. We found four distinct phenotypical clusters: one indicative for
necrosis (low blood flow/volume and low PET uptake), one with low perfusion and
intermediate PET values, one solely indicative of the high PET uptake, and one associ-
ated with relatively high tumour perfusion.
We could link these supervoxels subtype clusters to patient prognosis. Patients
with subregions with a high HX4 TBR, FDG SUV and intermediate BF and BV, had a
significantly worse prognosis compared to patients without a high absolute or relative
volume of these subregions. Our findings are in agreement with Wu et al. who found
in a similar type of analysis for FDG PET/CT that the most metabolically active and
metabolically heterogeneous subvolumes were prognostic for overall survival [11]. In
addition, we found that these metabolically active regions are highly hypoxic with a
rather average blood perfusion and blood volume. Hypoxia is a well-known factor
resulting in a worse prognosis in most solid tumours [25]. In NSCLC, a variety of
hypoxia PET tracers was used to evaluate overall survival or progression free survival. A
significantly worse overall survival was found for patients with tumours with high TBR
values [26, 27]. Also for progression free survival, a significant survival disadvantage
was observed for patients with higher hypoxia SUV or TBR values [26, 28, 29]. All above
studies showed a survival difference between hypoxic and non-hypoxic tumours,
however, the thresholds varied between studies and hypoxia tracers. For FDG PET, only
a subset of studies evaluating SUVmax found this to be prognostic [26, 27]. The tumour
volume with an increased metabolic activity was shown as independent prognostic
factor for survival in several studies. In these studies, patients with a larger metabolic
volume generally had a worse prognosis [30, 31]. Only few studies have been published
assessing the prognostic value of pretreatment DCE-CT imaging. Win et al. found
that low tumour permeability was prognostic for survival [32]. Lazanyi et al. found a
negative correlation between blood volume and progression in a subset of patients,
and a negative correlation between Ktrans and progression and overall survival for
all patients [33]. We did not study tumour permeability, due to limited DCE-CT
acquisition time optimized for blood flow and volume characterization, and could not
reproduce this effect in the cluster related to survival. Although one cluster (cluster 4)
showed increased perfusion values, no clear effect in outcome was observed.
One major advantage of our method is that defining thresholds is not required; no
prior knowledge of image features is necessary. The unsupervised clustering method
groups supervoxels based on the underlying data and the created clusters can be linked
to outcome. However, the analysis does require some user input at different levels of
the workflow. First, to create the supervoxels, we evaluated different combinations
of size and compactness and visually assessed the results by inspecting adherence
to local boundaries. We aimed to make the clusters small enough to maintain local
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structures, while large enough to reduce noise. Next, the hybrid hierarchical clustering
creates a tree, a dendrogram, of clusters, which can be cut at every height depending
on the desired number of clusters. Large clusters are more heterogeneous, while small
clusters are more difficult to link to outcome. We optimized this by evaluating the
within and between cluster sum of squares. Finally, the patients were assigned to the
different clusters based on their supervoxel distribution. We decided to group the
patients that had either a high absolute or high relative volume of supervoxels of a
certain cluster. We tested the prognostic value of the total tumour volume to confirm
that the observed results are not driven by tumour volume and found no significant
value (p = 0.327). The assignment of the patients to the different clusters could be
further evaluated and optimized with more patients available.
One factor that needs to be stressed is that in this study we analysed patients
of two clinical trials receiving either dose escalation based on FDG PET/CT, with or
without concurrent or sequential chemotherapy, or standard (chemo)radiation with
addition of a vasodilating drug. The heterogeneity in treatments and dose ranges
could have influenced the patient prognosis. The cohort is however too small to study
these influences. In addition, for the clustering, all supervoxels of all patients were
combined, increasing the influence of the larger tumours on the clustering results.
The data set used is rather unique with 36 NSCLC patients scanned shortly before
treatment using four different imaging modalities. Such a dataset is difficult to
obtain and only possible in a dedicated research setting. Our clustering methodology,
however, could be applied on any multiparametric imaging set, pre- or posttreatment
imaging. The availability of multiparametric imaging will probably increase in the
future, especially with for example MRI techniques that allow multiple sequences
within the same session to acquire a range of functional images. With the increasing
availability of multiparametric imaging, there will be a need for comprehensive
analysis methods of these images.
To conclude, we designed a data-driven methodology for the analysis of
pretreatment multiparametric imaging data in NSCLC patients on a subregional level.
We showed that such an intratumour classification of heterogeneous subregions may
allow to predict NSCLC patient prognosis after (chemo)radiation. This technique
permits further insight into the underlying biological characteristics using an
advanced analysis technique for multiparametric functional images.
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Supplementary data
Table S7.1. Number of supervoxels per cluster (C1–C4) and assignment of the patients to the
four clusters. Patients can be assigned to multiple clusters.
Patient per cluster
Number of supervoxels
(>median supervoxels or > 50%)
Patients assigned to cluster
C1 C2 C3 C4 C1 C2 C3 C4
1 0 16 16 28 0 0 0 1
2 0 4 0 0 0 1 0 0
3 0 122 70 10 0 1 1 0
4 1 82 83 1 1 1 1 0
5 0 8 0 11 0 0 0 1
6 0 1 0 0 0 1 0 0
7 0 97 34 175 0 1 1 1
8 0 0 1 1 0 0 0 0
9 0 0 1 5 0 0 0 1
10 0 0 2 9 0 0 0 1
11 14 69 16 188 1 1 0 1
12 0 0 1 0 0 0 1 0
13 1 22 0 3 1 1 0 0
14 0 10 1 7 0 1 0 0
15 5 16 0 13 1 0 0 1
16 16 42 22 20 1 1 1 1
17 0 5 83 29 0 0 1 1
18 0 25 14 0 0 1 0 0
19 12 407 245 63 1 1 1 1
20 0 11 21 6 0 0 1 0
21 0 27 51 4 0 1 1 0
22 717 468 339 220 1 1 1 1
23 2 46 70 24 1 1 1 1
24 0 0 1 85 0 0 0 1
25 19 275 101 3 1 1 1 0
26 0 5 38 36 0 0 1 1
27 1 0 1 0 1 0 0 0
28 0 62 5 5 0 1 0 0
29 0 20 3 21 0 1 0 1
30 0 3 17 2 0 0 1 0
31 0 7 83 25 0 0 1 1
32 0 12 1 16 0 0 0 1
33 19 122 20 101 1 1 1 1
34 1 4 0 0 1 1 0 0
35 0 40 60 28 0 1 1 1
Median 0 16 16 10
Patients per cluster 12 20 17 19
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Background
With the introduction of combined imaging modalities including PET/CT and
more recently PET/MRI, there is strong interest in utilizing these independent
modalities in a synergistic way. Multiparametric imaging research has been mainly
accelerated by the MRI community, as MRI offers the possibility to visualize diverse
properties of tissues by acquiring different sequences (e.g. ADC mapping, T1/T2-
weighted images). More recently, several research papers have been published
investigating multiparametric imaging in a variety of cancer types using combined
nuclear medicine imaging techniques, with one or more radioactive tracers, together
with advanced MR or CT imaging equipment [1–5]. The increased number of
standardization (or harmonization) procedures that are being rolled out in all
modalities are helping drive multiparametric imaging forward [6, 7]. These procedures
should remove some of the uncertainties and difficulties that multicentre trials
face in quantitative analysis and facilitate more robust quantitative imaging-derived
parameters [8].
A multitude of imaging techniques are currently available for visualizing tumour
morphology and biology in vivo. CT and MRI both provide morphological information.
Biological processes that are dysregulated in cancer cells and distinguish malignant
tissue from healthy tissue can be visualized using nuclear medicine-based techniques,
MRI, and CT. For many years, PET tracers focussed on general features of
tumours or normal tissues. The classic marker for ATP-independent GLUT-mediated
deoxyglucose uptake, which is often upregulated in tumours, is FDG. Uptake of
FDG is commonly considered an indicator of “metabolism” although it reflects only
a small part of the metabolic process. Another tumour hallmark that can be visualized
using PET imaging is the activity of thymidine kinase 1, an enzyme involved in DNA
synthesis, as a surrogate for most cell proliferation. Fluorothymidine (FLT) is the most
studied tracer for this purpose. Most solid tumours are, in addition, characterized
by a low oxygen levels, i.e. hypoxia. Frequently used hypoxia PET tracers, based
on 2-nitroimidazoles (e.g. FMISO, FAZA, HX4), visualize increased reductase activity
in cells with insufficient oxygen, but do not show the molecular consequences of
hypoxia. MRI and CT can be used for imaging of the tumour vasculature. The
chaotic and poor vasculature of tumours is often inadequate and results in diffusion-
limited or perfusion-limited hypoxia. Dynamic contrast-enhanced CT or MRI (DCE
CT/MRI) allows investigation of the vasculature (e.g. tumour permeability and blood
flow) by typically following injection of a contrast agent over time as it passes
through the tumour blood vessels. Diffusion-weighted MRI (DWI MRI) facilitates
mapping of diffusion patterns of water molecules, a characteristic related to cellular
density. These advanced MRI techniques have a role in the standard guidelines for
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distinguishing malignant involvement from benign conditions in prostate cancer and
pleural mesothelioma, for example [9, 10]. Novel PET tracers have been developed
for specific receptor imaging, including PET-labelled drugs. Examples include
18F-erlotinib, 89Zr-bevacizumab, 89Zr-trastuzumab and 68Ga-PSMA. The last of these
is increasingly used in oncology as it may lead to treatment changes [11].
Even though a wide range of imaging techniques are available, not many functional
imaging markers have gained wide acceptance in standard practice, except FDG PET.
Of all imaging techniques, no single modality or tracer can answer all questions,
and so multimodality imaging should be individually tailored to the specific research
question or clinical question.
How to move forward
It has been recognized for a long time that tumours are frequently heterogeneous
in their presentation and behaviour. Multiparametric imaging allows investigation
of this heterogeneity. Subvolumes with distinct properties inside tumours can be
identified. For example, information on perfusion in subvolumes combined with
hypoxia imaging may reveal differences between perfusion-limited hypoxia and
intrinsic tumour hypoxia [12–14], or may explain the lack of accessibility of targeted
agents to a receptor on the tumour cell.
The large amount of information we can currently gather from these advanced
imaging techniques is undoubtedly interesting. However, the next question is how to
identify which biological processes are relevant, how these processes influence patient
prognosis, and finally how to individualize treatment based on this information. We
envisage two distinct strategies to move forward.
Strategy 1: The agnostic data-driven approach
A way to link imaging studies to a clinically relevant outcome is through so-called
pattern of relapse studies. Such studies allow correlation of imaging features with
the patient or tumour outcome (e.g. recurrence location) using follow-up imaging
of various lesions [15–18]. Alternatively, the imaging characteristics with biological
properties can be validated in a surgical specimen [19–22]. Either of these data-
driven approaches are attractive because no complete molecular knowledge is needed:
the observations drive the identification of treatment resistant areas in a pragmatic,
agnostic way.
The drawback is clearly that no further biological precision can be obtained easily.
Another downside of this approach is its data-driven nature: many patients need to be
imaged before these patterns of relapse can be accurately quantified, especially when
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these features divide the cohort into smaller subgroups, resulting in insufficient data.
A comprehensive understanding of the combined imaging modalities is also essential.
All imaging modalities have their own inherent uncertainties, e.g. artefacts on MRI,
limited resolution of PET, uncertainties in kinetic modelling with DCE CT/MRI. These
uncertainties of the individual imaging modalities together with registration effects
could explain why correlations found between imaging modalities at the tumour and
subtumour levels are no longer present at the voxel level. For example, a simulation
study showed blurring of the underlying pathology because of the limited resolution
of PET scanners [23].
One possible way to integrate multiparametric imaging in treatment individualiza-
tion is by using radiotherapy “dose painting”. The radiation dose can be redistributed
over different tumour regions according to the expected treatment sensitivity derived
from imaging data to improve local tumour control without increasing toxicity. Sev-
eral clinical trials are looking into this approach, and treatment personalization can be
performed at different levels; ranging from the subvolume level to the very fine voxel
level [24–26]. Similarly to the pattern-of-relapse studies, dose painting requires de-
tailed analyses to find dose-response relationships between functional imaging, un-
derlying pathology, and outcome to design appropriate clinical trials.
Strategy 2: Biology-driven approach
Up to the present date, clinical guidelines are written for a defined population,
typically derived from phase III clinical trials. As subgroups become smaller eventually
coming down to a personalized level, the agnostic data-driven approach is no longer
possible. As all individuals and their disease are unique, so too will all tumours and
even all tumour cells be found to be unique [27]. Tailoring a treatment for each cell and
particularly proving that the outcome in the patient was due to this intervention would
be impossible. However, there is an opportunity for molecular imaging in this area. It is
possible to individualize the treatment by knowing more precisely the main molecular
characteristics of a tumour that are distributed in a more or less homogeneous way
throughout the tumour. A classical example is the exon 19 or 21 mutation of the
EGFR gene in adenocarcinoma of the lung. While resistance will eventually occur in
all patients, in the beginning, the mutations are found in nearly all tumour cells and
are spread homogeneously throughout the tumour [28]. Before the tumour increases
in size, it shows increasing inhomogeneity that can be visualized [29]. Before classical
“disease progression” occurs, more precise imaging could identify patients who may
be switched to an alternative therapy. It is expected that the combination of molecular
knowledge underpinning the tumour’s biology, specific imaging probes, and image
analyses techniques will be an integral part of precision medicine. Multiparametric
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imaging might facilitate this approach by selecting the appropriate molecular imaging
tools that quantify tumour properties or stratify patients. A recent example from
the preclinical arena for precision medicine is hypoxia-activated prodrugs that only
show efficacy in hypoxic tumours [30]. Molecular imaging using hypoxia PET tracers
could allow identification of those patients who would benefit from these drugs. This
preselection could be a necessity for targeted drugs that might be too expensive to
prescribe without knowing the efficacy in the individual patient.
A possible downside of this approach is that because the biology of tumours is
complex it might be difficult to select the appropriate imaging technique to define the
optimal treatment. As mentioned above, tumour cells will typically develop resistance
against a single treatment and different pathways will be activated.
The future of imaging for precision medicine
The two strategies above both have their advantages and disadvantages and are most
likely complementary. Both require reliable and more robust imaging biomarkers,
standardization, validated endpoints, genetic information, and more sophisticated
trial designs. An important question will be how to implement these more advanced
imaging approaches in clinical routine taking into account their availability and
logistic considerations. Patient stratification and treatment monitoring will certainly
be crucial steps for precision medicine in which imaging might play a major role.
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General discussion
Despite substantial improvements in treatment options over the past decades, cancer
remains one of the worldwide leading causes of mortality and morbidity. The
prognosis between cancer types varies widely, with lung cancer as the number
one cause of cancer related deaths [1]. To improve response rates, and to reduce
unnecessary toxicity and costs, it is essential to quickly select the treatment with
the highest expected benefit for the patient. Imaging can aid this treatment
personalization by stratifying patients based on their prognosis and by predicting
treatment efficacy. Additionally, imaging biomarkers can map tumour heterogeneities
in 3D, identify resistant tumour areas, and guide treatment adaptation [2].
The research presented in this thesis aims to explore the use of functional imaging
to characterize the tumour and tumour subvolumes, and subsequently to use these
functional imaging characteristics for the prediction of patient prognosis, for patient
stratification, and for treatment adaptation in non-small cell lung cancer (NSCLC),
and head and neck cancer (HNC). We used various imaging modalities to visualize
and quantify several features related to the different hallmarks of cancer. Positron
emission tomography (PET) based imaging was used to visualize drug uptake, hypoxia
levels, and tumour metabolism. Dynamic contrast-enhanced CT (DCE-CT) was used
to image tumour vasculature.
Visualization of drug uptake for patient stratification
Monoclonal antibodies (mAb) have the ability to bind to specific targets on the tumour
with high specificity and affinity. Although they have the potential to target cancer
cells very selectively, their clinical benefit widely varies between patients. Labelling
the antibodies with long-lived radionuclides, such as Zirconium-89, can show the
distribution of the antibody in the tumour on PET and is hypothesized to be related
to treatment success [3].
We showed, in the first part of this thesis, the clinical feasibility of labelling the
epidermal growth factor receptor (EGFR) targeting drug cetuximab, with Zirconium-
89 (Chapter 2). No additional toxicity was associated with administration of 89Zr-
cetuximab compared to standard cetuximab. Of the two dose schedules tested, the
lower dose of 60 MBq 89Zr-cetuximab was recommended for future studies as the
higher dose (120 MBq) did not provide improved image contrast. The subsequent
phase II clinical trial (Chapter 3), showed a large variation in 89Zr-cetuximab uptake
between the 17 included head and neck cancer patients. A discrepancy was shown
between EGFR expression and 89Zr-cetuximab, confirming previously reported results
in mice [4]. We hypothesized that for cetuximab to be beneficial, sufficient targets
9General discussion and future perspectives 173
should be present in the tumour (i.e. EGF receptors), and cetuximab should reach
these targets. In tumours lacking EGFR expression, response to the targeted drug
was unexpected, while in tumours with high EGFR expression, the accessibility of
the tumour was expected to be an important factor in cetuximab effectiveness. As
hypothesized, we observed a mix of low and high 89Zr-cetuximab uptake in patients
with high EGFR expression. However, in one patient with a low EGFR expression,
a remarkably high 89Zr-cetuximab uptake was observed. Unfortunately, we were
unable to link treatment outcome to these observed differences in 89Zr-cetuximab PET
uptake, due to the small heterogeneous patient group with heterogeneous treatments
from four different treatment arms.
Until now, to our knowledge, only one other clinical trial has been performed
with 89Zr-cetuximab. This study in colorectal cancer did attempt to correlate 89Zr-
cetuximab uptake and outcome, and showed promising results, though in a very small
patient cohort. They found a clinical benefit in four out of six patients with uptake
of 89Zr-cetuximab in the tumour, while in three out of four patients without uptake
progressive disease was observed [5].
89Zr PET imaging is not limited to cetuximab, labelling of other monoclonal
antibodies has been explored in several studies. The first feasibility study using
Zirconium-89 labelled antibodies, was published in 2006 [6]. Since then, several other
studies have looked into the feasibility, biodistribution, optimal dose, and best imaging
time point, for different mAb and various tumour sites [7–14]. A few studies have
attempted to correlate treatment outcome and 89Zr-mAb PET imaging. Bahce et al.
showed a positive trend, although not significant, between 89Zr-bevacizumab uptake
(SUVpeak) and overall survival and progression free survival in NSCLC patients treated
with chemotherapy plus bevacizumab [15]. Oosting et al. found for 89Zr-bevacizumab
in renal cell carcinoma, that high baseline SUVmax was associated with a longer time
to progression [16]. A study of 89Zr-fresolimumab in high-grade glioma, showed good
uptake of labelled antibody, however, since all patients experienced recurrences, PET
uptake could not be related to clinical benefit and the study was closed early [17].
Gebhart et al. used combined 89Zr-trastuzumab and FDG PET/CT to predict outcome
of HER2 positive breast patients. With the combined approach, they could accurately
predict morphological response and stratify patients based on their time to treatment
failure [18].
In addition to baseline 89Zr-mAb PET imaging, some studies have explored the
possibility of imaging during or shortly after treatment, to quantify early response to
mAb treatment. Gaykema et al. performed 89Zr-trastuzumab and 89Zr-bevacizumab
PET imaging at baseline and after 15 days, in breast cancer patients [19]. Changes
on 89Zr-trastuzumab were positively associated with the response on CT. A study with
89Zr-bevacizumab in neuroendocrine tumours also found a correlation between the
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change in 89Zr-bevacizumab, between baseline 2, and 12 weeks after treatment, and
the response on CT [20]. Van Es et al. examined the potential of 89Zr-bevacizumab
PET as early indicator of treatment efficiency, at 2 and 6 weeks after start treatment, in
metastatic renal cell carcinoma [21]. All patients that completed treatment had stable
disease, and thus the potential of 89Zr-bevacizumab could not be evaluated.
Overall, the majority of the initial clinical trials with 89Zr-mAb have shown the
potential of (early) response prediction in several cancer sides. Most studies have
found heterogeneous PET uptake between patients, which would be one of the
essential preconditions for patient stratification [22]. The trials performed so far are
limited in their size; the number of included patients ranges between 7 and 23, with
one exceptionally large trial of 56 patients [18]. Further validation in larger clinical
trials is required.
Imaging of tumour hypoxia, vasculature, and metabolism
Hypoxia has been recognized as an important target in oncology. Tumour cells are
about three times as sensitive to radiation in a well oxygenated environment compared
to in an anoxic environment, in cell culture [23]. The poor vasculature in hypoxic
regions may also limit the distribution of chemotherapy, while at the same time
hypoxia promotes a more aggressive and metastatic phenotype [24, 25]. In Chapter 4,
we first evaluated the prognostic value of PET imaging with the hypoxia tracer 18F-
HX4 in NSCLC. We found that patients with hypoxia at baseline had significantly
worse overall survival compared to non-hypoxic tumours. This is the first study
evaluating the prognostic value of HX4 PET. Previous studies with different PET
tracers, have also found hypoxia to be a negative prognostic factor for survival in
NSCLC. A significantly worse overall survival was found for patients with elevated 18F-
FAZA, 62Cu-ATSM, or 18F-FETNIM PET uptake [26, 27]. Progression free survival was
negatively correlated with high 18F-FAZA, 62Cu-ATSM, or 18F-MISO uptake [27–29].
Hypoxia is a characteristic of most solid tumours and has shown to be prognostic in
other tumour sites, such as head and neck cancer and cervix cancer [30].
In Chapter 4, we tried to overcome tumour hypoxia by adding the vasodilating
drug nitroglycerin to standard (chemo)radiotherapy. In a randomized phase II trial in
NSCLC, nitroglycerin combined with chemotherapy showed a significant benefit over
chemotherapy alone [31]. However this result could not be replicated in other trials
combining nitroglycerin with chemotherapy or chemoradiotherapy [32–35]. None of
the mentioned clinical trials used the baseline hypoxia status to select patients. This
is a general problem with hypoxia targeting studies; as patient stratification is rare, the
full potential of hypoxia targeting strategies are not fully explored [36]. We aimed to
analyse the effect of nitroglycerin on tumour hypoxia and tumour vasculature for each
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individual patient, to ultimately predict the benefit of nitroglycerin on a patient level.
We found a mixed response of increases and decreases in both hypoxia and blood flow
and blood volume. A substantial decrease in hypoxia, as a results of the nitroglycerin
patch, was only found in a small subset of patients which was not sufficient to analyse
any improvement in outcome from nitroglycerin.
PET imaging with 2-nitroimidazoles based PET tracers (e.g. HX4, FMISO, FAZA) is
the most widely studied method to visualize hypoxia. These PET tracers are, however,
not widely available and can be expensive, cumbersome, and time-consuming to
implement in routine. In Chapter 6, we studied the feasibility of modelling tumour
hypoxia based on other, more widely available, imaging modalities. We could create
virtual hypoxia PET images, by combining information from FDG PET/CT and DCE-
CT scans. This technique may help stratify patients based on hypoxia status in
absence of a hypoxia PET scan. The tumours were subdivided in small homogeneous
patches, i.e. supervoxels, and for each subregion, hypoxia levels were calculated. This
spatial distribution of hypoxia could, for example, also be used for dose painting.
Although promising results were obtained, these models still require further validation
in a larger patient cohort and preferable with different hypoxia PET tracers. In the
best performing model, FDG PET appeared to be the most important predictor of
hypoxia, while DCE-CT features only marginally increased the performance. The
information on the tumour vasculature, in this study extracted from DCE-CT images,
could possibly be gained from contrast CT scans. This should be investigated in further
validation studies. To our knowledge, this study is the first fully data-driven approach
to create virtual hypoxia maps. Other studies predicting hypoxia have been based
on mathematical models, or a combination of mathematical models with anatomical
input, for example from histology or MRI [37–39].
In Chapter 7, we explored an approach to combine multiple imaging modalities
and to use the combined knowledge to assess patient prognosis. As discussed in
Chapter 8, with the increasing availability of multiparametric imaging, there is an
increasing need for analyses methods that can incorporate all available knowledge,
and allow to assess multiple biological and functional properties simultaneously. We
have developed such a technique and tested this on the same imaging set that was
used as in Chapter 6, containing FDG PET/CT, hypoxia HX4 PET/CT and DCE-CT
scans. An advantage of this technique is that uncertainties caused by the registration
of the images or noise, are reduced by clustering similar voxels into supervoxels. The
supervoxels of all tumours were grouped into four phenotypical clusters. The cluster
with a high HX4 PET uptake, high FDG PET uptake, and intermediate blood flow and
blood volume, was predictive for overall survival. Patients with a substantially high
volume of this supervoxel cluster had a significantly lower overall survival compared
to patients with a low relative or absolute volume of the cluster. Wu et al. performed
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a similar analysis in NSCLC, but only for CT and FDG PET imaging, and also found
that the most metabolically active and metabolically heterogeneous subvolumes were
prognostic for overall survival [40].
Functional imaging for treatment adaptation — dose painting
Dose painting is an attractive method to integrate tumour biology into radiotherapy
treatment planning. It is likely that tumour heterogeneity affects radioresistance. If
given a uniform dose throughout the tumour, local recurrences have shown to arise
from small radioresistant niches [41, 42]. Increasing the total radiotherapy dose to
the tumour could theoretically increase the tumour control probability and is the
safest approach if no information on radioresistance is available, however, the dose
escalation that can be achieved is often limited by the healthy organs surrounding
the tumour. In NSCLC it was shown that total tumour dose escalation without proper
patient selection could even be harmful [43].
Dose painting requires an imaging surrogate to map the radioresistant tumour
regions. Which imaging surrogate correlates best with radioresistance, and would
therefore be best suitable for dose escalation, is still a matter of debate. Several imaging
features linked to one of the hallmarks of cancer have been proposed. In Chapter 5,
we compared for NSCLC, uniform dose escalation to the whole tumour, with boosting
based on FDG PET and hypoxia HX4 PET, and found that a significantly higher dose
could be achieved for the PET-based dose painting approaches, without increasing the
dose to the organs at risk. The highest planned doses were feasible for the hypoxia PET
plans, which had the smallest boost volumes. The FDG PET dose painting and uniform
boosting are currently under evaluation in the prospective randomized PET-boost trial
(NCT01024829) [44]. Results are expected around October 2018. The phase II clinical
trial contained an extensive imaging protocol of FDG PET/CT, hypoxia HX4 PET/CT
and DCE-CT. These images were also used for the analyses performed in Chapter 6
and Chapter 7.
In NSCLC, several other trials have evaluated dose painting or are currently
studying the approach. Wanet et al. performed a single arm feasibility study of FDG
PET boosting in 13 patients. In peripheral tumours, they could achieve an average
dose of 89.2 Gy at acceptable toxicity rates. In central tumours, however, they observed
severe toxicity at an average dose of 75 Gy [45]. Vera et al. recently reported their results
on a hypoxia dose painting trial in locally advanced NSCLC [29]. Patients without
hypoxic tumours received a standard dose of 66 Gy; patients with baseline hypoxia
on FMISO PET scans received an extra boost, where the extra boost was limited by the
dose constraints of the lungs and spinal cord. They found that baseline hypoxia had
a strong negative effect on patient prognosis, but they could not reverse this effect by
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increasing the radiotherapy dose to these areas. It has to be noted though, that out of
the 34 patients in the experimental arm, only 7 patients received a maximum dose of
80–86 Gy, 17 patients received a dose between 70 and 76 Gy, and for 10 patients, no
dose escalation could be achieved. Several other studies have been initiated and are
still ongoing. The multicentre phase III NARLAL2 trial (NCT02354274), is comparing
FDG PET dose painting with standard 66 Gy in 33 fractions [46]. The randomized
stage II–III RTEP7 trial (NCT02473133) is assessing dose redistribution based on FDG
PET during treatment, after 42 Gy [47]. A similar approach is being tested in the
randomized phase II RTOG-1106/ACRIN-6697 study (NCT01507428), where the plan
is adapted after 18–19 fractions based on the FDG PET/CT [48]. Clinical results for all
of these trials are awaited.
In head and neck cancer, the first clinical trial tested dose escalation in two
dose levels (72.5 Gy and 77.5 Gy) to FDG-PET-positive subvolumes. One treatment
related death in the second dose level halted the study [49]. A second study by the
same group explored an adaptive dose painting by number approach on FDG PET
voxel intensities combined with a conventional uniform dose. From the two dose
levels tested, 80.9 Gy and 85.9 Gy, significant late toxicities (i.e. mucosal ulcers) were
observed, and 80.9 Gy was found to be the maximum tolerated dose [50]. Another
phase I study tested uniform dose escalation of 82 Gy in the FDG high uptake region
in 15 patients. The acute toxicities were within the protocol defined criteria, however,
in two patients ulcerations did not heal and raised concerns regarding late toxicities
[51]. Ongoing studies in head and neck cancer include a phase II randomized trial
on FDG dose painting by numbers (NCT01341535) [52], a phase II trial comparing
standard irradiation of 70 Gy with adaptive FDG PET dose redistribution of 64–84 Gy
(NCT01504815) [53], and a phase II trial testing a 10 % dose increase in hypoxic areas
based on 18F-MISO PET [54].
Dose painting strategies are also under investigation in other tumour sites, prostate
[55, 56], or bone metastases [57] for example. The results of these studies, and the
ongoing studies in NSCLC and HNC, should gain more insight into the benefits and
limitations of dose painting.
Future perspectives
In this thesis, we showed some potential applications of integrating functional imaging
in the radiotherapy workflow. It is expected that in future, the combination of
more advanced and precise radiotherapy delivery techniques, sophisticated functional
imaging methods, and improved validated biomarkers and models, will further enable
treatment optimization and personalization.
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Advances in radiotherapy techniques
Radiotherapy techniques have made significant improvements over the last decades.
Modern external beam irradiation is delivered with highly conformal photon
beams in short treatment times. Small tumour (sub)volumes can be irradiated
accurately, with high doses, which is exploited during dose painting. Modern
clinical linear accelerators are, however, reaching their physical limit, and significant
further improvements in dose distributions are unexpected [58, 59]. Two exciting
developments that are expected to substantially improve radiotherapy treatment for
carefully selected patients, are the MRI-guided linear accelerator (MR-linac) and
proton therapy [59]. These developments are currently under clinical evaluation and
may be particularly important for a subset of NSCLC and head and cancer patients.
The MR-linac is a hybrid modality, combining a linac with magnetic resonance
imaging (MRI). The theoretical advantages of the MR-linac over cone-beam CT
(CBCT) guided linacs, are the optimal soft tissue contrast imaging, the possibility
to image during treatment, and image repeatedly without additional radiation dose.
The system has the potential to reduce the uncertainties in tumour location, and
enable fast replanning, gated irradiation, and tumour tracking. Consequently, the
reduced uncertainties may allow for dose escalation or reduction in normal tissue
toxicities, and adaptive focal boosting [60]. It remains to be seen if the uncertainty
reduction from having the MRI images outweigh the increased spatial uncertainty of
MRI compared to CT.
The other treatment technique currently installed or being installed in many
centres in Europe and worldwide is proton therapy. Proton beams have the unique
property to deposit almost all their energy at a particular depth, the so-called Bragg
peak. Whereas photon treatments cause ionization damage over the whole beam
length, proton beams release most of their energy towards the end of the beam and
have a minimal exit dose. These favourable beam characteristics could theoretically
target the tumour more accurately and reduce the dose to the organs at risk [61].
Both the MR-linac and proton therapy have the potential to deliver ionizing
radiation with high accuracy. Combining functional imaging and these more accurate
delivery techniques could optimize irradiating of biological target volumes. A main
disadvantage of both technologies, compared to CBCT-guided photon treatment, is
the increased costs. The clinical effectiveness and cost effectiveness are currently
under evaluation [61–63]. Proper patient selection, e.g. based on (functional) imaging,
is expected to be crucial to achieve the full potential of the MR-linac and proton
therapy.
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Developments in functional imaging and biomarkers
Even though a variety of functional imaging techniques were explored in this thesis,
including DCE-CT and several PET based approaches, this is only a small subset of the
functional imaging techniques currently under clinical investigation [64]. In Chapter 8,
we briefly mentioned some other functional imaging modalities, for example, 18F-
FLT PET, a biomarker for proliferation, or labelled drugs, such as, 68Ga-PSMA or
89Zr-bevacizumab. In this thesis, the PET tracer HX4 was used for hypoxia imaging.
Several other 18F labelled 2-nitroimidazole PET tracers are currently under evaluation,
that all have the same working principle, but have slightly different characteristics
[65]. Other, more indirect markers for hypoxia, that have been examined include
DCE-CT, 15O-labelled water, a variety of SPECT markers, and several MRI techniques,
e.g. blood oxygen level dependent (BOLD), diffusion-weighted imaging (DWI), and
oxygen-enhanced MRI [30, 36].
Despite the numerous imaging biomarkers used in clinical research, including
many showing great potential, only a few make the transition into clinical practise.
Crossing this translational gap will be one of the major challenges in imaging research.
Before biomarkers can be approved for clinical decision making, biomarkers need to
be reproducible (in a multicentre setting), biologically and clinically validated, and
cost-effective [2, 66]. Another challenge, as a consequence of the wide availability of
different imaging modalities and the availability of multiparametric imaging, is the
challenge of combining information from multiple imaging sources. Two approaches
to deal with this were discussed in Chapter 8.
In parallel to the developments in functional imaging techniques, more advanced
imaging analysis methods and big data approaches are gaining research interest.
These methods use tumour features based on image intensity, shape, and texture for
example, or deep learning approaches [67, 68]. Advanced image analysis methods
have the potential to improve predictive models and help patient stratification.
To conclude, radiotherapy delivery techniques and functional imaging modalities
are developing at a fast pace. The combination of very accurate radiation delivery
modalities with biologically validated targets, will allow further optimization and
personalization of treatment to increase the tumour control and reduce normal tissue
toxicities.
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BF Blood flow
BV Blood volume
CI Confidence interval
CR Coefficient of repeatability
CT Computed tomography
CTV Clinical target volume
D0.1 Dose received by maximal 0.1 % of the organ
DCE-CT Dynamic contrast-enhanced CT
Dmean Mean dose
DNA Deoxyribonucleic acid
DVH Dose-volume histogram
EGFR Epidermal growth factor receptor
EQD2 Equivalent dose in 2 Gy fractions
18F Fluorine-18
18F-FDG Fluorodeoxyglucose
18F-HX4 Fluortanidazole
FHV Fraction of hypoxic volume
GTV Gross tumour volume
GTVln GTV of the involved lymph nodes
GTVprim GTV of the primary tumour
Gy Gray
HF Hypoxic fraction
HNC Head and neck cancer
HNSCC Head and neck squamous cell carcinoma
HU Hounsfield unit
HV Hypoxic volume
IHC Immunohistochemistry
IQR Interquartile range
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Background and aim of the thesis
Cancer is a worldwide health problem with over 14 million new cases in 2012. The
number of new cancer cases is expected to increase and is estimated to reach almost
24 million by 2035. Despite substantial advances in treatment options, survival for
many cancer types remains poor. Treatment is challenging due to the similarity
between cancerous and healthy cells, and due to the heterogeneity of the disease.
To improve patient survival, and to reduce unnecessary toxicity and cost, it is
essential to quickly select the treatment with the highest expected benefit. Functional
imaging has the potential to guide treatment personalization by stratifying patients
based on their prognosis and on the predicted treatment benefit. Functional imaging
biomarkers can map tumour heterogeneities, identify resistant tumour regions, and
guide treatment adaptation.
In this thesis, the use of functional imaging to characterize the tumour and tumour
subvolumes was explored. Positron emission tomography (PET) was used to image
drug uptake, hypoxia levels, and tumour metabolism. Dynamic contrast-enhanced
CT (DCE-CT) was used to image tumour vasculature. Subsequently, these functional
imaging characteristics were tested as prognostic markers, for patient stratification,
and for treatment adaptation in non-small cell lung cancer and head and neck cancer.
Non-invasive imaging of drug uptake
In the first part of this thesis, non-invasive visualization and quantification of the
monoclonal antibody cetuximab was explored. Monoclonal antibodies have the
capability to bind to their targets with high specificity and affinity. Cetuximab, for
example, targets the epidermal growth factor receptor (EGFR). The clinical benefit of
monoclonal antibodies depend on the expression of the target in the tumour and on
how well the antibody can reach these targets. We investigated the accessibility of the
tumour to cetuximab with PET, by labelling cetuximab with radioactive Zirconium-89.
The clinical feasibility of this approach was first examined in a phase I study, as
described in Chapter 2. Nine patients, six lung cancer and three head and neck
cancer patients, were injected with two consecutive doses of 60 MBq 89Zr-cetuximab
or a single dose of 120 MBq 89Zr-cetuximab. No additional toxicity was associated
with administration of 89Zr-cetuximab compared to standard cetuximab, and both
presented dose schedules were considered safe. The higher 89Zr-cetuximab dose
did not result in improved image contrast and, therefore, a dose of 60 MBq was
recommended for future studies.
The promising results of the phase I trial, inspired a larger phase II trial in locally
advanced head and neck squamous cell carcinomas, as described in Chapter 3. A large
variation in 89Zr-cetuximab uptake was observed between the 17 scanned patients. We
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found that the best contrast in the tumour was achieved at 6–7 days after injection
of the PET tracer. Furthermore, it was shown that 89Zr-cetuximab PET provides
additional information on the accessibility of the tumour, which cannot be extracted
from EGFR expression levels or FDG PET/CT scans.
Hypoxia and DCE-CT imaging for outcome prediction and treatment
adaptation
In Part 2 we used functional imaging for outcome prediction and treatment
adaptation. In Chapter 4, the prognostic value of hypoxia HX4 PET/CT and dynamic
contrast-enhanced CT (DCE-CT) were evaluated. We found that patients with a
hypoxic tumour, as measured on the HX4 PET, had worse overall survival compared to
patients with non-hypoxic tumours. The patients in this chapter received, in addition
to standard (chemo)radiotherapy, the vasodilating drug nitroglycerin. Nitroglycerin
was added to target and reduce tumour hypoxia. The differences on the scans at
baseline and after administration of nitroglycerin revealed, however, a mixed response
to nitroglycerin: both increases and decreases in hypoxia levels and tumour blood flow
and blood volume were observed on HX4 PET and DCE-CT.
Several radiotherapy adaptation strategies, to selectively increase the radiotherapy
dose in radioresistant areas, were compared in the planning study in Chapter 5. We
found that selective boosting subvolumes based on FDG PET or hypoxia PET was
feasible in non-small cell lung cancer patients, without increasing the dose to the
organs at risk. The highest dose was achieved for the hypoxia-boosting plans. For
most patients, boosting the high metabolic subvolume (determined on FDG PET), also
resulted in boosting the hypoxic areas, although to a lower dose, but not vice versa.
Combining multiparametric imaging characteristics
In the third part of this thesis, different strategies were examined to combine multiple
(functional) imaging modalities on a subtumour level. In Chapter 6, we created
multiple models to predict hypoxia levels in non-small cell lung cancer. Hypoxia is
an interesting target for personalized radiotherapy treatment, however, hypoxia PET
imaging is not widely available, expensive, and time-consuming. We presented a
methodology to create virtual hypoxia images, based on the more widely available FDG
PET/CT and DCE-CT imaging.
The same multiparametric imaging data set, containing hypoxia HX4 PET/CT,
DCE-CT and FDG PET/CT, was utilized in Chapter 7 to identify subregions with
characteristics phenotypes and to relate these subregions to treatment outcome.
Two different clustering steps were performed based on all available imaging. First,
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clustering voxels in larger tumour regions to reduce registration uncertainties and
noise. Next, grouping these subregions of all patients into phenotypic clusters. We
found that one of the clusters, with high hypoxia levels, high metabolism (FDG
uptake), and intermediate tumour blood flow and blood volume, was related to a high-
risk tumour type. Patients with a large volume of this cluster had significantly worse
survival compared to patients with no, or only a small volume of this cluster.
How to move forward?
In Chapter 8, we discussed the opportunities and the challenges of the combined use
of multiple imaging modalities. We distinguished two complementary strategies, a
data-driven and biological-driven approach, to move forward with multiparametric
imaging. Finally, in Chapter 9, we discussed the results presented in this thesis and
the future perspectives of functional imaging in radiotherapy. We believe that the
combination of very accurate radiation delivery modalities with biologically validated
targets, will allow further optimization and personalization of treatment to increase
tumour control and reduce normal tissue toxicities.
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Achtergrond en doel van het proefschrift
Kanker is een wereldwijd gezondheidsprobleem met meer dan 14 miljoen nieuwe
diagnoses in 2012. Het wordt verwacht dat het aantal kankergevallen zal blijven
toenemen tot bijna 24 miljoen nieuwe gevallen in 2035. Voor vele kankersoorten
zijn de overlevingskansen van patiënten nog steeds gering, ondanks de substantiële
verbeteringen van de behandelopties. De behandeling van kanker wordt bemoeilijkt
doordat kankercellen erg lijken op gezonde cellen en door de heterogeniteit van de
ziekte.
Om de prognose van patiënten te verbeteren en om onnodige toxiciteit en kosten
te voorkomen, is het essentieel om zo snel mogelijk de meest geschikte behandeling te
kiezen. Functionele medische beeldvorming kan de personalisatie van behandelingen
verbeteren door patiënten te groeperen op basis van hun prognose en verwachte
profijt van een bepaalde behandeling. Functionele beeldvorming maakt het mogelijk
om de heterogeniteit van een tumor in kaart te brengen, resistente tumorgebieden te
identificeren en adaptieve behandeling te ondersteunen.
In dit proefschrift is het gebruik van functionele beeldvormingstechnieken voor het
karakteriseren van de tumor en tumor subvolumes verkend. Positronemissietomogra-
fie (PET) is gebruikt voor het visualiseren van een gelabeld medicijn, zuurstoftekort
(hypoxie) en het metabolisme van de tumor. Dynamische contrast-versterkte compu-
tertomografie (DCE-CT) is gebruikt voor het analyseren van de tumor vasculatuur. Ver-
volgens zijn de biomarkers berekend op basis van deze beeldvormingstechnieken ge-
test als potentiële prognostische markers, als markers voor patiënt stratificatie en voor
het aanpassen van de radiotherapie behandelplannen. Patiënten met niet-kleincellige
longkanker en hoofd-halstumoren zijn in de studies geanalyseerd.
Niet-invasieve beeldvorming van gelabelde medicijnen
In het eerste deel van dit proefschrift is de tumoropname van monoklonale
antilichamen gevisualiseerd en gekwantificeerd. Monoklonale antilichamen kunnen
zich met erg hoge affiniteit en specificiteit binden aan een doelwit. Cetuximab is
een voorbeeld van zo een antilichaam dat zich bindt aan de epidermale groeifactor
receptor (EGFR). Het succes van een behandeling met monoklonale antilichamen is
afhankelijk van de expressie van receptoren in de tumor en afhankelijk van hoe goed
het medicijn de tumor kan bereiken. Wij hebben de bereikbaarheid van de tumor
onderzocht met PET, door cetuximab te labellen met radioactief Zirconium-89.
De klinische haalbaarheid van deze methode is eerst onderzocht in een fase I
studie, zoals beschreven in Hoofdstuk 2. Negen patiënten, zes longkanker en drie
hoofd-halskanker patiënten, zijn geïnjecteerd met twee opeenvolgende doses van
60 MBq 89Zr-cetuximab of een enkele dosis van 120 MBq 89Zr-cetuximab. Geen extra
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toxiciteit werd geobserveerd na de toediening van 89Zr-cetuximab vergeleken met
standaard cetuximab en beide dosis schema’s zijn veilig bevonden. De hogere dosis
89Zr-cetuximab resulteerde niet in een verbeterd beeldcontrast en daarom wordt een
dosis van 60 MBq aangeraden voor toekomstige studies.
De veelbelovende resultaten van de fase I studie zijn de inspiratie geweest voor
een grotere fase II studie in patiënten met lokaal gevorderde hoofd-halstumoren,
zoals beschreven in Hoofdstuk 3. Een grote variatie in 89Zr-cetuximab opname werd
geobserveerd tussen de 17 gescande patiënten. Het beste contrast in de tumor werd
6–7 dagen na injectie van de PET tracer bereikt. Daarnaast hebben we laten zien dat
89Zr-cetuximab PET extra informatie geeft die niet verkregen kan worden door EGFR
expressie analyses of FDG PET/CT scans.
Hypoxie en DCE-CT beeldvorming voor prognose bepaling en
therapieadaptatie
In deel 2 hebben we functionele beeldvormingstechnieken gebruikt voor het bepa-
len van de patiënt prognose en voor het aanpassen van radiotherapie behandelplan-
nen. In Hoofdstuk 4 zijn de prognostische waarde van HX4 PET/CT en dynamische
contrast-versterkte computertomografie (DCE-CT) onderzocht. We hebben gevonden
dat patiënten met hypoxische tumoren, bepaald met HX4 PET, slechtere overlevings-
kansen hebben vergeleken met patiënten met niet-hypoxische tumoren. De patiën-
ten onderzocht in dit hoofdstuk kregen naast de standaard chemo(radiotherapie) het
vaatverwijdende middel nitroglycerine met als doel om hypoxie te verminderen. Het
verschil tussen de scans met en zonder nitroglycerine liet echter gemixte resultaten
zien: zowel toenames als afnames in hypoxie, perfusie en bloedvolume werden geob-
serveerd op de HX4 PET en DCE-CT scans.
Verschillende strategiën om selectief de bestralingsdosis in radioresistente gebie-
den te verhogen zijn vergeleken in Hoofdstuk 5. Selectieve dosis verhoging in subvolu-
mes gebaseerd op FDG PET en hypoxie PET was haalbaar in niet-kleincellige longkan-
ker patiënten, zonder de dosis in de omliggende organen te verhogen. De hoogste do-
sis kon behaald worden in de hypoxie plannen. Voor de meeste patiënten resulteerde
het verhogen van de dosis in de metabolisch actieve gebieden (FDG PET opname) ook
in een verhoging in de hypoxische gebieden, maar niet vice versa.
Combineren van multiparametrische beeldkarakteristieken
In het derde deel van dit proefschrift zijn verschillende manieren onderzocht om mul-
tiparametrische beeldkarakteristieken op een subtumor niveau te combineren. In
Hoofdstuk 6 hebben we verschillende modellen gemaakt om hypoxie te voorspellen
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in niet-kleincellige longkanker. Hypoxie is een interessant doelwit voor gepersonali-
seerde radiotherapie. Hypoxie PET is echter niet overal beschikbaar, duur en tijdro-
vend. Wij hebben een methodologie ontwikkeld om virtuele hypoxie beelden te re-
construeren op basis van de meer gangbare beeldvormingstechnieken FDG PET/CT
en DCE-CT.
Dezelfde multiparametrische dataset, bestaande uit hypoxie HX4 PET/CT, DCE-
CT en FDG PET/CT, is in Hoofdstuk 7 gebruikt voor het identificeren van tumor
subvolumes met karakteristieke fenotypes en om deze te linken aan de prognose
van de patiënten. Twee opeenvolgende clustering stappen zijn uitgevoerd op de
beschikbare data. Eerst zijn de voxels in grotere tumorregio’s gegroepeerd om
beeldregistratie onzekerheden en ruis te verminderen. Vervolgens zijn deze subregio’s
van alle patiënten gegroepeerd in fenotypische clusters. Eén van deze clusters,
gekenmerkt door zuurstoftekort (hoge HX4 PET opname), een hoog metabolisme
(hoge FDG PET opname) en een gemiddelde perfusie en bloedvolume, correleerde met
een hoog-risico tumor type. Patiënten met een groot (relatief) volume van dit cluster
hadden significant slechtere overlevingskansen vergeleken met patiënten zonder dit
cluster of met alleen een klein volume van het cluster.
Toekomstperspectieven
In Hoofdstuk 8 zijn de kansen en uitdagingen van het combineren van verschillende
beeldvormende technieken beschreven. Twee strategiën zijn beschreven voor
de toekomst van multiparametrische medische beeldvorming: een datagestuurde
en een biologiegestuurde strategie. In Hoofdstuk 9 zijn tenslotte de resultaten
van dit proefschrift en de toekomstperspectieven van functionele beeldvorming
in radiotherapie beschreven. De combinatie van precieze bestralingstechnieken
en gevalideerde biologische targets wordt verwacht bij te dragen aan de verdere
optimalisatie en personalisatie van radiotherapie om zodoende locale tumorcontrole
te verbeteren en de toxiciteit in normale weefsels te verminderen.
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Social relevance and target groups
Cancer is one of the leading causes of mortality and morbidity worldwide. For many
cancer types, the survival remains poor despite substantial advances in treatment
options. In this thesis, we examined the tumour biology with different functional
imaging modalities. A better understanding of the tumour biology and the tumour
characteristics related to treatment resistance could improve current treatment
options and help the development of new therapies.
To achieve the best treatment results, it is crucial to select the treatment with the
highest expected benefit as quick as possible. Therapy could be adapted based on
the patient prognosis. For example, treatment could be intensified in patients with
poor prognosis, while in patients with a good prognosis, de-escalation of therapy dose
could be considered. We used biomarkers derived from several functional imaging
modalities to stratify patients based on their expected prognosis and to evaluate the
expected treatment benefit. We showed that functional imaging could be used to
redistribute the dose in the tumour and sculpt the dose for a specific case to better
target the most resistant areas.
The ultimate aim of treatment personalization is to include the preference of the
patient in the treatment decision; to balance increasing local tumour control and
limiting toxicities to the surrounding healthy tissues based on the patient preference.
Personalization will first of all affect the patient, their family, and the physician.
In addition, it will befit the general population since cancer is a worldwide health
problem. Improving treatment options will economically benefit the whole society.
Activities and products
A subset of the images acquired for the research presented in this thesis is publicly
available (www.cancerdata.org). 89Zr-cetuximab PET/CT images of head and neck
cancer patients, and HX4 PET/CT and FDG PET/CT images of non-small cell lung
cancer patients are provided. The treatment plans generated for the planning study
of Chapter 5 are also available on the same website. Researchers and other interested
parties are free to reuse the images for their own research questions.
The methodologies used in Chapter 6 en Chapter 7 are largely based on open-
source software. The performed image registration, the generation of the supervoxels,
and the clustering of the supervoxels were all performed using freely available
software. The methodology described in these chapters to combine multiparamteric
images can easily be implemented and reused in other projects.
Functional imaging could have an important role in the further development of
prediction models. Prediction models are being developed to support physicians in
clinical decision-making. With the vast amount of information available for every
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patient, it becomes increasingly difficult for a physician to consider and incorporate all
this information. Prediction models can combine data of multiple sources to predict
patient prognosis. Some examples from the Maastro clinic research group are already
available on www.predictcancer.org. Functional imaging, e.g. HX4 PET/CT imaging,
has the potential to further improve these models and better support the physicians.
Eventually, these prediction models could be integrated in decision support systems
to help the patient in selecting a personalized treatment.
Innovation
Although the research presented in this thesis is based on a limited number of patients,
the data sets are unique and difficult to acquire. To our knowledge, there is only one
other clinical trial using 89Zr-cetuximab PET images. In that trial, ten patients with
advanced colorectal cancer were included. Our studies are the first to visualize and
quantify 89Zr-cetuximab PET uptake in head and neck cancer patients.
The combination of multiple functional images, as presented in Chapter 6 and
Chapter 7, provides a unique insight in multiple tumour characteristics at the same
time. With the increasing amount of data available, analysis methods are required that
can manage multiple scans and can combine the knowledge. In Chapter 7 we provided
an example of such a workflow.
In Chapter 4, we showed the prognostic value of hypoxia HX4 PET/CT imaging in
non-small cell lung cancer. Although hypoxia PET imaging has shown to be prognostic
before in several tumour types, this is the first study that shows the prognostic value of
the novel hypoxia PET tracer HX4.
Schedule and implementation
The benefit of boosting specific radioresistant parts of the tumour is still under clinical
evaluation. Maastro clinic is participating in a prospective phase II trial in non-small
cell lung cancer (NCT01024829). Several other studies are ongoing, as discussed in
the general discussion of this thesis. The results of these clinical trials will give more
insight into the potential of such a strategy.
The prognostic value of the hypoxia PET marker HX4, needs to be further validated
in a larger patient cohort. After validation, it can be implemented in prediction models.
The prediction of hypoxia based on other imaging modalities (CT, FDG PET and DCE-
CT) as presented in Chapter 6, could serve as a an alternative to hypoxia PET that is
easier to implement in a clinical workflow.
Combining multiple imaging data sets will become proportionally important with
the increasing amount of data available. The workflows presented in this thesis are
based on several open-source packages and could be directly applied to other data.
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